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Abstract	
	
Autism	 spectrum	disorders	 (ASD)	 are	 a	 group	of	 genetic	 disorders	 often	overlapping	with	
other	neurological	conditions.	Despite	the	remarkable	number	of	scientific	breakthroughs	of	
the	 last	 100	 years,	 the	 treatment	of	neurodevelopmental	 disorders	 (e.g.	 autism	 spectrum	
disorder,	intellectual	disability,	epilepsy)	remains	a	great	challenge.	Recent	advancements	in	
genomics,	 like	 whole-exome	 or	 whole-genome	 sequencing,	 have	 enabled	 scientists	 to	
identify	 numerous	 mutations	 underlying	 neurodevelopmental	 disorders.	 Given	 the	 few	
hundred	risk	genes	that	were	discovered,	the	etiological	variability	and	the	heterogeneous	
phenotypic	 outcomes,	 the	 need	 for	 genotype-	 along	 with	 phenotype-based	 diagnosis	 of	
individual	patients	becomes	a	requisite.		
	
Driven	by	 this	 rationale,	 in	a	previous	 study	our	group	described	mutations,	 identified	via	
whole-exome	 sequencing,	 in	 the	 gene	BCKDK	 –	 encoding	 for	 a	 key	 regulator	 of	 branched	
chain	amino	acid	(BCAA)	catabolism	-	as	a	cause	of	ASD.	Following	up	on	the	role	of	BCAAs,	
in	the	study	described	here	we	show	that	the	solute	carrier	transporter	7a5	(SLC7A5),	a	large	
neutral	 amino	 acid	 transporter	 localized	 mainly	 at	 the	 blood	 brain	 barrier	 (BBB),	 has	 an	
essential	role	in	maintaining	normal	levels	of	brain	BCAAs.	In	mice,	deletion	of	Slc7a5	from	
the	endothelial	cells	of	the	BBB	leads	to	atypical	brain	amino	acid	profile,	abnormal	mRNA	
translation	and	severe	neurological	abnormalities.	Additionally,	deletion	of	Slc7a5	from	the	
neural	progenitor	cell	population	leads	to	microcephaly.	Interestingly,	we	demonstrate	that	
BCAA	 intracerebroventricular	 administration	 ameliorates	 abnormal	 behaviors	 in	 adult	
mutant	 mice.	 Furthermore,	 whole-exome	 sequencing	 of	 patients	 diagnosed	 with	
neurological	disorders	helped	us	 identify	several	patients	with	autistic	 traits,	microcephaly	
and	motor	delay	carrying	deleterious	homozygous	mutations	in	the	SLC7A5	gene.		
	
In	conclusion,	our	data	elucidate	a	neurological	syndrome	defined	by	SLC7A5	mutations	and	
support	 an	 essential	 role	 for	 the	 BCAAs	 in	 human	 brain	 function.	 Together	 with	 recent	
studies	 (described	 in	 chapter	 two)	 that	 have	 successfully	made	 the	 transition	 into	 clinical	
practice,	our	findings	on	the	role	of	BCAAs	might	have	a	crucial	impact	on	the	development	
of	novel	individualized	therapeutic	strategies	for	ASD.	
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Chapter	1	–	Introduction	
	
1.1 Autism	Spectrum	Disorders		
The	term	autism	was	employed	for	the	first	time	in	the	early	1940s	by	Leo	Kanner	and	Hans	
Asperger	to	describe	a	group	of	children	that	displayed	unusual	behavior	and	preference	for	
isolation	 instead	of	 social	 interaction.	Nowadays,	 clinicians	and	 researchers	have	 replaced	
the	term	autism	with	“autism	spectrum	disorders”	(ASD)	to	indicate	a	group	of	syndromes	
that	share	a	heterogeneous	pattern	of	 inheritance	and	a	constellation	of	symptoms	which	
include	early	dysfunction	in	social	interactions,	communication	deficits	and	the	presence	of	
repetitive	 and	 restricted	 behaviors	 (Figure	 1)	 (Elsabbagh	 et	 al.,	 2012).	 Although	 in	 recent	
years	 a	 strong	 scientific	 and	 public	 interest	 has	 been	 directed	 towards	 ASD,	 making	 a	
diagnosis	 of	 autism	 is	 challenging	 due	 to	 the	 absence	 of	 early	 clinical	manifestations	 and	
biomarkers	 (Daniels	 &	Mandell,	 2014).	 Thus,	 diagnosis	 is	 predominantly	 made	 after	 two	
years	 of	 age	 and	 it’s	mainly	 phenotype-driven	 endorsed	 by	 the	 Diagnostic	 and	 Statistical	
Manual	of	Mental	Disorders	 (DSM)	 (Sharma,	Mishra,	&	Mishra,	 2015).	 Patients	diagnosed	
with	ASD	often	present	with	other	comorbidities	(see	section	1.2.)	like	intellectual	disability	
(ID	 –	 35-40%)	 (Matson	 &	 Shoemaker,	 2009),	 epilepsy	 (20-25%)	 (Canitano,	 2007),	 motor	
abnormalities	 or	 language	 delay.	 Typically	 ASD	 has	 been	 classified	 into	 syndromic	 (when	
ASD	 occurs	 in	 conjunction	with	 additional	 phenotypes)	 -	 Rett	 syndrome	 (RS)	 (Amir	 et	 al.,	
1999),	Fragile	X	syndrome	(FXS)	(Verkerk	et	al.,	1991),	tuberous	sclerosis	(TS)	(Kandt	et	al.,	
1992)	 and	 nonsyndromic	 (classic	 autism	 or	 idiopathic	 autism	 when	 ASD	 occurs	 with	 no	
additional	 symptoms).	 Evidence	 suggests	 that	 the	 causes	 involve	 both	 genetic	 and	
environmental	factors	(Y.	S.	Kim	&	Leventhal,	2015).		
 Social	and	Communication	Impairment	1.1.1
One	of	 the	most	essential	and	complex	behaviors	 that	define	human	 interactions	 is	 social	
behavior.	Social	behavior	relies	on	the	ability	of	people	to	properly	communicate	with	each	
other	(verbally,	non-verbally,	via	gestures	or	mimics),	to	sense,	process	and	interpret	social	
cues,	 to	 predict	 what	 someone	will	 do	 next	 and	 respond	with	 the	 appropriate	 behavior.	
Several	 brain	 areas,	 such	 as	 the	 medial	 prefrontal	 cortex,	 the	 amygdala	 or	 the	 anterior	
cingulate	cortex	are	at	interplay	making	up	the	so	called	“social	brain”	which	mediates	the	
social	 outcome	 (Frith,	 2007)	 (Figure	 2).	 Conversely,	 in	 ASD	 patients	 the	 social	 behavior	 is	
drastically	 impaired	 ranging	 from	 lack	 of	 basic	 communication	 skills,	 inability	 to	 initiate	
interactions	or	develop	relationships,	to	lack	of	social	or	emotional	reciprocity,	to	absence	of	
interest	in	others’	emotions	and	to	impairments	in	nonverbal	social	interactions	(Lord	et	al.,	
2000).	In	newborns	the	first	signs	of	impaired	social	behavior	are	represented	by	the	lack	of	
innate	preference	for	human	voices	and	faces	over	other	stimuli	 (Mills	&	Melhuish,	1974).	
Autistic	infants	display	altered	joint	attention	and	inability	to	share	eye	gaze	(Young,	Merin,	
Rogers,	 &	 Ozonoff,	 2009),	 while	 in	 older	 children	 lack	 of	 play	 with	 peers	 and	 isolation	
(Bauminger,	 Shulman,	 &	 Agam,	 2003)	 are	 the	 common	 alerts	 for	 testing	 them	 for	 ASD.	
Language	 onset	 in	 ASD	 children	 is	 usually	 very	 late	 and	 is	 characterized	 by	 stereotyped	
phrases,	 echolalia	 (repetition	of	 the	 same	word/sound),	 intonation	and	 rhythm	problems.	
Non-verbal	communication	is	also	affected	with	an	inability	to	express	feelings,	thoughts	or	
even	point	at	objects.	At	the	other	end	of	the	spectrum	are	the	ASD	children	that	develop	
an	 uneven	 language	 (i.e.	 monologue)	 in	 a	 very	 narrow,	 restricted	 area	 of	 interest	 (e.g.	
	
	
memorization,	 calendar	 calculation,	 music,	 math)	 without	 being	 able	 though	 to	 have	 a	
dialog	 about	 the	 same	 topics	 (Tager-Flusberg	 &	 Kasari,	 2013).	 The	 neurophysiological	
substrates	 underlying	 social	 abnormalities	 are	 still	 an	 enigma,	 but	 based	 on	 human	 and	
animal	 model	 studies	 the	 excitatory-inhibitory	 activity	 imbalance	 theory,	 which	 leads	 to	
hyper-	or	hypo-activation	of	certain	brain	structures,	could	explain	 the	mechanism	behind	
social	behavior	abnormalities	(Gogolla,	Takesian,	Feng,	Fagiolini,	&	Hensch,	2014;	Yizhar	et	
al.,	2011).		
 Repetitive	and	Restricted	Behavior		1.1.2
The	third	dimension	of	the	ASD	core	symptom	triad	describes	the	tendency	of	the	patients	
to	 insist	 on	 sameness	with	 adherence	 to	 routines	 (e.g.	 eating	 the	 same	 food	 in	 the	 same	
order,	never	 taking	a	detour	 form	a	 route)	and	display	of	a	 restricted	pattern	of	behavior	
with	 repetitive	 motor	 movements,	 use	 of	 objects	 or	 speech.	 The	 highly	 fixated	 interests	
include	also	unusual	 interest	 in	 sensory	environmental	 cues	with	hyper-	or	hyporeactivity	
and	 limited	 interest	 in	 spontaneous	 activities	 (Kanner,	 1968).	 Although	 the	 exact	
neurobiological	 mechanism	 leading	 to	 this	 peculiar	 phenotype	 is	 still	 not	 completely	
understood,	 several	 recent	 studies	 in	 ASD	 animal	 models	 managed	 to	 narrow	 down	 the	
onset	 of	 a	 specific	 repetitive	 behavior	 to	 the	 dopaminergic	medium	 spiny	 neural	 circuits	
within	 the	 striatum	 (Figure	 2)	 (Rothwell	 et	 al.,	 2014)	 thus	 paving	 the	 road	 for	 future	
discoveries.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	ASD	core	symptoms	with	comorbidities	and	associated	disorders.	
	
1.2 Comorbidities		
 Intellectual	Disability	(ID)	1.2.1
Is	 a	 neurodevelopmental	 disorder	 also	 referred	 to	 as	 cognitive	 impairment	 or	 mental	
retardation	 and	 it	 affects	 approximately	 1.5-2%	 of	 the	 Western	 population	 (Mefford,	
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Batshaw,	&	Hoffman,	2012).	ID	ranges	from	mild	to	profound,	and	it	can	be	associated	with	
other	 clinical	 findings	 (syndromic	 ID)	 or	 it	 occurs	 isolated	 (non-syndromic	 ID).	 Clinical	
diagnosis	 is	 based	 on	 significant	 limitations	 in	 daily	 activities	 and	 an	 IQ	 below	 70,	 which	
means	 that	 the	 diagnosis	 is	 not	 made	 until	 early	 adulthood.	 During	 early	 childhood	 the	
diagnosis	is	based	on	substantial	motor,	cognitive	and	speech	delays.	The	severe	forms	of	ID	
are	thought	to	have	a	genetic	origin,	but	in	at	least	50%	of	cases	the	cause	remains	elusive.	
Genetic	research	in	ID	has	increased	over	the	past	decade	and	thus	many	autosomal	or	X-
linked	mental	retardation	genes,	both	inherited	or	de	novo	(variants	that	occur	for	the	first	
time	 in	 the	proband	without	being	present	 in	 the	parental	genome),	have	been	 identified	
(Topper,	 Ober,	 &	 Das,	 2011),	 with	 FMR1	 (FXS)	 being	 one	 of	 the	most	 common	 inherited	
monogenic	causes	of	ID	and	ASD	in	male	patients	(Bagni,	Tassone,	Neri,	&	Hagerman,	2012).		
 Epilepsy		1.2.2
Is	a	neurological	condition	characterized	by	recurrent	spontaneous	seizures	that	are	due	to	
abnormal	neuronal	 activity,	 such	as	excessive	excitation	or	hypersynchronization,	 and	 can	
occur	as	a	result	of	developmental	defects	or	due	to	insults	(e.g.	trauma,	stress,	etc)	later	on	
in	 life.	 With	 over	 65	 million	 people	 affected	 worldwide,	 epilepsy	 is	 the	 most	 common,	
chronic	 neurological	 disorder	 (Thurman	 et	 al.,	 2011).	 Epilepsy	 can	 be	 observed	 as	
comorbidity	with	other	disorders	or	as	an	individual	condition	that	comes	in	many	different	
forms.	Although	in	many	cases	seizures	can	be	controlled,	the	treatment	gap	is	still	immense	
either	 due	 to	 costs	 or	 reduced	 accessibility	 or	 due	 to	 lack	 of	 response	 to	 medication	
(Cameron	et	al.,	2012).	Genetic	underpinnings	for	epilepsies	have	been	long	recognized	and	
over	 the	 past	 twenty	 years	 significant	 discoveries	 have	 been	 made	 such	 as:	 the	 large	
number	of	 epilepsy	 risk	 genes,	 the	 complexities	 of	 phenotype-genotype	 relationships	 and	
the	 contribution	 of	 somatic	 mutations	 and	 noncoding	 microRNAs	 to	 epilepsy	 onset	
(Noebels,	2015;	Poduri,	Evrony,	Cai,	&	Walsh,	2013).	
 Motor	abnormalities		1.2.3
Motor	symptomatology	in	autism	is	poorly	understood	and	has	received	less	attention	than	
the	classical	ASD	triad	of	symptoms	even	though	already	in	1943,	in	his	early	observations,	
Kanner	mentioned	that	children	with	ASD	presented	with	a	“clumsy”	gait	and	gross	motor	
patterns	 (Kindregan,	 Gallagher,	 &	 Gormley,	 2015).	 In	 recent	 years	 several	 studies	 have	
focused	 on	 the	 motor	 and	 sensory-motor	 behaviors	 of	 children	 with	 ASD,	 providing	
evidence	 that	 children	 diagnosed	 with	 ASD	 displayed	 less	 coordination	 and	 fewer	 motor	
capabilities	(Fournier,	Hass,	Naik,	Lodha,	&	Cauraugh,	2010).	The	most	frequently	reported	
motor	behaviors	range	from	imitation	disorders,	static	and	dynamic	postural	balance	issues,	
decreased	 postural	 control	 and	 gait	 deviations	 (Paquet,	 Olliac,	 Golse,	 &	 Vaivre-Douret,	
2016).		
	
1.3 Prevalence		
Over	the	past	twenty	years	there	has	been	a	steady	increase	in	the	ASD	cases	mainly	due	to	
increased	access	to	diagnostic	services	and	increased	awareness	of	the	condition	(Lenoir	et	
al.,	 2009).	 Consequently,	 ASD	 represents	 an	 issue	 of	 public	 concern,	 as	 the	 estimated	
prevalence	 in	 the	 USA	 is	 1	 in	 68	 births,	 making	 ASD	 one	 of	 the	 most	 common	
neurodevelopmental	 disorders	 (Autism,	 Developmental	 Disabilities	 Monitoring	 Network	
Surveillance	 Year	 Principal,	 Centers	 for	Disease,	&	 Prevention,	 2012).	 In	 addition,	 there	 is	
	
	
also	an	uneven	distribution	between	sexes,	with	a	male	to	female	ratio	of	approximately	4:1	
(Fombonne,	 2009).	 This	 strong	 male	 bias	 has	 been	 investigated	 and	 genetic	 studies	
suggested	 that	 females	 are	 protected	 from	 the	 effects	 of	 heritable	 and	de	 novo	 ASD	 risk	
variants	 due	 to	 sex	 chromosomal	 genes	 (Lu	 &	 Cantor,	 2012;	 Stone	 et	 al.,	 2004)	 or	 sex	
hormones	 (Sarachana,	 Xu,	 Wu,	 &	 Hu,	 2011),	 which	 are	 regulating	 the	 effects	 of	 genetic	
variation	on	the	onset	of	an	ASD	phenotype.	
	
1.4 Neuroanatomical	Abnormalities	in	ASD		
	
Figure	 2.	 Anatomical	 and	 functional	 brain	 areas	 affected	 in	 ASD,	 that	 are	 relevant	 to	 social	 behavior,	
communication	and	repetitive	movements	(adapted	from	(Barak	&	Feng,	2016)).	
 Cerebellar	Dysfunction	1.4.1
Motor	 abnormalities	 are	 a	 common	 observation	 among	 ASD	 patients	 (see	 section	 1.2.3.)	
and	 their	 symptomatology	 is	 reminiscent	 of	 patients	 diagnosed	 with	 cerebellar	 deficits.	
Therefore,	researchers	have	focused	on	these	aspects	revealing	that	cerebellar	deficiencies	
are	 common	 in	 ASD	 and	 are	 often	 characterized	 by	 reduced	 Purkinje	 and	 granule	 cells	
(Whitney,	Kemper,	Bauman,	Rosene,	&	Blatt,	2008).	Neuroimaging	studies	revealed	that	the	
cerebellum	(Figure	2)	is	involved	in	motor	deficits	via	connections	with	the	parietal	lobe	and	
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cortical	and	subcortical	brain	regions	as	well	as	via	a	lack	of	sensory	integration	of	external	
stimuli	(Rinehart	et	al.,	2006;	Schmahmann,	Rosene,	&	Pandya,	2004).		
 Regional	brain	structures		1.4.2
Neuroimaging	 studies	 have	 revealed	 a	 series	 of	 core	 regions	 that	 mediate	 clinical	
phenotypes	of	ASD.	The	temporal	sulcus	and	Broca’s	area	seem	to	be	related	to	deficits	in	
language	 processing	 (Redcay,	 2008)	 (Figure	 2);	 the	 frontal	 lobe,	 parietal	 cortex	 and	 the	
amygdala	mediate	impairments	of	social	behavior	(J.	E.	Kim	et	al.,	2010)	(Figure	2)	while	the	
orbitofrontal	cortex	and	the	caudate	nucleus	have	been	associated	with	repetitive	behaviors	
(Atmaca,	 Yildirim,	 Ozdemir,	 Tezcan,	 &	 Poyraz,	 2007)	 (Figure	 2).	 Interestingly,	 these	 key	
regions	 are	 not	 only	 specific	 for	 ASD	 manifestation	 but	 also	 for	 other	 disorders	 such	 as	
obsessive-compulsive	disorder,	anxiety	and	schizophrenia	(Zarei	et	al.,	2011).	
 Macrocephaly	and	microcephaly		1.4.3
In	his	initial	findings,	Kanner	mentioned	already	that	five	out	of	the	eleven	children	studied	
presented	 with	 larger	 heads.	 This	 feature	 was	 later	 observed	 in	 several	 other	 studies	
(Courchesne,	 Campbell,	 &	 Solso,	 2011),	 revealing	 that	 one	 out	 of	 six	 autistic	 subjects	
displayed	 macrocephaly	 (Fombonne,	 Roge,	 Claverie,	 Courty,	 &	 Fremolle,	 1999).	 Indeed,	
autism	 appears	 to	 be	 associated	 with	 either	 macrocephaly	 or	 microcephaly	 thus	 recent	
studies	 focused	 on	 understanding	 the	 pathological	 mechanism	 behind	 abnormal	 head	
growth.	 It	 has	 been	 shown	 that	 early	 overgrowth	 is	 caused	by	 an	 increased	 expansion	of	
cortical	 surface	 area	 rather	 than	 thickness	 before	 two	 years	 of	 age	 (Hazlett	 et	 al.,	 2011).	
Genome	wide	association	studies	(GWAS)	of	head	size	have	shown	a	polygenic	architecture	
in	the	general	population.	One	of	the	main	regulators	of	normal	brain	development	 is	 the	
evolutionarily	 conserved	Ser/Thr	protein	 kinase	Mammalian	Target	of	Rapamycin	 (mTOR).	
MTOR	signaling	is	essential	for	the	maintenance	and	differentiation	of	neuronal	progenitors	
(i.e.	 soma	 size,	 neurite	 outgrowth),	 neuronal	migration	 and	 synapse	 formation	 (Figure	 4).	
Mutations	 in	 a	 series	 of	 upstream	 and	 downstream	 effectors	 of	 mTOR	 have	 been	
investigated	 and	 the	 outcomes	 were	 similar:	 macrocephaly,	 seizures	 and	 behavioral	
abnormalities	 (Kwon	 et	 al.,	 2006;	 Reijnders	 et	 al.,	 2017).	 A	 subset	 of	 ASD	 cases	 with	
increased	 head	 size	 (>	 3	 standard	 deviations)	 and	 overall	 somatic	 overgrowth	 have	 been	
associated	 with	 mutations	 in	 the	 phosphatase	 tensin	 homolog	 (PTEN)	 gene	 –	 mTOR	
upstream	effector	-	which	antagonizes	the	phosphoinositol-3-kinase/AKT	signaling	pathway	
and	 suppresses	 cell	 proliferation	 (Klein,	 Sharifi-Hannauer,	 &	 Martinez-Agosto,	 2013;	
McBride	et	 al.,	 2010).	Additionally,	 a	 study	 investigating	 large	 ID	&	ASD	cohorts	 indicated	
that	 mTOR	 variation	 contributes	 significantly	 to	 macrocephaly	 and	 identified	 de	 novo	
mutations	 in	 a	 key	 upstream	mTOR	 regulator,	 RHEB	 (Reijnders	 et	 al.,	 2017).	 Conversely,	
several	 cases	 of	 autism	 with	 microcephaly	 have	 been	 reported	 (Fombonne	 et	 al.,	 1999;	
Miles,	2011).	Irrespective	of	head	over/undergrowth,	how	this	physical	abnormality	relates	
to	the	behavioral	and	neuroanatomical	features	of	ASD	remains	elusive.		
	
1.5 The	etiological	landscape	of	ASD	
On	average	a	newborn	acquires	between	50-100	new	genetic	variants,	resulting	in	0.86	new	
amino	acid	altering	mutations	per	individual	(Lynch,	2010)	and	the	recurrence	of	developing	
ASD	 in	siblings	of	an	affected	 individual	 range	from	7-19%	(Gronborg,	Schendel,	&	Parner,	
2013)	 with	 a	 heritability	 estimate	 of	 31-71%	 (Gaugler	 et	 al.,	 2014).	 Given	 such	 a	 high	
	
	
individual	liability,	a	plethora	of	variants	associated	with	ASD	have	been	found	in	hundreds	
of	different	genes	based	on	an	extensive	series	of	twin	studies	(Tick,	Bolton,	Happe,	Rutter,	
&	Rijsdijk,	 2016)	 and	GWAS	 (Gaugler	 et	 al.,	 2014),	making	ASD	one	of	 the	most	heritable	
neurodevelopmental	disorder.		
The	 identified	variants	 range	 from	chromosomal	abnormalities,	 to	 recessive	mutations,	 to	
single	 nucleotide	 changes	 (single	 nucleotide	 variants	 (SNV))	 and	 to	 loss	 or	 gain	 of	 up	 to	
thousands	 of	 nucleotides	 (copy	 number	 variants	 (CNV)).	 Several	 studies	 identified	 rare	
combinations	of	common	variants	and	many	de	novo	germline	variants	with	a	 large	effect	
size	as	contributors	to	the	total	ASD	genetic	risk	(Figure	3)	(Iossifov	et	al.,	2014;	Sanders	et	
al.,	 2015;	 Sanders	 et	 al.,	 2012).	 De	 novo	 germline	 mutations	 (DNM)	 occur	 usually	 in	
probands	 that	 posses	 also	 a	 normal	 allele	 (haploinssuficiency)	 and	 they	 are	 mostly	
represented	 by	 missense	 mutations	 –	 in	 general	 have	 gain-of–function	 effects	 and	
contribute	to	12%	of	diagnoses;	and	by	likely	gene	disrupting	(LGD)	mutations	–	comprising	
nonsense,	frameshift	or	splice	site	variants	that	have	predominantly	a	loss-of-function	effect	
and	 contribute	 to	 9%	 of	 diagnoses	 (Geisheker	 et	 al.,	 2017;	 Iossifov	 et	 al.,	 2014).	
Furthermore,	rare	genetic	variants,	both	de	novo	and	inherited,	are	causal	in	approximately	
11%	of	the	simplex	cases	(Sanders	et	al.,	2015).	Common	genetic	variants	contribute	to	ASD	
risk	 in	 a	 high	 percentage	 (49%)	 (Figure	 3)	 but	 the	 net	 effect	 to	 the	 individual	 liability	 is	
higher	in	the	case	of	rare	genetic	events	(Gaugler	et	al.,	2014).	However,	germline	mutations	
do	 not	 explain	 a	 considerable	 portion	 of	 ASD	 risk	 pointing	 out	 that	 other	 genetic	
contributions	 must	 be	 investigated.	 For	 instance,	 postzygotic	 (i.e.	 somatic)	 mutations	
explain	a	significant	proportion	of	ASD	cases,	as	shown	by	two	studies	published	earlier	this	
year	(Krupp	et	al.,	2017;	Lim	et	al.,	2017). 	
	
Figure	3.	Genetic	architecture	of	ASD	depicting	 the	variance	 in	autism	 liability	as	determined	by	genetic	and	
environmental	 factors.	 Non-additive	 effects:	 dominant,	 recessive	 or	 epistatic	 (adapted	 from	 (Gaugler	 et	 al.,	
2014)).	
	
The	combination	of	genetic	and	functional	analyses	has	shown	that	a	great	number	of	the	
genes	 involved	 in	 such	 neurological	 disorders	 could	 ultimately	 converge	 along	 a	 small	
number	 of	 biological	 pathways.	 Indeed,	many	 of	 the	 genes	 implicated	 in	 ASD	 encode	 for	
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proteins	involved	in	synaptic	function,	excitation/inhibition	balance,	amino	acid	metabolism,	
transcriptional	 regulation	 and	 chromatin	 remodeling	 pathways	 (de	 la	 Torre-Ubieta,	Won,	
Stein,	 &	 Geschwind,	 2016);	 (Pinto	 et	 al.,	 2014);	 (De	 Rubeis	 et	 al.,	 2014;	 Novarino	 et	 al.,	
2012a).	 Knowing	 the	 genetic	 basis	 of	 a	 disorder	 makes	 it	 possible	 to	 generate	 accurate	
models	that	would	allow	to	study	the	effects	of	any	given	mutation	and	to	 investigate	the	
underlying	mechanisms.	
Even	though	the	proportion	of	the	phenotypic	variance	due	to	genetic	 factors	 is	very	high	
for	autism,	one	should	not	disregard	the	importance	of	the	environmental	factors	(e.g.	viral	
infections)	 that	 may	 contribute	 to	 the	 etiology	 of	 autism	 (Figure	 3).	 Furthermore,	 the	
possibility	 that	 a	 genetic	 defect	 alters	 features	 of	 brain	 development	 by	 affecting	 the	
immune	 system	 is	 receiving	 more	 and	 more	 attention.	 Several	 studies	 have	 shown	 that	
mediators	of	 immune	functions	such	as	cytokines	and	chemokines	also	play	a	role	in	brain	
development	(e.g.	synaptogenesis)	(Edmonson,	Ziats,	&	Rennert,	2016).		
In	 addition	 to	 the	 already	 complex	 etiology	 of	 ASD,	 research	 has	 focused	 also	 on	
epigenetics,	a	prime	mediator	of	the	environmental	effects	on	genomes	and	phenotypes,	in	
order	to	characterize	changes	 in	ASD	that	are	due	to	a	molecular	 level	on	top	of	 the	DNA	
sequence,	without	modifications	to	the	sequence	itself.	Epigenetic	changes	occur	due	to	the	
recruitment	 of	 specific	 epigenetic	 “modifiers”	 that	 add	 specific	 small	 molecules	 (e.g.	
methyl/acetyl)	to	DNA	or	to	its	packaging	proteins	-	the	histones.	Methylation	is	one	of	the	
most	widely	 studied	epigenetic	marks	 and	 involves	 the	addition	of	 a	methyl	 group	 to	 the	
cytosine	in	a	CpG	dinucleotide.	Such	CpG	domains	are	reccurent	in	promoter	and	enhancer	
regions	 of	 the	 genome,	 and	 an	 increased	 methylation	 leads	 to	 a	 local	 closed	 chromatin	
structure	which	 in	many	cases	 is	associated	with	silencing	of	the	associated	gene	thus	the	
net	effect	will	 lead	to	the	lack	of	the	corresponding	functional	protein.	Epigenetic	changes	
are	influenced	both	by	genetic	(e.g.	local	DNA	sequence	variation	destroys	binding	affinity)	
and	 environmental	 (e.g.	 smoking,	 stress)	 variations	 and	 represent	 important	 etiological	
triggers	 for	 ASD	 onset	 (Loke,	 Hannan,	 &	 Craig,	 2015;	 Zhubi,	 Cook,	 Guidotti,	 &	 Grayson,	
2014).		
Thus,	given	the	complex	architecture	of	autism,	deciphering	the	various	etiologies	and	their	
role	in	the	pathophysiology	of	the	disease	is	very	challenging	due	to	the	high	number	of	risk	
genes	and	the	dynamic	gene-environment	interplay.		
	
1.6 Reversibility	of	ASD		
Although	approaches	like	DNA	microarrays	and	WGS	or	WES	have	revealed	many	mutations	
that	are	potentially	causative	for	ASD	onset,	there	are	still	no	definitive	cures	or	therapies	
available	for	this	group	of	disorders.	In	addition,	ASD	is	described	as	a	neurodevelopmental	
disorder,	 most	 often	 attributed	 to	 abnormalities	 that	 occur	 in	 one	 or	 more	 critical	
developmental	periods,	 implying	that	once	one	of	these	critical	windows	is	closed	it	might	
be	 difficult	 or	 even	 impossible	 to	 develop	 certain	 abilities	 (Espinosa	 &	 Stryker,	 2012).	 In	
other	words	 this	means	 that	 if	a	gene	 is	 required	 for	a	very	specific	developmental	 stage,	
restoring	its	activity	at	a	later	time	point	might	not	be	sufficient	to	repair	the	consequences	
of	 its	early	absence.	Therefore,	ASD	have	always	been	considered	 to	be	non-curable/non-
reversible	 disorders.	 Conversely,	 there	 are	 genes	 whose	 protein	 products	 are	 required	
throughout	the	entire	lifespan,	highlighting	the	potential	for	a	later	time	point	restoration.	
Recently,	 several	 studies	 have	 challenged	 this	 view,	 thus	 implying	 that	 correction	 of	
underlying	genetic	defects	in	certain	cases	may	allow	a	molecular	and	behavioral	plasticity	
	
	
mechanism	 in	 the	 adult	 brain	 that	 would	 compensate	 or	 even	 correct	 developmental	
defects	(Novarino	et	al.,	2012a;	Rothwell	et	al.,	2014;	Sztainberg	et	al.,	2015;	Tillotson	et	al.,	
2017).	
	
1.7 Pathophysiological	hypothesis	underlying	ASD			
Despite	accumulating	extensive	genetic	information	on	the	factors	predisposing	to	ASD,	the	
neurophysiological	substrates	 leading	to	the	onset	remain	poorly	understood.	Attempts	to	
elucidate	 these	 substrates	 have	 led	 to	 the	 emergence	 of	 several	 theories/hypothesis	
speculating	that	different	genetic	glitches	can	give	rise	to	a	similar	phenotype	thus	unifying	
genetic	factors	under	a	common	pathophysiological	umbrella	(Markram	&	Markram,	2010).	
Some	of	these	hypotheses	are	discussed	below.		
 Excitation/inhibition	(E/I)	imbalance	hypothesis	1.7.1
More	than	a	decade	ago	an	 influential	 study	postulated	that	autism	and	related	disorders	
may	arise	due	to	a	changed	ratio	between	excitation	and	inhibition	leading	to	an	increased	
excitability	of	cortical	circuitry	(Rubenstein	&	Merzenich,	2003).	Supportive	evidence	for	this	
hypothesis	 stems	 from	 a	 series	 of	 studies	 that	 modeled	 monogenic	 ASD	 syndromes	 in	
animals	(Table1).	
	
Table	1.	Monogenic	disorders	with	increased	autism	rate.		
Gene	..	 Disorder	 Rate	of	
Autism	
MR	 Function	
FMR1	 FXS	 15-30%	 +	 Translational	
repressor	
TSC1/2	 TS	 20-60%	 +	 mTOR	inhibitor	
PTEN	 Hamartoma	
Syndrome	
(ASD&macrocephaly)	
ND	 +	 PI3K/mTOR	
inhibitor	
MECP2	 Rett	syndrome	 100%	 +	 Transcriptional	
repressor	
UBE3A	 Angelman	syndrome	 40%	 +	 E3	ubiquitin	ligase	
CACNA1C	 Timothy	syndrome	 60%	 +	 L-type	 voltage-
gated	 calcium	
channel	(CaV1.2)	
SCN1A	 Dravet	syndrome	 ND	 +	 Sodium	 channel	
(NaV1.1)	
NLGN3/4	 Familial	ASD	 ND	 +	 Synaptic	adhesion	
NRXN1	 Familial	ASD	 ND	 +	 Synaptic	adhesion		
SHANK3	 Familial	ASD	 ND	 +	 PSD	scaffolding	
Many	monogenic	 disorders	 are	 associated	 with	 autism	 and	 cognitive	 impairment.	 This	 table	 illustrates	 the	
estimated	rate	of	ASD	in	each	disease	and	the	presence/absence	of	mental	retardation	(MR).	ND	–	prevalence	
of	autism	association	with	the	disorder	not	determined	(adapted	from	(Kelleher	&	Bear,	2008)).		
	
Particularly,	heterozygous	loss	of	function	mutation	of	the	sodium	channel	subunit	SCN1A	is	
causing	Dravet	syndrome	(DS),	which	is	a	severe	form	of	childhood	epilepsy	associated	with	
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ASD.	Generation	of	 a	mouse	model	 lacking	one	 copy	of	 the	 Scn1a	 gene	 selectively	 in	 the	
GABAergic	forebrain	neurons	(the	main	cell	type	affected	by	this	mutation)	recapitulates	all	
major	symptoms	like	seizures,	hyperactivity	or	social	dysfunction	(Han	et	al.,	2012;	Tai,	Abe,	
Westenbroek,	 Scheuer,	 &	 Catterall,	 2014).	 Interestingly,	 in	 this	 case	 a	 channelopathy	
(dysfunction	 of	 a	 sodium	 channel)	 leads	 to	 an	 interneuronopathy	 since	 the	 NaV1.1	 (the	
protein	 product	 of	 the	 Scn1a	 gene)	 is	 mainly	 present	 on	 the	 axon	 initial	 segments	 of	
parvalbumin-positive	 (Pv+)	 fast-spiking	 and	 somatostatin	 –positive	 interneurons	 in	 the	
neocortex	and	hippocampus	 (Ogiwara	et	al.,	2007;	Tai	et	al.,	2014).	Hence,	 loss	of	 its	one	
copy	prevents	inhibitory	activity	of	the	Pv+	neurons	and	leads	to	the	E/I	imbalance.		
Another	 disorder	 associated	 with	 both	 epilepsy	 and	 autistic	 behavior	 (20-60%	 of	 cases)	
(Numis	et	al.,	2011)	is	TS,	named	after	the	presence	of	cortical	malformations	that	resemble	
tubers.	TS	 is	an	autosomal	dominant	disorder	caused	by	mutations	 in	 the	genes	TSC1	and	
TSC2	which	are	both	part	of	an	upstream	complex	 that	 is	 inhibiting	mTORC1	 (mammalian	
target	 of	 rapamycin	 complex	 1)	 signaling,	 thus	 controlling	 processes	 like	 translation	 and	
growth	 in	 many	 tissues.	 In	 order	 to	 understand	 the	 underlying	 pathophysiology	 mouse	
models	 were	 generated	 in	 which	 the	 Tsc1	 gene	 was	 deleted	 selectively	 in	 glia/neural	
progenitor	 cells/forebrain	 excitatory	 neurons	 and	 they	 all	 presented	 with	 epilepsy	
highlighting	 multiple	 potential	 pathways	 for	 seizure	 onset	 (Carson,	 Van	 Nielen,	
Winzenburger,	&	Ess,	2012;	Wong	&	Crino,	2012).	Conditional	deletion	of	Tsc1	 selectively	
from	 hippocampal	 pyramidal	 neurons	 revealed	 that	 the	 primary,	 cell-autonomous	 effect	
was	 a	 weakened	 inhibition	 caused	 by	 defective	 mTOR	 activity	 which	 in	 turn	 altered	 the	
excitatory	 and	 inhibitory	 synaptic	 transmission	 leading	 to	 hippocampal	 hyperexcitability	
(Bateup	et	al.,	2013).		
A	 particular	 disorder	 where	 both	 enhanced	 inhibition	 and	 reduced	 excitation	 have	 been	
reported	in	mouse	models	is	the	RS.	RS	is	a	neurodevelopmental	syndrome	characterized	by	
mental	 retardation,	 autism	 and	 seizures.	 It	 is	 caused	 by	mutations	 in	MECP2,	 one	 of	 the	
most	dosage-sensitive	genes	involved	in	neuronal	functional	integrity,	covering	a	wide	range	
of	 phenotypes	 based	 on	 deletion/duplication/truncation	 mutations	 (Amir	 et	 al.,	 1999).	
Although	both	types	of	defects	have	been	reported,	reduced	excitation	had	a	 larger	effect	
and	it	has	been	recapitulated	across	several	studies	including	neocortical	neurons	from	KO	
mice	 (Dani	 &	 Nelson,	 2009),	 hippocampal	 neurons	 cultured	 from	 KO	mice	 (E.	 D.	 Nelson,	
Kavalali,	 &	 Monteggia,	 2006)	 and	 induced	 pluripotent	 stem	 cells	 from	 RS	 patients	
(Marchetto	et	al.,	2010).		
Thanks	to	technological	advancements	made	in	the	field	of	optogenetics	the	E/I	imbalance	
hypothesis	 could	 be	 tested	 in	 freely	moving	 animals.	 By	 building	 a	 series	 of	 optogenetic	
tools	 that	 enabled	 a	 combinatorial	 interrogation	 of	 E/I	 imbalance,	 scientists	were	 able	 to	
increase	inhibitory	cell	excitability	in	the	medial	prefrontal	cortex	of	mice	and	consequently	
rescue	social	deficits	caused	by	E/I	balance	elevation	in	real-time	(Yizhar	et	al.,	2011).			
Even	though	such	hypothesis	represent	a	very	minimalistic	concept	because	different	brain	
circuits	may	be	characterized	by	different	excitation	and	inhibition	requirements	in	order	to	
maintain	 a	 proper	 function	 (i.e.	 social	 behavior),	 they	 are	 useful	 for	 explaining	 specific	
misregulations	of	brain	circuits	involved	in	developmental	disorders	(S.	B.	Nelson	&	Valakh,	
2015).	 Namely,	 this	 hypothesis	 unifies	 evidences	 like	 the	 observation	 that	many	 ASD	 risk	
genes	 are	 linked	 to	 gain-of-function	 phenotypes	 in	 ion	 channels	 and	 synaptic	 proteins	
(Bourgeron,	2009),	the	hyperactivity	of	the	frontal	brain	regions	(J.	E.	Kim	et	al.,	2010)	and	
the	 fact	 that	 approximately	 30%	of	ASD	patients	 present	with	 clinically	 apparent	 seizures	
(Canitano,	2007).			
	
	
 Protein	synthesis	defects	in	ASD		1.7.2
Modeling	monogenic	disorders	 (Table	1)	associated	with	ASD	 in	animals	revealed	not	only	
altered	excitation/inhibition	balance,	as	seen	in	1.7.1,	but	also	a	set	of	negative	regulators	of	
synaptic	 protein	 synthesis	 which	 eventually	may	 lead	 to	 defective	 synaptic	 development,	
altered	plasticity	and	autistic	phenotypes	(Figure	4).			
A	 supportive	 evidence	 in	 this	 sense	 is	 the	 FXS,	 an	 X-linked	 form	 of	 mental	 retardation	
associated	 with	 ASD	 (15-30%)	 caused	 by	 the	 silencing	 of	 the	 FMR1	 gene,	 whose	 protein	
product,	 the	 fragile	 X	 mental	 retardation	 protein	 (FMRP),	 binds	 to	 specific	 mRNAs	 and	
represses	their	translation	(Figure	4).	FMRP	interacts	with	approximately	400	mRNAs	and	in	
FXS	 its	 absence	 leads	 to	 a	 translational	 de-repression	 of	 the	 targets	 with	 exaggerated	
protein	synthesis	(Brown	et	al.,	2001).	Knockout	mouse	models	of	the	FXS	recapitulate	the	
human	 phenotype	 and	 display	 an	 increase	 in	 cerebral	 protein	 synthesis	 explaining	 one	
prominent	 theory	 of	 FXS	 which	 states	 that	 a	 consequence	 of	 the	 increased	 protein	
translation	 leads	 to	 an	exaggerated	 long-term	depression	 (LTD)	of	 excitatory	 synapses	 via	
enhanced	mGluR5	signaling	(Darnell	&	Klann,	2013).	
In	the	same	vein,	the	altered	protein	translation	hypothesis	is	also	supported	by	TS	disorder.		
Already	 mentioned	 in	 section	 1.7.1,	 TS	 leads	 to	 an	 excitation/inhibition	 imbalance	 via	
excessive	mTORC1	activation.	One	of	the	main	effector	mechanisms	of	mTORC1	is	activation	
of	 the	 eukaryotic	 cap-dependent	 translation	 via	 binding	 of	 elongation	 initiation	 factor	 4E	
(eIF4E)	 to	 the	5’	mRNA	cap	which	 in	 turn	allows	 recruitment	of	other	elongation	proteins	
and	initiates	translation	(Richter	&	Sonenberg,	2005).	The	translation	process	is	impeded	by	
a	 family	 of	 unphosphorylated	 elongation	 binding	 proteins	 (4EBPs).	 Active	 mTORC1	
phosphorylates	4EBPs	making	them	unable	to	stall	translation	thus	allowing	cap-dependent	
initiation.	 Inactivation	 of	 Tsc1/2	 in	 hippocampal	 neurons	 upregulates	 mTORC1	 activity	
supporting	thus	enhanced	4EBPs	phosphorylation	and	increased	protein	translation	(Figure	
4).		
Loss-of-function	mutations	in	PTEN,	another	negative	regulator	of	mTORC1	signaling,	leads	
to	 hamartoma-tumor	 syndromes	 which	 include	 in	 their	 clinical	 spectrum	 ASD	 and	
macrocephaly	 (McBride	 et	 al.,	 2010).	 It	 is	 interesting	 to	 observe	 the	 association	 between	
PTEN	and	macrocephaly	especially	in	view	of	the	role	of	the	mTOR	pathway	in	regulating	cell	
proliferation	and	cell	growth,	effect	most	likely	mediated	via	translational	control	(Figure	4).	
To	support	this,	mouse	KO	models	of	Pten	cause	neuronal	hypertrophy	and	macrocephaly	
(Tilot,	Frazier,	&	Eng,	2015).		
In	addition	to	the	mTORC1	upstream	effects	of	TSC1/2	deletion,	downstream	mutations	in	
genes	like	elongation	initiation	factor	4E-binding	protein	2	(EIF4EBP2)	–	an	eIF4E	repressor	
downstream	 of	 mTORC1,	 led	 to	 altered	 protein	 translation.	 Deletion	 of	 mouse	 Eif4ebp2	
engenders	 ASD-like	 behavior,	 an	 enhanced	 translation	 of	 neuroligin	 (synaptic	 adhesion	
protein)	mRNAs	 and	 augmented	 excitatory	 synaptic	 activity.	Moreover,	 pharmacologically	
adjusting	the	eIF4E	activity	leads	to	correction	of	E/I	imbalance	and	rescue	of	social	behavior	
deficits	of	the	Eif4ebp2	knockout	mice	(Gkogkas	et	al.,	2013).		
Taken	together,	the	association	of	mutations	in	FMR1,	TSC1/2,	PTEN	and	EIF4EBP2	with	ASD	
indicates	 that	 indeed	 alterations	 in	 translational	 repression	 may	 serve	 as	 a	 plausible	
mechanism	leading	to	autistic	phenotypes.		
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Figure	4.	Neuronal	signaling	pathways	in	translational	regulation.			
The	 PI3K/mTOR	 and	 Ras/ERK	 pathways	 couple	 synaptic	 activity	 to	 downstream	 translational	 processes	 and	
play	 key	 roles	 in	 protein	 synthesis-dependent	 LTP	 (long-term	potentiation)	 and	 LTD	 (long-term	depression).	
These	 signaling	 pathways	 get	 recruited	 downstream	 of	 the	 activation	 of	 NMDA	 receptors,	 group	 I	
metabotropic	glutamate	 receptors	 (mGluR)	and	neurotrophin	Trk	 receptors	 (RYK).	Availability	of	cap-binding	
elongation	 factor	 eIF4E	 via	 phosphorylation	 of	 4E-BP	 is	 a	 main	 mechanism	 through	 which	 these	 pathways	
regulate	protein	 translation.	Depicted	 are	 also	main	 repressors	 of	 these	pathways	 (PTEN,	 TSC1/2	or	 FMRP).	
When	 mutated,	 the	 repressors	 cannot	 fulfill	 their	 normal	 constraints	 on	 synaptic	 activity-induced	 protein	
synthesis	 leading	 to	 an	 excessive	 translation	 that	 could	 explain	 one	 of	 the	 pathophysiological	 mechanisms	
behind	ASD.	à	-	phosphorylation;	----|	-	dephosphorylation	(adapted	from	(Kelleher	&	Bear,	2008)).	
	
	
	
	
	
	
	
	
	
PTEN
TSC1/2
Ras
Ras
ERK
PDK
Akt
mTOR
eIF4E 4E-BP
4E-BP
S6K
S6
eIF4E eIF4G
40S
CAP 5’UTR 3’UTRCoding sequence
PI3K
FMRP FMRP
New 
proteins
mGluR
mGluR
RYK RYK
RYK
NMDA
NMDA
Ca2+
AMPA
LTP
LTD
	
	
1.8 Discussion		
	
From	 the	 first	 description	 back	 in	 the	 early	 ‘40s	 the	 understanding	 of	 ASD	 has	 changed	
substantially.	Based	on	 the	evidence	provided	 in	 this	 chapter,	 one	 can	 conclude	 that	ASD	
research	 has	 achieved	 much:	 it	 reached	 a	 consensus	 about	 behavioral	 definition;	
acknowledged	 the	 increased	 prevalence;	 clarified	 specific	 comorbidities	 that	 accompany	
ASD;	 discovered	 numerous	 rare	 and	 common	 genetic	 variants	 together	 with	 potential	
epigenetic	 and	 environmental	 factors	 contributing	 to	 the	 overall	 ASD	 risk;	 challenged	 the	
irreversibility	 concept;	 postulated	 the	 potential	 of	 convergence	 along	 common	 biological	
pathways	 for	 many	 risk	 genes	 and	 used	 a	 systems-level	 approach	 to	 understand	
neurobiology	and	pathophysiology.		
However,	 the	 advances	 in	 ASD	 understanding	 brought	 also	 an	 increased	 complexity.	
Addressing	the	wide	genetic	heterogeneity	and	the	possible	treatments	still	remain	a	major	
challenge.	 Recent	 endeavors	 aimed	 at	 using	 genotype-	 along	 with	 phenotype-	 driven	
diagnosis	will	be	presented	 in	the	next	chapters,	highlighting	the	current	state	of	the	field	
and	paving	potential	avenues	for	individualized	interventions.		
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2 Chapter	 2	 -	 Genomics	 in	 neurodevelopmental	 disorders:	 an	 avenue	 to	
personalized	medicine	
	
2.1 Introduction		
The	past	decade	has	seen	a	rapid	development	of	precise	technological	and	methodological	
advancements	 in	genetics	and	genomics,	 thus	allowing	an	unprecedented	 identification	of	
mutations	 that	 are	 involved	 in	 complex	 neurodevelopmental	 conditions.	
Neurodevelopmental	disorders	(NDDs)	are	characterized	by	mental	impairments	that	persist	
throughout	life,	hampering	development	and	learning,	they	affect	more	than	3%	of	children	
worldwide	and	they	can	be	attributed	to	mutations	at	over	1000	loci	(Shashi	et	al.,	2014).			
Understanding	the	etiology	of	NDDs	faces	many	challenges	that	range	from	delineating	the	
heritable	genetic	components,	to	defining	individual	factors	that	predispose	to	NDD	risk	and	
to	establishing	whether	the	hundreds	of	risk	genes	implicated	might	converge	along	a	few	
biological	 pathways	 (de	 la	 Torre-Ubieta	 et	 al.,	 2016).	 In	 addition,	 the	 clinical	 and	 genetic	
heterogeneity	of	NDDs	make	diagnosing	a	lengthy	and	costly	process	complicating	the	quest	
for	personalized	medicine.	However,	the	identification	of	bona	fide	genetic	risk	factors	and	
the	use	of	 functional	genomics	 to	progress	 from	mutation	 to	phenotype	 represent	a	 solid	
foundation	 for	 the	development	of	 individualized	 therapeutic	approaches.	 In	 the	previous	
chapter	(See	chapter	1)	some	features	of	these	disorders	were	already	mentioned	and	here	
the	 importance	of	 genomics	 in	 elucidating	 the	etiology	of	NDDs	 is	 further	emphasized.	 In	
addition,	 advantages	 and	 limitations	 in	 the	 use	 of	 animal	 or	 stem	 cell	 models	 to	 study	
patient-specific	genetic	mutations	are	described.	Eventually,	the	gap	between	research	and	
translational	 medicine	 is	 bridged	 with	 a	 series	 of	 preclinical	 (See	 chapter	 3)	 and	 clinical	
findings	 that	 created	 an	 evidence-based	 framework	 of	 how	 personalized	 medicine	 can	
advance	the	treatment	of	NDDs.		
	
2.2 	Dissecting	the	genetics	of	NDDs	
Sequencing	of	the	human	and	other	mammalian	genomes	has	provided	an	important	set	of	
tools	 to	 start	 understanding	 the	 human	 genetic	 variation.	 The	 first	 steps	 to	 elucidate	 the	
genetic	 heterogeneity	 of	 NDDs	 were	 done	 by	 using	 karyotyping	 or	 fluorescence	 in	 situ	
hybridization	(FISH).	As	the	need	for	more	accurate	detection	of	nucleotide	variations	in	the	
context	of	developmental	disabilities	grew,	chromosome	microarray	(CMA)	technology	was	
developed	and	rapidly	implemented	as	part	of	first-line	evaluation	for	children	with	a	NDDs	
(Manning,	Hudgins,	Professional,	&	Guidelines,	2010;	Volkmar	et	al.,	2014).	CMA	has	set	the	
stage	for	genetic	variation	detection	but	it	was	the	advent	of	WGS	and	WES	that	led	to	the	
identification	of	many	inherited	and	de	novo	germline	variants	significantly	contributing	to	
the	total	NDD	risk	(Figure	5a,b).	
The	 study	 of	 1133	 children	with	 severe,	 undiagnosed	 developmental	 disorders,	 and	 their	
parents,	 using	 a	 combination	 of	 WES	 and	 array-based	 detection	 of	 chromosomal	
rearrangements,	 revealed	 12	 novel	 genes	 associated	 with	 NDDs.	 These	 results	 are	 of	
importance	as	they	increase	the	proportion	of	children	that	could	be	diagnosed,	from	28%	
to	 31%.	 Moreover	 they	 encourage	 nationwide	 studies	 and	 the	 sharing	 of	 plausibly	
pathogenic	 variants	 observed	 in	 undiagnosed	 patients	 on	 web	 portals	 such	 as	 DECIPHER	
(Deciphering	Developmental	Disorders,	2015).	In	a	similar	fashion,	WES	of	families	(parents,	
affected	child	and	one	unaffected	sibling)	from	the	Simons	Simplex	Collection,	enabled	the	
	
	
discovery	of	120	new	candidate	genes	with	rare	de	novo	SNV	associated	with	ASD	(Iossifov	
et	al.,	2014),(De	Rubeis	et	al.,	2014;	Sanders	et	al.,	2012)	and	the	identification	of	a	subclass	
of	candidate	genes	(e.g.	RIMS1,	CUL7)	where	transmitted	mutations	may	create	a	sensitized	
background	but	they	are	not	completely	penetrant	(Krumm	et	al.,	2015).	DNM	represent	an	
important	 cause	 of	 NDDs,	 hence	 the	 term	de	 novo	 paradigm	 for	 NDDs	was	 coined.	WES	
effectively	detected	DNM	in	patients	presenting	with	ID	(de	Ligt	et	al.,	2012;	Vissers	et	al.,	
2010)	 and	 epilepsies	 (Lin	 et	 al.,	 2017;	 Nava	 et	 al.,	 2014).	 To	 complete	 the	 mutational	
characteristics	 of	 NDDs-relevant	 risk	 genes	 and	 to	 delineate	 genic	 and	 non-genic	
susceptibility	 variants,	 researchers	 have	 used	 WGS	 of	 quartet	 families	 (parents	 and	 two	
affected	 siblings).	 The	 results	 showed	 that	 affected	 siblings	 often	 carry	 different	 relevant	
mutations	 and	 they	 also	 demonstrated	 higher	 clinical	 variability	 than	 those	 that	 shared	 a	
risk	variant	(Yuen	et	al.,	2015).		
WES	and	WGS	are	already	powerful	when	used	individually	but	researchers	have	sought	to	
cumulate	 their	 strengths	 and	 studied	 over	 17000	 DNM	 from	 3500	 trios	 across	 different	
NDDs	(ASD,	ID,	epilepsy).	The	findings	were	of	importance	for	they	not	only	showed	that	the	
elevated	DNM	 (a	 catalog	 of	 all	 the	DNM	 identified	 among	NDDs	 is	 freely	 available	 in	 the	
NPdenovo	database)	frequency	is	dominated	by	loss-of-function/deleterious	SNV	but	it	also	
identified	53	candidate	genes	that	are	associated	with	more	than	one	disorder,	suggesting	a	
possible	shared	genetic	etiology.	This	association	of	one	or	more	independent	phenotypes	
with	the	same	gene	or	variation	in	the	same	gene	is	called	phenotypic	pleiotropy	(Li	et	al.,	
2016).	 To	 better	 understand	 the	 pathophysiology	 of	 NDDs,	 it	 is	 then	 pertinent	 to	 ask	
whether	 such	 genes,	 that	 are	 associated	 with	 more	 than	 one	 disorder,	 are	 involved	 in	
common	processes,	or	are	active	only	in	discrete	brain	areas	at	specific	developmental	time	
points	(See	chapter	1	–	The	genetic	landscape	of	ASD).	
Thus,	the	abovementioned	technologies	represent	powerful	tools	for	the	molecular	genetic	
dissection	of	patients	affected	by	NDDs.	Their	venturing	into	clinical	practice	and	association	
with	the	routine	phenotype-driven	diagnosis	holds	a	promise	for	personalized	diagnosis	and	
therapy	of	NDDs.		
	
2.3 	The	promise	of	genetics			
The	 early	 occurrence	 of	 genetic	 glitches	 and	 the	 relatively	 late	 onset	 of	 symptoms	 that	
enable	 the	 diagnosis	 of	 NDDs,	 represent	 a	 major	 pitfall	 in	 identifying	 the	 cause	 and	
delivering	 the	 right	 kind	 of	 therapy.	 To	 complicate	 things	 further,	 for	 most	 of	 the	 NDDs	
therapies	hinge	largely	on	behavioral	or	educational	interventions	(Warren	et	al.,	2011)	and	
on	treating	associated	rather	than	core	symptoms	of	the	disorder.	Thus,	for	the	majority	of	
people	with	NDDs	 the	outcomes	are	poor	or	very	poor	 in	adulthood	 (Fountain,	Winter,	&	
Bearman,	2012).	Given	such	challenges,	 it	 is	relevant	to	ask	how	could	genetics	contribute	
to	their	improvement.		
First	 and	 foremost,	 genetic	 testing	 can	 lead	 to	 active	 monitoring	 and	 early	 intervention,	
even	before	the	onset	of	the	disorder.	Furthermore,	knowing	the	genetic	cause	of	a	disorder	
may	implicate	a	specific	biological	pathway	in	its	onset.	Therefore,	targeted	pharmacological	
interventions	could	be	made	with	already	existing	drugs.	Studies	reported	that	55%	of	187	
genetic	findings	led	to	changes	in	clinical	management	(Henderson	et	al.,	2014)	and	10	out	
of	118	probands	undergoing	WES	benefited	from	a	revised	diagnosis	and	clinical	assessment	
(Dixon-Salazar	et	al.,	2012).	Lastly,	since	NDDs	are	associated	with	cognitive	and	behavioral	
profiles,	genetic	 information	can	guide	the	choice	of	behavioral	 treatment	(Bruining	et	al.,	
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2014).	Nonetheless,	despite	these	advantages,	the	multiple	guidelines	proposing	the	use	of	
genetic	testing	for	individuals	with	NDDs	are	not	implemented	constantly	in	clinical	practice	
(Volkmar	et	al.,	2014).	This	is	either	due	to	scarcity	of	resources,	or	due	to	a	lack	of	medical	
staff	 prepared	 to	 analyze	 and	 interpret	 genetic	 results.	 To	 circumvent	 this,	 a	 proper	
dissemination	of	up	to	date	findings	about	NDDs	genetics	to	all	clinical	staff	is	desirable.	On	
the	other	hand,	 there	 is	genetic	counseling,	which	would	have	an	 informative	 role	among	
parents	 or	 families.	Given	 that	 the	 recurrence	 rate	with	 one	previously	 affected	 sibling	 is	
around	15%,	 in	 case	of	ASD/ID,	decisions	 regarding	 future	pregnancies	 can	be	made	with	
caution	 as	 long	 as	 the	 parents	 have	 access	 to	 specialized	 genetic	 counseling	 information	
(Wood	et	al.,	2015).		
	
2.4 Modeling	NDDs:	potentials	and	limitations		
Along	 with	 the	 genetic	 advancements	 of	 the	 past	 decade	 came	 also	 the	 generation	 and	
characterization	 of	 numerous	 models	 for	 NDDs.	 An	 ideal	 model	 of	 a	 human	 disorder	 is	
characterized	by	construct	validity	(model	mimics	the	genetic	insult	that	causes	the	disease),	
face	 validity	 (the	 model’s	 phenotype	 resembles	 the	 one	 of	 the	 human	 disease)	 and	
predictive	 validity	 (the	 model	 and	 the	 patients	 respond	 similarly	 to	 certain	 treatments)	
(Sztainberg	&	Zoghbi,	 2016).	 Several	 systems	 (cells,	 rodents,	primates)	have	been	used	 to	
generate	 models	 of	 NDDs	 that	 can	 partially	 reproduce	 disease	 features	 and	 can	 be	 of	
interest	for	understanding	underlying	mechanisms	as	long	as	researchers	acknowledge	their	
limitations	and	do	not	overestimate	their	implications	(Figure	5c).		
The	most	favored	model	organism,	the	mouse,	has	been	extensively	employed	for	modeling	
neurological	disorders	with	a	known	genetic	cause,	such	as	FXS	(Fmr1	KO)	(FXS)	(Bernardet	
&	Crusio,	2006),	Dravet	syndrome	(DS)	(Scn1a	KO)	(Han	et	al.,	2012),	Nrxn1a	KO	(Grayton,	
Missler,	 Collier,	 &	 Fernandes,	 2013),	Nlgn3	 KO	 (Baudouin	 et	 al.,	 2012),	 Phelan-McDermid	
syndrome	(PMDS-Shank	3	KO)	(Wang	et	al.,	2011)	or	RS	(Mecp2	KO)	(Hulbert	&	Jiang,	2016).	
Modeling	NDDs	in	mice	has	many	advantages	since	they	share	95-98%	genomic	equivalence	
with	 humans,	 have	 a	 relatively	 rapid	 reproduction	 time,	 are	 cost-effective	 and	 allow	
scientists	 to	 precisely	 manipulate	 their	 genome	 in	 a	 temporal/spatial	 specific	 manner.	
However,	 mice	 also	 present	 with	 important	 limitations	 like	 evolutionary	 distance	 from	
humans,	 the	 impossibility	 to	assess	certain	 features	as	 language	and	 facial	 recognition.	To	
overcome	 some	 of	 the	 limiting	 features,	 non-human	 primate	 models	 complement	 the	
mouse	 assays	 and	 due	 to	 their	 well-developed	 prefrontal	 cortex	 are	 expected	 to	 more	
closely	model	complex	behavior	and	higher	cortical	functions	(K.	K.	Watson	&	Platt,	2012),	
whereas	 zebrafish	 and	 invertebrates	 assure	 efficient,	 high-throughput	 genetic	 screens	
(McCammon	&	Sive,	2015).		
Alongside	 animal	 models,	 in	 vitro	 use	 of	 stem	 cell	 biology	 enabled	 the	 generation	 and	
characterization	of	human	neurons.	Employing	either	human	embryonic	stem	cells	(hESCs)	
or	 human	 induced	 pluripotent	 stem	 cells	 (hiPSCs)	 differentiated	 into	 functional	 neurons,	
researchers	managed	to	recapitulate	several	neuronal	synaptic	defects	for	monogenic	forms	
of	NDDs	like	RS	(Marchetto	et	al.,	2010),	FXS	(Elsabbagh	et	al.,	2012;	Urbach,	Bar-Nur,	Daley,	
&	Benvenisty,	2010),	Prader-Willi	and	Angelman	syndromes	(AS)	(Chamberlain	et	al.,	2010),	
PMDS	(Shcheglovitov	et	al.,	2013),	DS	(Jiao	et	al.,	2013)	and	Timothy	syndrome	(Birey	et	al.,	
2017;	S.	P.	Pasca	et	al.,	2011).	The	genomic	conservation,	the	high	experimental	tractability,	
the	ability	to	model	diseases	with	cells	obtained	directly	from	affected	 individuals	and	the	
unlimited	source	of	cells	to	generate	these	models	are	just	some	of	the	advantages	of	stem	
	
	
cell	based	 technologies.	Conversely,	 the	high	heterogeneity	among	 iPSCs	clones,	 the	early	
postnatal	developmental	stages	exhibited	by	neurons	differentiated	in	vitro,	the	lack	of	high	
order	 connectivity	 or	 the	 difficulty	 to	 model	 neuronal	 migration	 and	 lamination	 in	 a	 2D	
system	are	some	of	the	obvious	shortcomings	of	iPSC-derived	disease	models.	Fortunately,	
recently	several	researchers	developed	protocols	for	the	generation	of	3D	cortical	organoids	
(mini-brains/spheroids)	providing	avenues	to	study	features	of	cortical	lamination	and	brain	
development	 in	 vitro	 (Hattori,	2014;	A.	M.	Pasca	et	al.,	 2015)	 thus	 contributing	additional	
tools	for	studying	the	mechanisms	underlying	NDDs	(Birey	et	al.,	2017;	Quadrato,	Brown,	&	
Arlotta,	2016).		
	
2.5 Bridging	 the	 gap	 between	 research	 and	 clinic	 –	 personalized	
therapeutic	approaches	for	NDDs			
Axiomatically	 the	 biggest	 advantage	 of	 genetic	 studies	 is	 to	 provide	 clues	 about	 the	
underlying	neurobiology	of	NDDs	and	transition	those	clues	into	clinical	practice	(Figure	5d).		
At	 present,	 the	 available	 treatment	 for	 NDDs	 consists	 of	 a	 combination	 of	 behavioral	
therapies	 (Zarafshan,	 Salmanian,	 Aghamohammadi,	Mohammadi,	 &	Mostafavi,	 2017)	 and	
drugs	approved	for	ameliorating	comorbidities	like	irritability,	anxiety	and	seizures,	while	in	
many	cases	the	core	symptoms	of	NDDs	remain	unsolved.		
However,	the	combination	of	genetics	and	functional	analysis	led	to	the	discovery	of	several	
molecular	 pathways	 involved	 in	 NDDs	 that	 were	 targeted	 to	 evaluate	 novel	 therapeutic	
strategies.	Particularly,	inhibiting	the	mechanistic	target	of	rapamycin	(mTOR)	led	to	rescue	
of	 physiological,	 morphological	 and	 behavioral	 abnormalities	 in	 mice	 modeling	 diseases	
associated	 with	 protein	 translation	 defects	 like	 TS	 (Tsai	 et	 al.,	 2012),	 PTEN-associated	
macrocephaly	 (Zhou	 et	 al.,	 2009)	 or	 15q11-13	 duplication	 syndrome	 (Oguro-Ando	 et	 al.,	
2015).	Multiple	 clinical	 trials,	with	pending	 results,	 are	 investigating	 the	pharmacokinetics	
and	pharmacodynamics	of	rapamaycin	and	its	analogs	(sirolimus,	everolimus)	for	treating	TS	
with	 associated	 ASD	 (Budde	 et	 al.,	 2016;	 Kohrman,	 2012).	 Increasing	 levels	 of	 IGF1	 and	
BDNF	via	 transcriptional	modulation	 through	phosphatidylinositol	3-kinase	 (PI3K)	 signaling	
also	rescued	certain	physiological	and	behavioral	anomalies	in	RS	mouse	models	(Castro	et	
al.,	2014;	Kline,	Ogier,	Kunze,	&	Katz,	2010).	Clinical	studies	investigating	the	use	of	human	
recombinant	IGF1	in	treating	patients	with	RS	(Pini	et	al.,	2016)	or	with	PMDS	(Kolevzon	et	
al.,	2014)	show	some	promising	results.	IGF1	administration	leads	to	a	higher	endurance	to	
social	 and	 cognitive	 testing	 in	patients.	Modulation	of	excitation/inhibition	 ratio	has	been	
completed	with	antagonists	of	mGluRs	or	agonists	of	GABA	A	and	GABA	B	 receptors,	 and	
has	 shown	 varying	 degrees	 of	 preclinical	 efficacy	 in	 mouse	 models	 of	 FXS	 displaying	
increased	mGluR5	signaling	(Darnell	&	Klann,	2013).	However,	several	finished	clinical	trials	
with	FXS	patients	did	not	report	encouraging	results.	Contrary	to	what	was	predicted	by	a	
decade	 of	 studies	 in	 FXS	 animal	 models,	 administration	 of	 mavoglurant,	 an	 mGluR5	
antagonist	 (Berry-Kravis	 et	 al.,	 2016)	 or	 arbaclofen,	 a	 GABA	 B	 receptor	 agonist	 (Lozano,	
Martinez-Cerdeno,	&	Hagerman,	2015;	Veenstra-VanderWeele	et	al.,	2017),	to	adolescents	
and	adults	showed	no	significant	improvement	of	behavioral	traits	in	a	randomized,	double-
blind,	 placebo-controlled	 phase	 2	 trial.	 Conversely,	 in	 a	 mouse	 model	 of	 PMDS	 with	
complete	 deletion	 of	 Shank3,	 researchers	 reported	 a	 decreased	 mGluR5	 signaling	 in	 the	
striatum	and	cortex.	The	administration	of	a	benzamide	derivative	leads	to	an	augmentation	
of	 mGluR5	 activity	 and	 rescues	 the	 functional	 and	 behavioral	 defects	 in	 mice.	 Thus,	
pharmacological	 treatments	aimed	at	 increasing	mGluR5	activity	may	 represent	an	option	
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for	 patients	 with	 SHANK3	 mutations	 (Vicidomini	 et	 al.,	 2017;	 Wang	 et	 al.,	 2016).	 The	
contrasts	between	mGluR5	activity	 in	FXS	and	PMDS	suggest	that	the	dysfunction	 leads	to	
distinct	 phenotypes	 in	 different	 brain	 regions/genetic	 backgrounds	 highlighting	 the	
importance	 of	 genetically	 discriminating	 between	 different	 forms	 of	 NDDs	 and	 the	
convergence	onto	a	common	molecular	pathway	underlying	NDDs	pathophysiology	(Figure	
5d).		
Recently,	new	approaches	for	the	treatment	of	ASDs	have	been	proposed	using	compounds	
for	 which	 the	 study	 rationale	 was	 based	 on	 genetic	 findings.	 For	 instance,	 AS	 is	 mostly	
caused	 by	 loss-of-function	mutations	 in	 the	maternal	 allele	 of	 the	 imprinted	 UB3A	 gene,	
while	the	paternal	allele	is	silenced	by	a	long	noncoding	RNA	(UBE3A	antisense	transcript).	
Using	 antisense	 oligonucleotides	 (ASOs)	 (Figure	 5d)	 the	 paternal	 allele	 was	 unsilenced	
restoring	the	UB3A	protein	levels	and	leading	to	improvement	of	cognitive	deficits	in	an	AS	
mouse	model	(Meng	et	al.,	2015).	Following	a	similar	rationale,	ASOs	were	used	at	restoring	
normal	 levels	 of	MeCP2	 and	 rescuing	 neurological	 deficits,	 both	 impaired	 social	 behavior	
and	seizures,	in	a	mouse	carrying	an	extra	copy	of	Mecp2	(Sztainberg	et	al.,	2015).	Replacing	
a	 defective	 gene	may	 as	 well	 be	 achieved	 by	 gene	 therapy	 using	 adeno-associated	 virus	
(AAV)	 vectors	 (Gadalla	 et	 al.,	 2017).	 However,	 making	 ASOs	 and	 AAV	 amenable	 to	
translation	 into	 clinical	 trials	 is	 challenging	 due	 to	 their	 safety,	 pharmacokinetics	 and	
distribution	in	the	brain	(Beaudet	&	Meng,	2016).	In	a	similar	vein,	WES	of	consanguineous	
families	with	ASD,	ID	and	epilepsy	led	to	the	identification	of	mutations	in	the	gene	BCKDK	
(Branched	 Chain	 Ketoacid	 Dehydrogenase	 Kinase),	 encoding	 an	 enzyme	 regulating	 the	
catabolism	of	the	branched-chain	amino	acids	 (BCAAs).	The	Bckdk	mouse	model	displayed	
abnormal	 brain	 amino	 acid	 profiles	 and	 dietary	 supplementation	with	 the	missing	 BCAAs	
reversed	 certain	 neurological	 phenotypes	 (Figure	 5d).	 Furthermore,	 BCAAs	 dietary	
supplementation	in	patients	led	to	a	normalization	of	their	plasma	BCAA	levels,	pointing	out	
the	 potential	 of	 BCAA	 supplementation	 as	 therapy	 in	 patients	 with	 BCKDK	 mutations	
(Garcia-Cazorla	et	al.,	2014;	Novarino	et	al.,	2012a).	
Besides	 identifying	new	 targets	 for	 therapy,	 genetic	 findings	are	 suitable	 for	personalizing	
existing	 pharmacotherapy	 or	 behavioral	 interventions.	 In	 this	 sense,	 WES	 with	 targeted	
gene	analysis	(e.g.	SCN8A,	KCNQ2)	is	an	effective	diagnosis	tool	for	patients	with	epilepsies	
influencing	 anti-epileptic	 drug	 selection,	 adverse	 effect	minimization	 and	 consideration	of	
epilepsy	surgery	based	on	each	patient’s	genetic	script	(Balestrini	et	al.,	2017).	In	the	case	of	
people	with	SHANK3	deletions,	they	tend	to	have	more	advanced	receptive	communication	
skills	than	verbal	language	ability	(Phelan	&	McDermid,	2012)	thus	they	could	rather	benefit	
from	assistive	communication	strategies	that	may	not	have	been	in	focus	unless	the	genetic	
cause	of	their	ASD	was	known.		
Newly,	 a	 very	 common	 trend	 uses	 genetic	 findings	 for	 the	 application	 of	 targeted	 drug	
repurposing	 based	 on	 single	 gene	 defects	 (Figure	 5d).	 Such	 an	 approach	 already	 appears	
promising	 for	 personalizing	 therapies	 for	 epilepsy	 cases	 arising	 from	 gain-of-function	
mutations	 in	 ion-channel	 subunit	 genes	 (e.g.	 GRIN2A,	 GRIN2B,	 SCN8A).	 Nonetheless,	
important	 barriers	 remain	 in	 order	 to	 translate	 these	 approaches	 to	 non-ion	 channel	
epilepsy	 genes	 and	 loss-of-function	mutations	 (Hu,	 Chen,	Myers,	 Yuan,	&	Traynelis,	 2016;	
Symonds,	Zuberi,	&	Johnson,	2017).	Likewise,	recent	observations	indicate	that	metformin,	
a	 worldwide	 first-line	 therapy	 for	 type	 2	 diabetes,	 rescues	 core	 phenotypes	 in	 adult	 FXS	
mice	 due	 to	 a	 normalization	 of	 ERK	 signaling,	 of	 eIF4E	 phosphorylation	 and	 of	 matrix	
metalloproteinase	 9	 expression	 (MMP-9)	 (Gantois	 et	 al.,	 2017).	 Given	 that	 the	 previously	
mentioned	clinical	trials	with	mGluR5	antagonists	have	failed,	metformin	represents	a	new	
	
	
therapeutic	avenue	for	clinical	studies	involving	FXS	patients.	Administration	of	oxytocin,	a	
peptide	 usually	 administered	 to	 initiate	 uterine	 contractions	 that	 also	 appears	 to	 be	
involved	 in	modulating	 social	behavior,	 improved	ASD-like	 social	deficits	 in	 several	mouse	
models	 (Insel,	 2010)	 and	 in	 a	 Shank3-deficient	 rat	 (Harony-Nicolas	 et	 al.,	 2017),	 but	 the	
clinical	effectiveness	of	oxytocin	on	ASD	should	still	be	considered	tentative	due	to	mixed	
findings	(Ooi,	Weng,	Kossowsky,	Gerger,	&	Sung,	2017).	
	
	
	
Figure	5.	Genomic	sequencing	guides	the	way	from	patient	DNA	to	personalized	medicine.			
(A).	 Patient	 DNA	 used	 for	 sequencing.	 (B).	 Next	 generation	 sequencing	 helps	 deciphering	 the	 genetic	 code	
within	exons	(dark	blue	section	-	whole	exon	sequencing)	or	throughout	the	entire	genome	(dark	and	light	blue	
section	-	whole	genome	sequencing).	Mutations	are	identified	in	a	series	of	genes	that	are	NDDs	predisposing	
(pink	ovals).	(C).	The	mutations	are	regenerated	in	models	(mice,	organoids	or	hESC	derived	neurons)	in	order	
to	 understand	 their	 underlying	 mechanism.	 (D).	 Disease	 modeling	 reveals	 targets	 that	 enable	 the	
implementation	of	personalized	medicine.	ASO	(antisense	oligonucleotides	-	gray	panel)	and	BCAA	(branched	
chain	amino	acids	-	beige	panel)	are	two	examples	of	personalized	therapies	probed	in	mouse	models.	mGLUR	
(metabotropic	glutamate	receptor)	activity	(green	panel)	needs	to	be	decreased	in	FXS	and	increased	in	PMDS.	
Drug	 repurposing	 (blue	 panel)	 enables	 the	 usage	 of	 the	 same drug	 for	 different	 diseases	 due	 to	 novel	
mechanisms	identified.		
	
2.6 	Discussion	
Genetic	 findings	 provide	 a	 solid	 causal	 foundation	 for	 understanding	 the	 relationship	
between	molecular	pathways,	cellular	and	circuit	dysfunction	and	eventually	behavior.		
The	clinical	impact	of	genetic	knowledge	is	already	relevant	in	daily	practice,	where	for	one	
third	of	the	individuals	with	a	NDD	the	genetic	etiology	can	be	established	thus	guiding	the	
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identification	 of	 treatable	 somatic	 comorbidities	 and	 the	 implementation	 of	 genetic	
counseling.		
Research	done	with	animal	models	and	in	human	cell	lines	helped	putting	into	context	the	
observations	from	post-mortem	human	brains	and	the	genetic	glitches	identified	in	patients	
suffering	 from	NDDs.	However,	 for	every	question	answered	there	 is	at	 least	another	one	
arising	due	to	the	very	complex	genetic	nature	of	NDDs	acknowledging	the	evermore	need	
for	an	interdisciplinary	approach	combining	genetics,	functional	genomics	and	experimental	
design	 and	 their	 integration	 into	 a	 robust	 biological	model.	 Disease	modeling	 is	 indeed	 a	
lengthy	process	that	requires	years	of	research	but	in	the	end	it’s	a	requisite	that	allows	a	
safe	knowledge	transition	from	the	bench	to	the	clinic.		
Based	 on	 considerations	 derived	 from	 experimental	 modeling,	 potential	 treatments	 for	
certain	NDDs	made	it	to	the	clinical	trial	avenue	and	most	of	them	have	simply	failed.	Such	
endeavors	robustly	point	out	the	current	obstacles	in	the	translatability	process:	finding	the	
critical	time	window	for	treatment,	given	the	developmental	roles	of	many	NDDs	genes	and	
the	right	outcome	measurement,	choosing	the	right	 target,	designing	correctly	 the	clinical	
trials,	placebo	effects	or	the	mere	lack	of	overlap	between	preclinical	models	and	humans.	
In	 this	 sense,	 one	of	 the	most	 pertinent	 examples	 is	 the	one	of	 the	 FXS	 trials	where	one	
plausible	 explanation	 of	 the	 negative	 results	 could	 be	 the	 fact	 that	 the	mGluR5	 theory	 is	
either	not	valid,	either	the	cohort	was	not	properly	stratified	(e.g.	per	age)	or	 it	manifests	
differently	in	humans	compared	to	rodents.	Furthermore,	identifying	objective	measures	of	
response,	such	as	biomarkers	(Loth	et	al.,	2016)	that	are	robust	and	ideally	have	a	parallel	in	
animal	models,	will	add	to	the	current	efforts	of	shifting	from	the	one-size-fits-all	model	to	
personalized	treatment	models.	In	chapter	3	a	potential	personalized	treatment	model	will	
be	described	based	on	preclinical	data	that	could	set	the	road	for	a	possible	transition	into	a	
future	clinical	trial.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
3 Chapter	3	-	 Impaired	amino	acid	transport	at	the	blood	brain	barrier	 is	a	
cause	of	autism	spectrum	disorder	
	
3.1 Summary		
	
In	 a	 previous	 article,	 abnormalities	 in	 the	 branched	 chain	 amino	 acid	 (BCAA)	 catabolic	
pathway	were	described	as	a	cause	of	ASD.	Here	we	show	that	the	solute	carrier	transporter	
7a5	 (SLC7A5),	 a	 large	 neutral	 amino	 acid	 transporter	 localized	 at	 the	 blood	 brain	 barrier	
(BBB),	has	an	essential	role	in	maintaining	normal	levels	of	brain	BCAAs.	In	mice,	deletion	of	
Slc7a5	 from	 the	 endothelial	 cells	 of	 the	 BBB	 leads	 to	 atypical	 brain	 amino	 acid	 profile,	
abnormal	 mRNA	 translation	 and	 severe	 neurological	 abnormalities.	 Furthermore,	 we	
identified	 several	 patients	 with	 autistic	 traits	 and	 motor	 delay	 carrying	 deleterious	
homozygous	 mutations	 in	 the	 SLC7A5	 gene.	 Finally,	 we	 demonstrate	 that	 BCAA	
intracerebroventricular	 administration	 ameliorates	 abnormal	 behaviors	 in	 adult	 mutant	
mice.	Our	data	elucidate	a	neurological	syndrome	defined	by	SLC7A5	mutations	and	support	
an	essential	role	for	the	BCAA	in	human	brain	function.		
	
3.2 Introduction	
Autism	spectrum	disorders	(ASD)	is	a	group	of	syndromes	of	heterogeneous	etiologies.	The	
genetic	architecture	of	ASD	 is	very	complex	and	mutations	 in	a	single	gene	rarely	account	
for	a	significant	proportion	of	ASD	patients.	Despite	their	genetic	heterogeneity,	ASD	may	be	
less	diverse	functionally.	Indeed,	in	many	instances	the	great	number	of	genes	implicated	in	
neurological	disorders	converges	on	a	smaller	number	of	biological	pathways	(See	chapter	
1)	(De	Rubeis	et	al.,	2014).	
We	 recently	 identified	 mutations	 in	 the	 gene	 branched	 chain	 keto-acid	 dehydrogenase	
kinase	(BCKDK)	in	several	patients	with	ASD,	ID	and	epilepsy	(Novarino	et	al.,	2012a,	2012b).	
BCKDK	 is	the	enzyme	responsible	for	the	rate-limiting	step	in	the	catabolic	pathway	of	the	
Branched	Chain	Amino	Acids	 (BCAAs),	 a	 group	of	essential	 amino	acids	 comprising	 valine,	
leucine	 and	 isoleucine.	 The	 most	 direct	 consequence	 of	 BCKDK	 mutations	 is	 a	 hyper-
catabolism	 of	 the	 BCAAs,	 resulting	 in	 abnormally	 low	 levels	 of	 serum	 and	 brain	 BCAAs	
(Novarino	et	al.,	2012a,	2012b).				
The	brain	is	dependent	on	a	constant	supply	of	BCAAs	from	the	periphery.	Should	BCAAs	be	
substantially	 important	 for	 the	brain,	 factors	 facilitating	BCAA	uptake	might	be	 critical	 for	
the	 proper	 function	 of	 the	 central	 nervous	 system.	 The	 Large	 Neutral	 Amino	 Acid	
Transporter	 1	 (LAT1)	 is	 encoded	 by	 the	 SLC7A5	 gene	 (Verrey,	 2003).	 The	 transporter	 is	
localized	 at	 the	 blood	 brain	 barrier	 (BBB)	 and	 forms	 a	 heterodimer	with	 the	 glycoprotein	
CD98,	encoded	by	the	SLC3A2	gene.	
Here	we	studied	a	mouse	model	in	which	Slc7a5	was	deleted	from	the	BBB	and	found	that	
Slc7a5	 is	particularly	 important	 to	set	brain	BCAA	 levels	within	a	normal	 range.	Mice	with	
defective	BCAA	transport	at	the	BBB	show	abnormal	activation	of	the	amino	acid	response	
(AAR)	 pathway	 and	 a	 corresponding	 reduction	 in	 mRNA	 translation	 along	 with	 neuronal	
activity	 imbalance	and	behavioral	problems.	To	probe	whether	SLC7A5	 is	 essential	 also	 in	
humans,	we	performed	genetic	analysis	of	a	cohort	of	neurological	pediatric	patients.	We	
identified	and	functionally	validated,	mutations	in	SLC7A5	 in	several	patients	with	ASD	and	
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motor	 coordination	problems.	Notably,	neurological	 abnormalities	 can	be	 treated	 in	adult	
mice	by	3-week	long	intracerebroventricular	(i.c.v.)	BCAA	delivery.	
	
3.3 Methods		
	
Experimental	model	and	subject	details		
	
*Unless	otherwise	specified,	experiments	were	performed	by	Dora	Clara	Tărlungeanu.	
	
Mice			
Experiments	 were	 performed	 in	 accordance	 with	 protocols	 approved	 by	 the	 Institutional	
Animal	Care	and	Use	Committee	at	IST	Austria.	Generation	of	the	Tie2-Cre	and	Slc7a5	floxed	
lines	 has	 been	 described	 previously	 (Kisanuki	 et	 al.,	 2001;	 Sinclair	 et	 al.,	 2013).	 For	 all	
experiments	 we	 made	 use	 of	 littermates	 derived	 from	 crossing	 Cre	 negative	 Slc7a5fl/fl	
females	with	Cre	positive	Slc7a5fl/+	males.	Mice	were	backcrossed	to	the	N10	generation	in	
C57BL/6J	 mice.	 Overall,	 Tie2Cre;Slc7a5fl/fl	 transgenic	 animals	 were	 viable	 and	 fertile.	 Mice	
were	housed	together	with	their	littermates	in	groups	of	3-4	animals	per	cage	and	kept	on	a	
regular	 12	 h	 light/dark	 cycle	 (7:00-19:00	 light	 period).	 Food	 and	water	were	 available	 ad	
libitum.	Experiments	were	carried	out	under	pathogen-free	conditions	and	health	status	of	
the	mouse	 line	was	 routinely	 checked	by	a	veterinary.	Experiments	were	carried	out	with	
randomly	 chosen	 littermates	 of	 the	 same	 sex.	 Both	 males	 and	 females	 were	 used	 with	
exception	of	 the	 three-chamber	 test	 for	which	only	males	were	employed.	The	genotype,	
age	 and	 developmental	 stage	 of	 the	 employed	 animals	 are	 specified	 separately	 for	 each	
experiment.	For	all	the	experiments	the	animals	were	drug	and	test	naïve	but	when	possible	
mice	were	employed	for	different	tests	starting	with	the	 less	aversive	test	 (see	behavioral	
study	description).		
	
Human	subjects	and	sample	collection	
Patients	were	 identified	from	a	cohort	of	over	2500	families,	with	at	 least	one	member	of	
the	family	displaying	a	childhood	onset	neurological	condition	of	likely	genetic	origin,	from	
several	 world-wide	 recruitment	 efforts	 targeting	 patients	 with	 intellectual	 disability,	
structural	brain	diseases	or	neurodevelopmental	disorders.	Recruitment	was	focused	in	the	
major	population	centers	of	the	Middle	East	including	Morocco,	Libya,	Egypt,	Saudi	Arabia,	
Kuwait,	UAE,	Oman,	Jordan,	Pakistan,	Turkey	and	Iran,	with	consanguinity	rates	(i.e.	rate	of	
marriage	between	first	or	second	cousins)	of	approximately	50%	compared	with	<1%	is	US	
and	Western	 Europe.	 Among	 the	 recruited	 cohort,	 consanguinity	 was	 present	 in	 63%	 of	
parents,	 suggesting	 some	 bias	 in	 sampling	 towards	 those	 with	 affected	 children	 due	 to	
recessive	 disease.	 Sampling	 was	 performed	 on	 both	 parents	 and	 all	 available	 genetically	
informative	siblings	to	include	affected	and	unaffected	members,	as	well	as	extended	family	
members	if	appropriate,	consistent	with	IRB	guidelines.	All	patients	were	evaluated	directly	
by	one	of	the	co-authors	with	specialty	training	in	neurology,	child	neurology	and/or	clinical	
genetics,	and	in	accordance	with	local	medical	practices.	All	patients/families	enrolled	in	IRB	
approved	 protocols	 based	 at	 referral	 institutions,	 and	 each	 family	 provided	 consent	 for	
study.	Sequencing	was	performed	on	at	least	one	but	sometimes	two	affected	or	the	father-
mother-affected	 trio	per	 family.	 Families	1426	and	1465	were	 identified	and	employed	 in	
this	 study	 because	 of	 comprising	 patients	 with	 homozygous	 disruptive	 mutations	 in	 the	
	
	
SLC7A5	gene.	Diagnosis	of	autism	was	set	prior	to	whole	exome	sequencing	and	according	
to	internationally	accepted	guidelines	(DSM-V	and	CARS	interview).	Videos	documenting	the	
neurological	examination	and	clinical	features	documentation	were	obtained	in	most	of	the	
cases.	
	
Patient	1426-5	(female)	was	born	at	full	term	by	normal	delivery	to	a	healthy	mother	after	
an	uneventful	 pregnancy.	 There	was	no	history	of	 intellectual	 disability	 or	 epilepsy	 in	 the	
family.	No	chromosomal	abnormalities	were	identified.	Occipito-frontal	head	circumference	
(OFC)	was	 -2	 SD	 at	 birth	 and	 -5	 SD	 in	 late	 childhood.	 The	 girl	 never	 learned	 to	walk;	 she	
shows	increased	tone,	clonus	and	dystonia	since	5	years	of	age.	She	can	bear	some	weight	
on	 the	 legs	 with	 support.	 She	 shows	 impaired	 social	 interaction,	 eye-to-eye	 gaze,	 and	
restrictive	behaviors	but	has	a	social	smile.	She	can	understand	simple	commands	but	does	
not	have	speech.	CARS	(childhood	autism	rating	scale)	score	at	the	age	of	33	was	31	(autism	
cutoff	 30).	 She	 has	 no	 seizures	 and	 she	 does	 not	 take	 any	medication.	 She	 has	 no	 other	
health	problems.	There	are	no	progressive	features.		
	
Patient	 1426-6	 (male),	 1426-8	 (female),	 1426-16	 (male)	 and	 1426-19	 (male)	 presentation	
and	 history	 are	 essentially	 similar	 to	 patient	 1426-5.	 In	 late	 childhood	 all	 the	 patients	
present	 with	 various	 degrees	 of	 microcephaly	 (see	 Figure	 10B).	 CARS	 score	 for	 patients	
1426-6	and	1426-8	were	31	and	34	at	the	age	of	17	and	12	years,	respectively.	Patient	1426-
16	died	of	an	unrelated	cause	during	the	preparation	of	this	manuscript;	therefore	there	is	
not	updated	information	for	this	patient.	
Importantly,	 all	 the	 affected	 individuals	 of	 family	 1426	 have	 normal	 plasma	 amino	 acid	
concentrations	(Table	S5).			
	
Patient	1465-3	(male)	was	the	second	child,	born	to	consanguineous	parents	(who	were	first	
cousins)	at	full	term,	after	an	uneventful	pregnancy.	He	presented	with	intractable	epilepsy	
and	neurodevelopmental	delay	during	his	infancy	period.	The	medical	history	of	the	family	
is	 notable	 for	 a	 previous	 case	 of	microcephaly.	 The	 patient	 began	walking	 at	 48	months.	
Upon	examination,	his	weight,	height	and	head	circumference	measurements	were	under	
3rd	 percent,	 he	 was	 hypotonic	 and	 microcephalic	 with	 slightly	 dysmorphic	 face.	 He	 was	
unable	to	speak.	He	had	joint	laxity	in	his	lower	extremities	and	pes	planus	in	both	feet.	
Patient	 1465-4	 (male)	 has	 also	 been	 born	 at	 full	 term	 after	 a	 normal	 pregnancy,	 but	
displayed	similar	symptoms	of	abnormal	development.	Like	his	brother,	he	was	brought	to	
medical	attention	due	 to	 intractable	 seizures,	which	 started	when	he	was	 six	months	old.	
When	 he	 was	 24-months-old	 he	 was	 able	 to	 sit	 without	 support.	 He	 never	 developed	
speech.	At	the	time	of	examination,	he	was	found	to	have	microcephaly,	hypotonia,	slightly	
dysmorphic	face,	scoliosis,	decreased	subcutaneous	fatty	tissue	and	joint	laxity	in	his	hands	
and	lower	extremities.	He	was	unable	to	speak	or	write,	and	was	able	to	walk	with	support.	
	
*Patient	 recruitment	and	 characterization	was	done	by	Majdi	Kara	 -	 Libya,	 Fatma	Mujgan	
Sonmez	-	Turkey,	Kaya	Bilguvar	-	USA,	Anide	Johansen	-	USA,	Seham	Esharif	-	Libya,	Tawfeg	
Ben-Omran	-	Qatar,	Meral	Topcu	-	Turkey,	Murat	Gunel	-	USA	and	Joseph	Gleeson	-	USA.		
	
Cell	lines	
Mutant	and	control	fibroblasts	were	generated	from	explants	of	dermal	biopsies	following	
informed	consent	under	protocols	approved	by	the	University	of	California	San	Diego	or	Yale	
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University.	Primary	skin	fibroblasts	from	affected	and	unaffected	passage-matched	controls	
were	cultured	 in	Dulbecco’s	Modified	Eagle	Medium	supplemented	with	10%	 fetal	bovine	
serum	and	1X	Penicillin-Streptomycin.	Cell	 lines	were	maintained	 in	a	5%	CO2	incubator	at	
37oC.	Cell	lines	were	routinely	tested	to	exclude	Mycoplasma	contaminations.		
	
Protein	model	
The	 SLC7A5	 homology	 model	 was	 built	 based	 on	 the	 X-ray	 structure	 of	 the	
agmatine/arginine	 AdiC	 transporter	 from	 E.	 Coli	 in	 the	 outward-occluded	 arginine-bound	
conformation	(PDB	identifier	3L1L	(Gao	et	al.,	2010)).	SLC7A5	and	AdiC	are	members	of	the	
amino	 acid-polyamine-organocation	 (APC)	 transporter	 superfamily	 and	 exhibit	 sequence	
identity	of	about	22%	(Geier	et	al.,	2013;	Saier,	Yen,	Noto,	Tamang,	&	Elkan,	2009).	We	used	
PyMOL	to	visualize	the	model	and	predict	possible	mutation	effect	on	the	protein	structure	
(DeLano,	2002).	
	
*In	silico	design	was	done	by	Avner	Schlessinger	–	USA.	
	
Amino	acid	analysis		
	
Plasma	amino	acid	analysis	in	mice	
Adult	mice	were	 euthanized	 by	 cervical	 dislocation,	 decapitated	 and	 blood	was	 collected	
(200	 µL)	 from	 their	 trunks	 into	 commercially	 available	 anticoagulant	 treated	 tubes	 (e.g.	
heparin	 tubes	 Vacuette,	 Greiner	 Bio	 One).	 Cells	 were	 removed	 from	 plasma	 by	
centrifugation	 for	 10	 min	 at	 2000	 X	 g	 at	 4°C.	 Following	 centrifugation	 the	 plasma	
supernatant	was	transferred	into	clean	polypropylene	tubes	and	kept	at	-70°C	until	assayed	
for	amino	acid	concentrations	by	High	Performance	Liquid	Chromatography	(HPLC).	Mouse	
plasma	amino	acid	values	 reported	 in	Table	S1	 represent	mean	±	SEM	obtained	 from	n=4	
mice	per	genotype.	HPLC	measurements	were	done	at	Archimed	Life	Gmbh,	Austria.	
	
	
Plasma	amino	acid	analysis	in	humans	
Patient	 blood	 samples	 were	 collected	 under	 fasting	 conditions.	 Blood	 samples	 were	
collected	on	Guthrie	 cards	and	analyzed	by	 LC-MS/MS	and	 flow	 injection	analysis-tandem	
mass	spectrometry	(FIA-MS/MS)	(Novarino	et	al.	2012).	Plasma	amino	acid	values	reported	
in	Table	S5	are	the	result	of	a	single	blood	amino	acid	test.	Similarly,	previous	investigation	
didn’t	reveal	serum	amino	acid	levels	abnormalities.	
	
*Patient	 recruitment	and	 characterization	was	done	by	Majdi	Kara	 -	 Libya,	 Fatma	Mujgan	
Sonmez	-	Turkey,	Kaya	Bilguvar	-	USA,	Anide	Johansen	-	USA,	Seham	Esharif	-	Libya,	Tawfeg	
Ben-Omran	-	Qatar,	Meral	Topcu	-	Turkey,	Murat	Gunel	-	USA	and	Joseph	Gleeson	-	USA.	
	
Brain	amino	acid	analysis	in	mice		
Adult	mice	were	euthanized	by	cervical	dislocation,	decapitated	and	the	left	hemisphere	of	
the	 brain	was	 collected,	weighed	 and	 immediately	 homogenized	 in	 1	ml	 of	 ice-cold	 radio	
immunoprecipitation	 assay	 (RIPA)	 buffer	 (50	 mM	 Tris-HCl,	 pH=7.4,	 1%	 NP-40,	 0.5%	 Na-
deoxycholate,	 0.1%	 SDS,	 150	 mM	 NaCl,	 2	 mM	 EDTA	 –	 all	 from	 Sigma-Aldrich)	 in	 the	
presence	 of	 cOmplete	 Protease	 Inhibitor	 Cocktail	 (Complete,	 Roche).	 The	 tissue	 was	
disrupted	using	a	glass	homogenizer,	transferred	into	a	collecting	tube,	and	left	on	ice	for	1	
	
	
hour.	The	homogenate	was	centrifuged	 for	40	minutes	at	100,000	X	g	at	4°C	 in	a	SW41Ti	
rotor	in	a	Beckman	Optima	XPN-80	ultracentrifuge	(Beckman	Coulter),	the	supernatant	was	
collected	and	deproteinized	by	the	addition	of	an	equal	volume	of	a	solution	of	8%	(wt/vol)	
5-sulfosalicylic	 acid	 (Sigma-Aldrich)	 and	 stored	 at	 -70°C	 until	 assayed	 for	 amino	 acid	
concentrations.	At	the	time	of	the	assay,	the	samples	were	thawed,	mixed,	centrifuged	for	
30	 min	 at	 5,000	 X	 g	 at	 4°C	 to	 remove	 the	 precipitated	 protein	 and	 assessed	 by	 HPLC	
(performed	 at	 Archimedlife	 GmbH).	 Four	 to	 eight	 animals	 per	 genotype/per	 time	 point	
(E14.5,	 P2	 and	 P40)	 were	 employed	 for	 determination	 of	 brain	 amino	 acid	 levels.	 HPLC	
analysis	 was	 performed	 blinded	 to	 genotype.	 Brain	 amino	 acid	 samples	 were	 tested	 in	
duplicate	in	2	to	3	independent	experiments	except	for	the	E14.5	for	which	all	the	samples	
were	 measured	 in	 duplicate	 but	 collected	 and	 measured	 at	 the	 same	 day.	 HPLC	
measurements	were	done	at	Archimed	Life	Gmbh,	Austria.	
	
RNA-sequencing	
Adult	mice	were	euthanized	under	anesthesia	and	the	brains	were	quickly	dissected	on	ice.	
The	cerebellum	was	used	for	RNA	extraction	by	using	700	µL	Trizol	(Thermo	Fisher	Scientific)	
for	 homogenization	 and	 140	 µL	 chloroform	 (Sigma-Aldrich),	 followed	 by	 centrifugation	 at	
12000g	for	15	minutes	at	4°C.	The	upper	aqueous	phase	was	transferred	to	a	new	tube	and	
1.5	 volumes	 of	 100%	 ethanol	 were	 added.	 Total	 RNA	 was	 extracted	 by	 using	 the	 RNA	
Clean&Concentrator-5	 prep	 Kit	 (Zymo	 Research).	 RQ1	 RNase-Free	 DNase	 (Promega)	
treatment	was	also	applied	as	described	in	the	kit	instructions	manual.	RNA	sample	quality	
was	checked	by	using	the	NanoDrop	spectrophotometer	(Thermo	Fisher	Scientific)	and	the	
Bioanalyzer	2100	with	the	RNA	6000	Nano	kit	(Agilent).	Then	1.5	µg	total	RNA	was	used	to	
generate	 cDNA	 libraries	by	 following	 the	manufacturer’s	 instructions	 in	 the	SENSE	mRNA-
Seq	Library	Prep	Kit	V2	(Lexogen).	Quality	check	of	the	generated	libraries	was	assessed	by	
using	 the	 Bioanalyzer	 2100	 with	 the	 High	 Sensitivity	 DNA	 Analysis	 Kit	 (Agilent).	 Libraries	
were	sequenced	on	Illumina	HiSeq	2500	instrument.	
	
Western	blot		
Adult	mice	were	euthanized	under	anesthesia,	the	brain	was	dissected	and	homogenized	in	
ice-cold	RIPA	buffer	(50	mM	Tris-HCl,	pH=7.4,	1%	NP-40,	0.5%	Na-deoxycholate,	0.1%	SDS,	
150	mM	NaCl,	2	mM	EDTA	–	all	from	Sigma-Aldrich)	supplemented	with	cOmplete	Protease	
Inhibitor	 Cocktail	 (Complete,	 Roche)	 and/or	 with	 phosphatase	 inhibitor	 cocktail	 3	 (Sigma	
Aldrich).	After	1	hour	of	incubation	on	ice,	the	lysates	were	centrifuged	at	4°C	at	14.000g	for	
15	minutes.	The	protein	concentration	of	the	supernatant	was	measured	using	the	BioRad	
protein	assay	method	 (BioRad).	 For	 the	Western	blot,	30-50	μg	proteins	were	mixed	with	
Laemmli	 buffer	 6x	 (375	 mM	 Tris	 pH=6.8,	 12%SDS,	 60%	 glycerol,	 600	 mM	 DTT,	 0.06%	
bromphenol	blue	–	all	fro	Sigma-Aldrich),	heated	to	95°C	and	then	separated	on	6-15%	SDS-
PAGE	 gels	 in	 running	 buffer	 (3.03	 g	 Tris	 base,	 14.1	 g	 glycine,	 1	 g	 SDS	 –Sigma-Aldrich,	 1	 L	
MilliQ	 water).	 Proteins	 were	 transferred	 to	 a	 nitrocellulose	 membrane	 using	 a	 transfer	
buffer	(3.03	g	Tris	base,	14.1	g	glycine,	1	L	MilliQ	water)	for	2	hours	at	4°C	in	a	Bio-Rad	Micro	
Cell	Western	blotting	apparatus	(300	mA	constant	intensity).	The	membranes	were	blocked	
for	 1	 hour	 with	 5%	 milk	 in	 1x	 TBS	 with	 1%	 Tween	 (TBST)	 and	 incubated	 with	 primary	
antibody	 overnight	 at	 4°C.	 After	 4x10	 min	 washes	 with	 TBST,	 the	 membranes	 were	
incubated	 with	 the	 secondary	 antibody	 for	 1	 hour	 at	 room	 temperature.	 Horseradish	
peroxidase	coupled	anti-IgG	antibody	was	detected	using	an	enhanced	chemiluminescence	
substrate:	 Pierce	 ECL	 kit/Super	 Signal	 West	 Pico	 kit/Super	 Signal	 West	 Femto	 Maximum	
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Sensitivity	Substrate	(Thermo	Fisher	Scientific).	The	following	primary	antibodies	were	used:	
rabbit	 anti-4E-BP1	 (1:1000,	 Cell	 Signaling,	 9644);	 rabbit	 anti-phospho-4E-BP1(1:1000,	 Cell	
Signaling,	2855);	 rabbit	anti-eIF4E	 (1:1000,	Cell	Signaling,	2067);	 rabbit	anti-phospho-eIF4E	
(1:1000,	 Cell	 Signaling,	 9741);	 rabbit	 anti-eIF2	 alpha	 (1:1000,	 Cell	 Signaling,	 9722);	 rabbit	
anti-phospho-eIF2	 alpha	 (1:1000,	 Cell	 Signaling,	 3398);	 rabbit	 anti-S6K	 (1:1000,	 Cell	
Signaling,	 2708);	 rabbit	 anti-phspho-S6K	 (1:1000,	 Cell	 Signaling,	 9234);	 rabbit	 anti-VGAT	
(1:200,	 Millipore,	 AB5062P);	 mouse	 anti-Tubulin	 beta	 3	 (1:1000,	 BioLegend,	 MMS-435P).	
Secondary	 antibodies:	 donkey	 anti-rabbit	 HRP	 (1:1000,	 Thermo	 Scientific,	 A16035);	 goat	
anti-mouse	HRP	(1:1000,	Thermo	Scientific,	31432).	Each	western	blot	was	repeated	at	least	
in	2	independent	experiments.	
	
Polysome	profiling	
Adult	mice	were	euthanized	by	cortical	dislocation,	dissected	and	the	brains	were	removed.	
Cortices	were	separated	and	lysed	in	Lysis	Buffer	(20	mM	HEPES	pH	7.4,	150	mM	KCl,	5	mM	
MgCl2,	 0,5	mM	DTT,	 100	 µg/mL	 cycloheximide-	 Sigma-Aldrich,	 Roche	 Complete	 Protease	
Inhibitors	 (EDTA-free),	 40	 U/mL	 RNAsin	 -	 Promega,	 20	 U/mL	 Superasin	 –	 Thermo	 Fischer	
Scientific)	using	a	dounce.	Lysates	were	centrifuged	for	10	min	at	2000	x	g	at	4°C	and	the	
resulting	 supernatants	were	supplemented	with	NP-40	and	Triton	X-100	 (both	 to	1%)	and	
incubated	on	 ice	for	5	min.	After	centrifugation	for	10	min	at	20000	x	g	at	4°C	the	debris-
free	 supernatants	 were	 flash-frozen	 and	 stored	 at	 -80°C	 until	 further	 use.	 Thawed	
supernatants	were	 loaded	 onto	 14	 ×	 95mm	Polyclear	 centrifuge	 tubes	 (Seton)	 containing	
17.5–50%	 sucrose	 gradients	 (in	Gradient	 Buffer	 containing	 20	mM	Tris-HCl	 pH	7.4,	 5	mM	
MgCl2,	 150	mM	NaCl,	 1	mM	DTT,	 100	µg/mL	 cycloheximide);	 the	 sucrose	 gradients	were	
generated	 using	 the	 Gradient	 Master	 108	 programmable	 gradient	 pourer	 (Biocomp)	 and	
were	 centrifuged	 for	 2.5	 h	 at	 35,000	 r.p.m.	 in	 a	 SW40Ti	 rotor	 in	 a	 Beckman	 L7	
ultracentrifuge	 (Beckman	 Coulter).	 After	 centrifugation	 gradients	 were	 fractionated	 and	
measured	for	RNA	content	using	a	Piston	Gradient	Fractionator	(Biocomp)	attached	to	a	UV	
monitor	(BioRad).	Data	represents	mean	±	SEM	obtained	from	n=9	KO	and	10	WT	mice	from	
N=2	independent	experiments.			
	
*Polysome	 profiling	was	 done	 by	 Dora	 Clara	 Tărlungeanu	 in	 collaboration	with	 Christoph	
Janiesch	and	Kent	Duncan	–	ZMN	Hamburg,	Germany.	
	
Immunohistochemistry	
Adult	 mice	 were	 anesthetized	 by	 intraperitoneal	 injection	 (i.p.)	 of	 Ketamin	 100mg/kg,	
Xylazine	10mg/kg	and	Acepromazin	3mg/kg	as	a	mixture	in	one	syringe.	Unconscious	state	
of	the	mouse	was	verified	by	pinching	the	hind	limb	(interdigital	reflex).	The	diaphragm	was	
opened	from	the	abdominal	side	to	expose	the	heart.	A	small	incision	was	made	in	the	right	
atrium	and	a	butterfly	needle	was	placed	in	the	left	ventricle	to	infuse	phosphate	buffered	
saline	(PBS	–	Sigma-Aldrich)	solution	(25	mM	Phosphate	Buffer	(PB),	0.9%	NaCl)	at	7	ml/min	
for	 2	minutes	using	 a	perfusion	pump.	Afterwards	 the	PBS	was	exchanged	with	 a	 fixative	
solution	 consisting	 of	 4%	 Paraformaldehyde	 (PFA-	 Sigma-Aldrich)	 +	 0.05%	Glutaraldehyde	
(Sigma-Aldrich)	solution	in	0.1M	PB	(5-10	minutes).	The	brains	were	removed	and	post-fixed	
overnight	in	4%	PFA	at	4°C.	Next,	brains	were	cryoprotected	in	30%	sucrose	solution	at	4°C	
for	 one	 day	 and	 embedded	 in	 Optimum	 Cutting	 Temperature	 (O.C.T.,	 Tissue	 Tek)	 or	
removed	from	the	sucrose	and	kept	on	dry	ice	and	sliced.	Free-floating	20	µm	sections	were	
cut	using	either	a	Microm	HM560	cryostat	(Thermo	Fisher	Scientific)	or	a	sliding	VT	1200S	
	
	
vibratome	 (Leica	 Microsystems).	 Cryostat	 sliced	 sections	 were	 used	 for	 stainings	 that	
required	antigen	retrieval	(e.g.	SLC7A5	staining)	whereas	the	vibratome	sliced	sections	were	
used	for	non-antigen	retrieval	staining	and	were	collected	in	PBS.	Slices	were	washed	twice	
with	PBS	 (10	min)	 at	 room	 temperature	and	 then	antigen	 retrieval	was	performed	 for	20	
min	at	98°C	in	Target	Retrieval	Solution	(Dako)	pH=6	in	an	electric	pot.	Samples	were	cooled	
to	 room	 temperature	and	 then	washed	again	 twice	with	PBS	 (10	min).	 The	 sections	were	
permeabilized	in	0.5%	Triton-X	100	in	PBS	for	30	minutes	and	then	blocked	for	40	min	in	5%	
normal	 goat	 serum	 (Sigma-Aldrich)	 in	 0.5%	 Triton-X	 100	 in	 PBS	 at	 room	 temperature.	
Sections	were	 then	 incubated	 overnight	with	 primary	 antibody	 at	 4°C.	 The	 sections	were	
washed	(3x10	min)	with	0.01%	Triton-X	100	in	PBS	and	incubated	with	secondary	antibody	
for	1	hour	at	room	temperature	in	a	dark	place.	Sections	were	incubated	with	DAPI	(10	min)	
and	then	washed	(3x10	min)	with	0.01%	Triton-X	100	in	PBS	and	mounted	onto	glass	slides	
with	 Mowiol	 (Sigma-Aldrich).	 Fluorescent	 signal	 was	 detected	 using	 a	 LSM	 700	 inverted	
confocal	microscope	(Zeiss).	The	following	primary	antibodies	were	used:	rabbit	anti-SLC7A5	
(1:200,	 received	 from	 Prof.	 Kanai	 (Matsuo	 et	 al.,	 2000));	 rat	 anti-MECA32	 (1:600,	 Novus	
Biologicals,	NB100-77668);	rabbit	anti-Parvalbumin	(1:500,	Abcam,	ab11427);	rat	anti-Ctip2	
(1:400,	 Abcam,	 ab18465);	 rabbit	 anti-Cux1	 (1:400,	 Santa	 Cruz,	 sc13024);	 rabbit	 anti-
Somatostatin	(1:1000,	Penlabs,	T-4103);	rabbit	anti-Calretinin	(1:4500,	Swant,	7697);	rabbit	
anti-VGAT	 (1:200,	 Millipore,	 AB5062P);	 rabbit	 anti-Neuroligin	 2	 (1:500,	 Synaptic	 System,	
129203).	The	secondary	antibodies	used	were:	donkey	anti-rabbit	(1:1000,	Alexa	Fluor	488,	
Life	 Technologies,	 A-21206);	 goat	 anti-rat	 (1:1000,	 Alexa	 Fluor	 647,	 Life	 Technologies,	 A-
21247).	 Immunohistochemistry	 experiments	 were	 repeated	 in	 at	 least	 3	 independent	
experiments.	
	
Nissl	staining		
Adult	 mice	 were	 anesthetized	 and	 perfused	 with	 PFA	 4%	 as	 described	 in	 the	
immunohistochemistry	section.	The	brains	were	removed	and	post-fixed	for	2	hours	 in	4%	
PFA	at	4°C.	Next,	brains	were	transferred	to	70%	ethanol	overnight	at	4°C.	The	next	day	the	
ethanol	 was	 replaced	 with	 fresh	 70%	 ethanol	 for	 another	 hour	 at	 room	 temperature,	
followed	 by	 90%	 ethanol	 for	 3	 hours	 at	 room	 temperature	 and	 eventually	 100%	 ethanol	
overnight	 at	 room	 temperature.	On	 the	 following	 day	 brains	were	 placed	 in	 a	 1:1	mix	 of	
100%	 ethanol	 :	 paraffin	 solution	 (ethanol	 is	 added	 from	 time	 to	 time	 to	 avoid	 complete	
evaporation)	 for	 12	 hours	 at	 65°C	 and	 then	 moved	 to	 paraffin	 overnight	 at	 65°C	 in	 an	
incubator.	 After	 this	 step	 brains	 were	 left	 to	 solidify	 in	 paraffin	 blocks	 and	 then	 10	 µm	
sections	were	cut	on	a	HM	355S	Microtome	(Thermo	Fisher	Scientific).	Paraffin	slices	were	
cleared	with	warm	Roti-Histol	(Carl	Roth)	for	10	min	and	passed	through	absolute	ethanol	to	
water	(96%,	90%,	70%,	50%,	30%,	water)	each	step	for	5	min.	Slices	were	then	kept	 in	1%	
Cresyl	 Violet	 acetate	 (Thermo	 Fisher	 Scientific)	 solution	 for	 4	min,	 followed	by	 destaining	
solution	(100	ml	ethanol	with	2	ml	100%	acetic	acid)	for	5-10	sec,	absolute	ethanol	for	30	
sec	and	final	absolute	ethanol	for	1	min.	At	the	end	slices	were	cleared	with	Roti-Histol	(10	
min)	and	mounted	with	DPX	(Sigma-Aldrich).	Images	were	acquired	using	the	BX53	upright	
light	 microscope	 with	 an	 attached	 DP70	 digital	 camera	 (Olympus)	 and	 processed	 with	
Photoshop	CS5.1	(Adobe	Systems).	Nissl	staining	observation	was	repeated	with	3	mice	per	
genotype	at	two	different	developmental	stages.	
	
Electrophysiology	
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Littermates	of	the	same	sex	but	different	genotypes	were	randomly	used	to	prepare	brain	
slices.	 Acute	 sagittal	 slices	 (300	 µm)	 were	 prepared	 from	 the	 cortex	 and	 from	 the	
cerebellum	of	19	to	22	days	old	mice	(here	referred	as	P21).	Animals	were	anesthetized	by	
an	i.p.	injection	of	a	mixture	of	ketamin	(100	mg/kg),	xylazin	(10	mg/kg)	and	acepromazin	(3	
mg/kg),	then	transcardially	perfused	with	 ice-cold	carbogenated	solution	containing	(mM):	
64	 NaCl,	 25	 NaHCO3,	 2.5	 KCl,	 1.25	 NaH2PO4,	 10	 glucose,	 120	 sucrose,	 7	MgCl2	 and	 0.5	
CaCl2	 (all	 from	 Sigma-Aldrich,	 unless	 otherwise	 stated).	 After	 decapitation,	 brains	 were	
removed	 for	 sectioning	 in	 the	 same	 ice-cold	 cutting	 solution	 using	 a	 VT	 1200S	 vibratome	
(Leica	 Microsystems).	 Slices	 were	 recovered	 in	 room-temperature	 carbogenated	 regular	
artificial	cerebrospinal	fluid	(mM):	125 NaCl,	2.5 KCl,	1.25 NaH2PO4,	25 NaHCO3,	25 glucose,	
1 MgCl2	 and	 2 CaCl2	 (~320 mOsm,	 7.2–7.4 pH)	 for	 30	min	 and	 transferred	 to	 a	 recording	
chamber	(RC-41LP,	Warner	Instruments)	for	experiments	typically	between	1	and	7	h	after	
slicing.	Slices	were	visualized	under	infrared-differential	interference	contrast	(IR-DIC)	using	
a	 BX-51WI	 microscope	 (Olympus)	 with	 a	 QIClickTM	 charge-coupled	 device	 camera	 (Q	
Imaging	 Inc,	 Surrey).	Cerebellar	Purkinje	 cells	 and	 cortical	 layer	2-3	pyramidal	 cells	with	a	
prominent	apical	dendrite	were	visually	 identified	with	a	microscope	equipped	with	IR-DIC	
optics	mainly	by	location,	shape	and	Clampex	online	membrane	test	parameters.	
Borosilicate	glass	recording	microelectrodes	(World	Precision	Instruments)	were	pulled	on	a	
P-1000	 horizontal	 puller	 (Sutter	 Instruments)	 and	 backfilled	 with	 an	 internal	 solution	
containing	 (mM):	 115 cessium	 methanesulphonate,	 8 NaCl,	 10 HEPES,	 0.3 EGTA,	 10	
Cs4BAPTA,	5 lidocaine	N-ethyl	chloride,	4 MgATP,	0.3	NaGTP,	and	0.2%	biocytin.	Internal	pH	
was	 adjusted	 to	 ~7.3	 with	 CsOH	 and	 osmolarity	 adjusted	 to	 ~295 mOsm	 with	 sucrose.	
Typical	 internal	 resistance	 was	 around	 1.7–3.5 MΩ.	 After	 seal	 rupture	 and	 internal	
equilibrium	(5 min	to	allow	proper	dialysis	of	Cs+	internally),	cells	were	recorded	with	series-
resistance	 values	 <10	 MΩ	 (recording	 traces	 were	 excluded	 for	 data	 analysis	 if	 series	
resistance	 changed	by	 >25%).	 Slices	were	perfused	with	 room	 temperature	 carbogenated	
regular	 aCSF	 at	 a	 rate	 of	 approximately	 2 ml/min−1.	 Miniature	 excitatory	 postsynaptic	
currents	(mEPSCs)	were	recorded	at	a	holding	potential	of	–70	mV	and	miniature	inhibitory	
postsynaptic	 currents	 (mIPSC)	 at	 the	 reversal	 potential	 for	mEPSC	 (+	 10	mV).	 All	 voltage	
clamp	 traces	 were	 recorded	 in	 the	 presence	 of	 1 μM	 tetrodotoxin	 (Bio	 Trend)	 with	
theoretical	 liquid	 junction	 potential	 not	 corrected	 for.	 Signals	 were	 filtered	 at	 0.1 kHz,	
digitized	 at	 10 kHz	 and	 data	 acquired	 using	 a	 MultiClamp	 700B	 amplifier	 and	 a	 Digidata	
1550A.		
	
*Electrophysiology	 experiments	 for	 Slc7a5	 mouse	 line	 were	 done	 by	 Elena	 Deliu	 –	 IST	
Austria,	for	Bckdk	mouse	line	were	done	by	Emanuela	Morelli	–	IST	Austria.	
	
Electron	microscopy		
21	days	old	mice	were	anesthetized	by	i.p.	injection	of	Ketamin	100mg/kg,	Xylazine	10mg/kg	
and	Acepromazin	3mg/kg	as	a	mixture	in	one	syringe.	Unconscious	state	of	the	mouse	was	
verified	by	pinching	the	hind	limb	(interdigital	reflex).	The	diaphragm	was	opened	from	the	
abdominal	 side	 to	 expose	 the	 heart.	 A	 small	 incision	was	made	 in	 the	 right	 atrium	and	 a	
butterfly	 needle	was	 placed	 in	 the	 left	 ventricle	 to	 infuse	 PBS	 at	 7	ml/min	 for	 2	minutes	
using	 a	 perfusion	 pump.	 Afterwards	 the	 PBS	 was	 exchanged	 with	 a	 fixative	 solution	
containing	 4%	 PFA	 +	 5%	 Glutaraldehyde	 in	 0.1M	 PB	 (5-10	 minutes).	 The	 brains	 were	
removed	and	post-fixed	overnight	in	a	0.4%	PFA	in	0.1M	PB	at	4°C.	70	µm	sections	were	cut	
using	 a	 Vibroslicer	 (Leica	 Microsystems),	 collected	 in	 PB	 and	 stored	 in	 PB+0.02%	 NaN3.	
	
	
Sections	were	washed	in	PB	and	osmified	with	2%	osmium	(Agar	Scientific	Ltd)	in	0.1M	PB	
for	45	min	at	room	temperature.	They	were	then	washed	in	0.1M	PB	(10	min)	and	distilled	
water	 (3x10	min),	and	contrasted	with	0.1%	uranylacetate	(Agar	Scientific)	 in	50%	ethanol	
solution	 for	 30	 min	 at	 room	 temperature	 in	 the	 dark.	 Samples	 were	 washed	 in	 distilled	
water	(3x10	min)	and	dehydrated	in	ascending	ethanol	solutions	(50%,	70%,	90%,	96%	and	
100%	for	10	min	each),	infiltrated	in	propylene	oxide	(2x10	min)	and	embedded	in	Durcupan	
ACM	 (Sigma-Aldrich):	 propylene	oxide	mix	1/2	 for	 1h	at	 room	 temperature,	 2/1	 for	 1h	at	
room	 temperature	 and	 mere	 Durcupan	 overnight	 at	 room	 temperature.	 Samples	 were	
mounted	on	siliconized	coverslips,	placed	on	a	heating	plate	for	30	min	at	37°C	and	put	in	an	
oven	for	2	days	at	60°C	to	polymerize	resin.	The	region	of	interest	(layer	2/3	somatosensory	
cortex)	was	cut	and	re-embedded	in	a	resin	block	for	further	slicing.	70	nm	ultrathin	serial	
sections	were	 cut	using	an	UC7	ultramicrotom	 (Leica	Microsytems),	 collected	on	 formvar-
coated	copper-slot	grids	and	examined	 in	FE-SEM	Merlin	VP	Compact	with	STEM	detector	
(Zeiss).		
	
*Sample	preparation	was	done	by	Dora	Clara	Tărlungeanu	in	collaboration	with	the	Electron	
Microscopy	facility	–	IST	Austria.	
	
Behavioral	studies	
All	behavioral	studies	were	carried	out	during	the	light	period.	Mice	were	habituated	to	the	
test	 room	for	at	 least	1	h	before	each	 test.	 In	order	 to	 recover,	mice	were	given	one	day	
between	tests.	All	behavior	apparatuses	were	cleaned	between	each	trial	with	70%	ethanol.	
All	 behavioral	 tests	were	 performed	 starting	with	 the	 least	 aversive	 task	 first	 and	 ending	
with	the	most	aversive.	Behavioral	 tests	were	performed	with	P55	to	P65	mice	except	 for	
the	 juvenile	 social	 interaction	 test	 for	which	 P25	 to	 P35	 animals	were	 employed	 and	 the	
ultrasonic	vocalization	test	for	which	P2	to	P10	pups	were	used.	Data	are	presented	as	mean	
±	SEM.	
Open	field	test	
Exploratory	behavior	 in	a	novel	environment	was	assessed	by	a	20	min	session	in	an	open	
field	chamber	(45cmL	x	45cmW	x30cmH)	made	out	of	grey	Plexiglas.	The	animal	was	placed	
in	 the	 center	 of	 the	 arena	 and	 then	 recording	 was	 started.	 Locomotor	 activity	 (distance	
traveled	and	velocity)	in	the	center/periphery	of	the	arena	as	well	as	rearing	were	recorded	
by	using	a	video	camera	and	analyzed	using	the	EthoVision	XT	11.5	software	(Noldus).		
Three	chamber	test	
Mice	were	tested	for	sociability	as	described	previously	(Moy	et	al.,	2007).	Specifically,	the	
testing	 apparatus	was	 a	 rectangular	 clear	 Plexiglas	 three	 chambers	 box	 (60cm	 (L)	 x	 40cm	
(W)	x	20	cm	(H)).	The	dividing	walls	had	doorways	allowing	access	to	each	chamber.	Age	and	
sex	matched	animals	were	used	for	all	tests.	C57BL/6J	mice	were	used	as	stranger	mice	and	
were	habituated	to	placement	 inside	the	wire	cage.	Each	test	animal	was	 first	placed	 into	
the	 center	 chamber	 with	 open	 access	 to	 both	 left	 and	 right	 chamber,	 each	 chamber	
containing	an	empty	round	wire	cage.	The	wire	cage	(12cmH,	11cm	diameter)	allows	nose	
contact	between	mice	but	prevents	fighting.	After	10	min	of	habituation,	during	the	social	
phase,	 an	age-matched	 stranger	was	placed	 in	 the	 left	 chamber	while	 a	novel	object	was	
placed	 into	 the	 right	 chamber.	 The	 test	 animal	 was	 allowed	 to	 freely	 explore	 the	 social	
apparatus	for	10	min	and	show	whether	it	prefers	to	interact	with	the	novel	object	or	with	
the	stranger	mouse.	At	the	end	of	the	first	10	min,	each	mouse	was	tested	in	a	second	10	
min	 session	 to	 evaluate	 the	preference	 for	 a	 novel	 stranger,	which	was	placed	 inside	 the	
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right	 wire	 cage.	 Number	 of	 nose	 contacts	 (<5cm	 proximity)	 with	 the	 caged	 mouse	 was	
calculated.		
Juvenile	social	interaction	
Juvenile	social	interactions	were	assessed	in	25-35	days	old	mice	in	the	Noldus	PhenoTyper	
3000	 Observer	 chamber	 (30cm	 (L)	 x	 30cm	 (W)	 x	 35	 cm	 (H))	 as	 previously	 described	
(Silverman	et	al.,	2011).	Prior	to	the	interaction	session	mice	were	individually	housed	for	1	
hour.	Two	animals	were	placed	simultaneously	in	the	chamber	and	then	recording	started.	
Three	 types	 of	 interactions	 were	 assessed:	 wild-type/knockout;	 wild-type/wild-type	 and	
knockout/knockout,	between	age	and	sex	matched	subjects.	 Interactions	were	tracked	for	
10	min	using	a	digital	 camera	 incorporated	 in	 the	PhenoTyper	 chamber.	 Ineractions	were	
scored	using	 the	EthoVision	XT	11.5	software	 (Noldus)	and	 included	number	of	nose-nose	
sniffing	and	distance	between	subjects.			
Walking	beam	test	
Fine	 motor	 coordination	 and	 balance	 was	 assessed	 by	 the	 beam	 walking	 assay	 (Carter,	
Morton,	&	Dunnett,	2001).	This	test	essentially	examines	the	ability	of	the	animals	to	remain	
upright	 and	 to	 walk	 on	 an	 elevated	 and	 relatively	 narrow	 beam.	 The	 beam	 apparatus	
consists	of	several	1	meter-long	beams	with	diameters	of	5	cm,	3	cm	and	1	cm,	resting	50	
cm	above	the	floor	on	two	poles.	During	the	test	a	mouse	is	placed	on	one	extremity	of	the	
beam	and	a	black	box	was	placed	at	the	end	of	the	beam	as	finish	point.	The	test	took	place	
over	3	consecutive	days,	2	days	training	and	1	day	testing	(3	trials	per	day).	In	between	trials	
mice	were	allowed	to	rest	in	their	cages	for	10	min.	On	the	training	days	mice	were	allowed	
to	cross	the	5	and	3	cm	beams	while	on	the	test	day	mice	walked	on	the	1	cm	beam.	A	nylon	
hammock	was	stretched	below	the	beam	to	cushion	any	falls.	A	video	camera	was	set	on	a	
tripod	to	record	the	performance.	Performance	on	the	beam	was	quantified	by	measuring	
the	latency	to	cross	the	beam.		
Isolation-induced	ultrasonic	vocalizations	(USVs)	in	mouse	pups	
Whistle	 like	sounds	(between	30-90	kHz)	were	recorded	from	newborn	pups	as	previously	
described	(Scattoni,	Crawley,	&	Ricceri,	2009).	A	microphone	(part	of	the	Noldus	UltraVox	XT	
system)	was	 placed	 inside	 a	 dark,	 soundproof	 polycarbonate	 box	 (37cm	 (L)	 x	 37cm	 (W)	 x	
57cm	(H)).	Neonatal	pups	(postnatal	days	2,	4,	6,	8,	10)	were	separated	from	their	mother	
and	placed	inside	the	recording	chamber.	USVs	were	recorded	for	3	minutes	and	afterwards	
the	pup	was	placed	back	with	its	mother	until	weaning	time.		
Gait	measurement	test	
Gait	was	 analyzed	 by	 performing	 the	 footprint	 test	 as	 previously	 described	 (Carter	 et	 al.,	
2001).	 Specifically,	 the	 fore	 and	 hind	 paws	 were	 painted	 with	 nontoxic	 dyes	 of	 different	
colors	and	then	the	mouse	was	allowed	to	walk	in	a	straight	line	(in	a	narrow	corridor	using	
as	bait	a	cage	at	the	end	of	the	walkway)	over	absorbent	paper.	The	footprint	patterns	were	
then	analyzed	for	stride	length,	sway	length	and	stance	length.		
Marble	burying	test	
Stereotyped	behavior	was	assessed	by	placing	adult	mice	(60	days	old)	into	an	usual	animal	
cage	 (30cm	 (L)	 x	 20cm	 (W)	 x	 20cm	 (H),	 Tecniplast)	 filled	with	 5cm	deep	 chip	 bedding,	 as	
previously	described	(Deacon,	2006).	Bedding	was	reused	between	sex	matched	animals.	A	
regular	pattern	of	glass	marbles	(5	rows	of	4	marbles)	was	placed	on	the	bedding	and	the	
subject	was	allowed	to	explore	for	25	min.	The	number	of	buried	(to	2/3	of	their	depth	in	
bedding)	marbles	was	counted.		
Hind	limb	clasping	test	
	
	
As	 previously	 described	 (Guyenet	 et	 al.,	 2010),	 mice	 were	 grasped	 by	 their	 tail	 and	
suspended.	Hind	limb	position	was	observed	for	10	seconds.	If	the	hind	limbs	were	retracted	
towards	 the	 abdomen	 then	 the	mouse	was	marked	 as	 positive	 for	 clasping.	 The	 test	was	
repeated	three	times.	At	the	end	of	the	test	the	mouse	was	placed	back	into	its	cage.	The	
test	was	repeated	three	times	for	each	animal.		
Kyphosis	test	
Kyphosis	 is	 a	 characteristic	 curvature	 of	 the	 spine	 that	 is	 common	 in	 mouse	 models	 of	
certain	neurological	disorders	(Guyenet	et	al.,	2010).	The	mouse	was	removed	form	its	cage	
and	placed	on	a	flat	surface.	While	it	was	walking,	we	observed	whether	it	was	able	to	easily	
straighten	its	spine	completely.	If	it	was	not	the	case,	the	mouse	was	marked	as	positive	for	
kyphosis.	 At	 the	 end	 of	 the	 test	 the	mouse	 was	 placed	 back	 into	 its	 cage.	 The	 test	 was	
repeated	three	times	for	each	animal.	
	
Intracerebroventricular	dye	injection	
40	days	old	mice	were	injected	s.c.	with	meloxicam	5	mg/kg	one	hour	prior	surgery	in	order	
to	achieve	analgesia	and	then	anesthetized	initially	with	isoflurane	4%	and	O2	0.5-1L/min	in	
a	 gas	 chamber.	Once	 anesthetized	 (checked	by	 toe	 pinching),	 the	mouse	was	 placed	 in	 a	
Kopf	stereotaxic	 frame	and	a	nose	cone	was	placed	over	 the	nose	with	 isoflurane	volume	
turned	 down	 to	 2%	 to	 maintain	 the	 anesthesia.	 After	 sterilizing	 the	 surgical	 site	 with	
betadine,	a	midline	incision	was	made	over	the	skull	and	a	small	hole	was	drilled	above	the	
left	lateral	ventricle.	Using	a	Hamilton	syringe,	connected	to	the	Kopf	stereotactic	frame,	10	
µL	 of	 dye	 was	 delivered	 into	 the	 ventricle	 in	 order	 to	 check	 later	 on	 the	 injection	 site	
accuracy.	The	coordinates	used	relative	to	bregma	were:	anterioposterior	 (AP)	=	 -0.5	mm,	
medial	lateral	(ML)	=	-1.1	mm,	dorsal	ventral	(DV)	=	-3	mm.	To	allow	diffusion	of	the	dye	into	
the	brain,	 the	needle	was	 left	 for	5	min	at	the	site	of	 injection.	The	 incision	was	manually	
closed	 using	 a	 topical	 tissue	 adhesive	 (GLUture,	World	 Precision	 Instruments).	 Two	 hours	
later	the	mouse	was	euthanized	and	the	brain	was	kept	overnight	in	4%	PFA.	The	next	day	
the	brain	was	embedded	 in	3%	agarose	blocks	and	then	sliced	(100	µm)	using	a	VT	1200S	
vibratome	 (Leica	Microsystems)	 in	 order	 to	 assess	 the	 diffusion	 of	 the	 dye	 in	 the	 entire	
ventricular	system	and	to	confirm	the	correct	positioning	of	the	needle	in	the	left	ventricle.		
	
Serial	surgical	implantation	of	cannula	and	osmotic	pumps	
One	day	before	the	surgery,	a	micro-osmotic	pump	(ALZET	model	1007D)	was	filled	with	100	
µL	of	a	saline	amino	acid	solution	(isoleucine	100	mM,	leucine	100	mM).	The	pump	was	then	
connected	 through	 a	 plastic	 catheter	 to	 a	 cannula	 with	 a	 0.5	 mm	 spacer	 attached	 to	 it	
(ALZET	Brain	Infusion	Kit	3).	The	pump	was	designed	to	deliver	the	solution	at	a	rate	of	0.5	
µL/hour	for	7	days.	The	pump	and	cannula	assembly	was	kept	 in	saline	overnight	at	37oC.	
Adult	mice	were	 injected	 s.c.	with	meloxicam	5	mg/kg	one	hour	prior	 surgery	 in	order	 to	
achieve	analgesia	and	then	anesthetized	initially	with	isoflurane	4%	and	O2	0.5-1L/min	in	a	
gas	chamber.	Once	anesthetized	(checked	by	toe	pinching),	the	mouse	was	placed	in	a	Kopf	
stereotaxic	frame	and	a	nose	cone	was	placed	over	the	nose	with	isoflurane	volume	turned	
down	 to	 2%	 to	 maintain	 the	 anesthesia.	 Eyes	 were	 covered	 with	 ointment	 in	 order	 to	
prevent	drying	out.	During	surgery	metamizol	200mg/kg	was	administered	subcutaneously	
(s.c.)	to	ensure	maintenance	of	analgesia.	After	sterilizing	the	surgical	site	with	betadine,	a	
midline	 incision	was	made	 over	 the	 skull	 and	 a	 subcutaneous	 pocket	was	 created	 on	 the	
back	 of	 the	 animal.	 The	 pump	was	 then	 inserted	 inside	 the	 pocket	 and	 a	 small	 hole	was	
drilled	 above	 the	 left	 lateral	 ventricle	 following	 the	 coordinates	 identified	 during	 the	
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calibration	study	performed	with	dye	injections	and	as	previously	described	(DeVos	&	Miller,	
2013),	AP	=	-0.5	mm,	ML	=	-1.1	mm,	DV	=	-2.5	mm.	The	incision	was	manually	closed	using	a	
topical	 tissue	 adhesive	 (GLUture,	 World	 Precision	 Instruments).	 The	 incision	 site	 was	
sterilized	with	 betadine	 and	 an	 ointment	was	 applied	 to	 keep	 the	 spot	moisturized.	 One	
week	later	the	pump	was	replaced	with	a	200	µL	micro-osmotic	pump	(ALZET	model	2002)	
filled	with	the	same	amino	acid	solution	as	mentioned	above.	The	replacement	procedure	
was	done	following	the	same	steps	as	described	for	the	100	µL	pump.	The	mice	were	singly	
caged	until	the	time	for	behavioral	testing	(e.g.	walking	beam	test,	gait	measurement,	open	
field	test).	Behavioral	tests	were	performed	with	P55	to	P65	mice.	At	the	end	of	the	three-
week	 administration,	 mice	 were	 euthanized	 and	 their	 brains	 were	 dissected	 for	 HPLC	
protein	 analysis.	 Data	 represent	 means	 ±	 SEM;	 n=10	 (untreated)	 control,	 n=4	 (treated)	
control,	n=11	(untreated)	mutant	and	n=8	(treated)	mutant	mice.	
	
Whole	exome	sequencing,	homozygosity	profile	and	variant	prioritization	
DNA	was	extracted	from	peripheral	blood	leukocytes	using	salt	extraction.	For	family	1426	
blocks	 of	 homozygosity	 were	 determined	 by	 HomozygosityMapper.	 Whole-Exome	
Sequencing	 and	 variant	 analysis	was	 performed	using	 solution	hybrid	 SureSelect	 reagents	
(Agilent,	Mountain	View,	CA)	and	sequenced	on	an	Illumina	GAIIx	or	HiSeq2000	instrument	
(Gnirke	 et	 al.,	 2009).	 The	 sequence	 reads	 were	 aligned	 to	 the	 human	 genome	 (hg19),	
genetic	 variants	 were	 delineated	 using	 the	 Genome	 Analysis	 ToolKit	 (GATK	 1.1)	 software	
and	SAMTools	(v1.4-r985)	algorithms,	for	both	single	nucleotide	polymorphisms	(SNPs)	and	
Indels.	
Variants	were	prioritized	using	the	following	criteria:	
1.	The	variant	was	predicted	to	perturb	protein	function.	All	synonymous	and	
intronic	variants	were	excluded	unless	the	variant	was	within	a	predicted	splice	site	(+	or	-2	
bp	 from	 splice	 junction).	 Any	 variation	 that	 was	 predicted	 to	 alter	 gene	 expression	 or	
protein	function	was	included.	These	included	nonsynonymous	variations	in	coding	regions	
(i.e.	missense)	or	 alterations	 resulting	 in	 frameshifts,	 premature	 stop	 codons,	 loss	of	 stop	
codons,	coding	INDELS,	and	splice	sites	(i.e.	±	2	nucleotides	from	an	exon	junction).	
2.	The	variant	was	rare	as	defined	by	allele	frequency	of	less	than	0.2%.	Allele	frequencies	
were	determined	by	an	in-house	database	of	over	1500	Middle	Eastern	exomes,	and	public	
databases	provided	by	The	Exome	Variant	Server	from	NHLBI	GO	Exome	Sequencing	Project	
(ESP)	and	dbSNP135.		
3.	The	variant	was	present	in	a	region	of	homozygosity	as	defined	by	HomozygosityMapper		
4.	 The	 variant	was	 highly	 conserved	 throughout	 evolution	 as	 determined	by	 a	 number	 of	
conservation	 scores	 including	 GERP,	 PhastCons,	 and	 PolyPhen2.	 Variations	 with	 negative	
GERP	 scores	 or	 vertebrate	 PhastCons	 scores	 less	 than	 .8	 were	 excluded.	 Typical	
conservation	 criteria	 for	 the	 candidate	 genes	 provided	 in	 this	 study	 were	 GERP	 >	 4	 and	
vertebrate	PhastCons	>	.9.	
5.	The	variant	segregated	with	the	disease	in	the	family	pedigree.	All	variants	following	the	
above	criteria	were	considered	for	each	family	independent	of	its	predicted	severity	(i.e.	no	
variants	were	excluded	based	upon	type	of	mutation).	
	
The	 remaining	 variants	were	 ranked	by	 type	of	mutation	 (indels	 >	 nonsense	 >	missense),	
amino	acid	conservation	across	species	and	protein	damage	prediction	based	upon	location	
of	 the	mutation	 in	a	 specialized	protein	domain.	 The	variants	were	annotated	 for	novelty	
and	 compared	 with	 dbSNP	 (build	 132)	 and	 control	 samples	 analyzed	 by	 whole-exome	
	
	
sequencing	experiments	performed	by	our	human	genomics	groups.	Variants	were	analyzed	
against	 the	 RefSeq	 gene	 definitions,	 a	 list	 that	 includes	 18,933	 specific	 genes.	 Where	
multiple	isoforms	gave	varying	results	the	one	most	likely	to	lead	to	protein	disruption	was	
chosen.		
	
*WES	 analysis	was	 done	 by	 Ahmet	Okay	 Caglayan	 –	 Turkey/USA	 and	Gaia	Novarino	 -	 IST	
Austria.	
	
Sanger	sequencing	
Primers	 were	 designed	 using	 the	 Primer3	 program	 and	 tested	 for	 specificity	 using	
ENSEMBL's	BLAST	software.	PCR	products	were	treated	using	Exonuclease	I	(Thermo	Fisher	
Scientific)	and	Shrimp	Alkaline	Phosphatase	 (Affymetrix)	and	sequenced	using	 the	Big	Dye	
terminator	 cycle	 sequencing	 Kit	 v.3.1	 (Applied	 Biosystems)	 on	 an	 ABI	 3100	 DNA	 analyzer	
(Applied	Biosystems).	The	sequence	data	were	analyzed	using	Sequencher	4.9	(Gene	Codes).	
	
Leucine	uptake	assay		
Leucine	 uptake	 was	 performed	 as	 previously	 described	 (Sinclair	 et	 al.,	 2013).	 Briefly,	
300.000	cells	were	plated	in	a	single	well	of	6	well	plates	two	days	before	the	assay.	The	day	
of	the	experiment	the	cells	were	washed	twice	with	HBSS	and	incubated	in	HBSS	containing	
[3H]	leucine	(Perkin	Elmer)	0.5	uCi/ml	alone	or	in	the	presence	of	10	mM	leucine	or	3	mM	
BCH	 (Wang	 et	 al.,	 2011).	 Cells	 were	 incubated	 at	 37°C	 for	 1	 hour.	 At	 the	 end	 of	 the	
incubation	 each	well	 was	washed	 twice	with	 cold	 PBS	 and	 lysed	with	 1	mM	NaOH	 for	 2	
hours	at	37°C.	Total	 leucine	uptake	was	measured	by	 liquid	scintillation	counting	 (Packard	
Tri-Carb	2100TR).		
	
Cloning,	mutagenesis	and	expression	of	the	human	SLC7A5	wild-type	and	mutants		
The	 construct	 pH6EX3-wt	 SLC7A5	 obtained	 as	 previously	 described	 (Galluccio,	 Pingitore,	
Scalise,	 &	 Indiveri,	 2013)	 and	 containing	 the	 SLC7A5	 cDNA	 was	 used	 for	 site-directed	
mutagenesis.	Specific	mutants	of	the	SLC7A5	cDNA	were	obtained	by	PCR	overlap	extension	
methods,	as	previously	done	for	other	proteins	(Galluccio	et	al.,	2015),	using	the	primers	in	
Table	S4.	
	
To	 supply	 tRNA	 for	 rare	 codons,	 Rosetta(DE3)pLysS	 E.	 coli	 strain	 was	 transformed	 either	
with	SLC7A5	wild	type	or	mutant	proteins	(Galluccio	et	al.,	2013)	and	selected	on	agar	plates	
supplemented	 with	 ampicillin	 and	 chloramphenicol.	 A	 colony	 was	 picked	 and	 cultured	
overnight	at	37	°C	under	rotary	shaking	(about	200	rpm)	in	selective	LB	broth	and	the	day	
after	 was	 diluted	 1:10	 in	 same	 medium.	 When	 the	 culture	 reached	 the	 mid	 logarithmic	
phase	of	growth,	0.4	mM	IPTG	was	added	and	temperature	was	lowered	at	28°C	for	4	hours	
as	previously	described	(Galluccio	et	al.,	2013).	
	
Purification	of	human	SLC7A5	wild-type	and	mutants	
Pellets	from	induced	cell	 lysates	were	used	for	protein	purification	as	previously	described	
(Napolitano	 et	 al.,	 2015).	 In	 brief,	 after	 washing	 (0.1	 M	 Tris	 HCl	 pH	 8.0),	 pellets	 were	
solubilized	using	a	20	mM	Tris/HCl	pH	8.0	buffer	containing	10	mM	DTE,	0.8	%	sarkosyl,	3.5	
M	urea,	10	%	glycerol,	200	mM	NaCl.	Solubilized	cell	lysates	were	centrifuged	(12,000	g,	10	
min,	4	°C)	and	the	supernatants	were	applied	on	a	His	Trap	HP	column	(5	ml	Ni	Sepharose),	
connected	to	fast	protein	liquid	chromatography	(FPLC)	ÄKTA	start	and	equilibrated	with	10	
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mL	buffer	(20	mM	Tris	HCl	pH	8.0,	10	%	glycerol,	200	mM	NaCl,	0.1	%	sarkosyl,	and	DTE	2	
mM).	During	purification	procedure,	column	was	washed	with	10	mL	of	washing	buffer	(20	
mM	Tris	HCl	pH	8,	10	%	glycerol,	200	mM	NaCl,	0.1	%	n-Dodecyl	β-D-maltoside	and	3	mM	
DTE	–	all	 from	Sigma-Aldrich).	Then,	proteins	were	eluted	by	an	 isocratic	 step	of	400	mM	
imidazole	in	the	above	described	buffer.	Fractions	6-8	(2.5	mL)	were	pooled	and	desalted	on	
a	 PD-10	 column	 using	 a	 desalting	 buffer	 (20	mM	Tris	 HCl	 pH	 8.0,	 10%	 glycerol,	 0.05%	 n-
Dodecyl	β-D-maltoside	and	10	mM	DTE).	
	
Reconstitution	of	human	SLC7A5	wild	type	and	mutants	in	proteoliposomes	
The	purified	SLC7A5	wild	type	and	mutants	were	reconstituted	by	removing	the	detergent	
using	the	batch-wise	method	as	previously	described	(Napolitano	et	al.,	2015).	In	brief,	4	μg	
of	 protein	 (in	 200	 μL)	 were	 mixed	 to	 100	 μL	 of	 10%	 C12E8,	 100	 μL	 of	 10%	 egg	 yolk	
phospholipids	 (w/v)	 in	 the	 form	 of	 sonicated	 liposomes	 prepared	 as	 previously	 described	
(Scalise	et	al.,	2014),	20	mM	Tris	HCl	pH	7.5,	10	mM	DTE,	100	mM	K-gluconate	and	10	mM	l-
His,	 except	 where	 differently	 indicated,	 in	 a	 final	 volume	 of	 700	 μL.	 The	 mixture	 was	
incubated	with	0.5	g	Amberlite	XAD-4	resin	under	rotatory	stirring	(1200	rev/min)	at	room	
temperature	(25	°C)	for	90	min	(Napolitano	et	al.,	2015).	
	
Transport	measurements	
After	 reconstitution	 uptake	 and	 efflux	 experiments	 were	 conducted	 at	 25°C.	 For	 uptake	
experiments,	600	μL	of	proteoliposomes	were	passed	through	a	Sephadex	G-75	column	(0.7	
cm	diameter	×	15	cm	height)	pre-equilibrated	with	20	mM	Tris	HCl	pH	7.5	and	sucrose	at	
appropriate	 concentrations	 to	 balance	 the	 internal	 osmolarity.	 Transport	 was	 started	 by	
adding	 5	 μM	 [3H]His	 to	 the	 proteoliposomes.	 For	 efflux	 experiments,	 proteoliposomes	
containing	 2	 mM	 His,	 were	 preloaded	 with	 5	 μM	 [3H]His	 at	 high	 specific	 radioactivity	
(1μCi/ml)	 for	 30	 min	 by	 transporter-mediated	 exchange	 equilibration.	 Proteoliposomes	
were	 then	 passed	 through	 Sephadex	 G-75,	 as	 above	 described,	 to	 remove	 external	
compounds.	 Efflux	 was	 started	 by	 adding,	 or	 not,	 1	 mM	 of	 unradiolabelled	 His.	 In	 both	
uptake	 and	 efflux	 assays,	 transport	 was	 stopped	 by	 adding	 a	 mix	 of	 10	 μM	 2-amino-2-
norbornanecarboxylic	 acid	 (BCH)	 and	 1	 μM	 HgCl2	 at	 the	 desired	 time	 interval.	 In	 control	
samples,	 the	 inhibitor	 was	 added	 at	 time	 zero.	 At	 the	 end	 of	 the	 transport	 assay,	 each	
sample	of	proteoliposomes	(100	μL)	was	passed	through	a	Sephadex	G-75	column	(0.6	cm	
diameter	 ×	 8	 cm	 height)	 to	 separate	 the	 external	 from	 the	 internal	 radioactivity.	
Proteoliposomes	were	eluted	with	1	mL	50	mM	NaCl	and	collected	 in	4	mL	of	scintillation	
mixture,	vortexed	and	counted.	The	experimental	values	were	corrected	by	subtracting	each	
sample	 inhibited	at	 time	 zero.	 For	 kinetic	measurements,	 the	 initial	 rate	of	 transport	was	
measured	by	stopping	the	reaction	after	10	min,	i.e.,	within	the	initial	linear	range	of	[3H]His	
uptake.		
	
Ultracentrifugation	of	proteoliposomes	
SLC7A5	 WT	 and	 SLC7A5-A246V	 reconstituted	 proteoliposomes	 were	 passed	 through	
Sephadex	G-75	column	and	500	µl	were	ultracentrifuged	(110,000	g,	1	h	30	min,	4°C).	Pellets	
were	 washed	 with	 20	 mM	 Tris	 HCl	 pH	 8.0	 and	 ultracentrifuged	 again.	 Pellets	 were	
solubilized	 with	 3%	 SDS	 and	 subjected	 to	 SDS-PAGE	 12%	 run	 and	 western	 blot	 analysis.	
SLC7A5	WT	and	mutants	were	 immuno-detected	using	anti-SLC7A5	antibody	1:2000,	upon	
overnight	 incubation	 at	 4°C.	 The	 reaction	 was	 detected	 by	 Electro	 Chemi	 Luminescence	
(ECL)	assay	after	incubation	with	secondary	antibody	anti-rabbit	1:5000.	
	
	
	
*Proteoliposome	experiments	were	done	by	Michele	Galluccio,	Mariafrancesca	Scalise	and	
Cesare	Indiveri	–	University	of	Calabria,	Italy.		
	
Quantification	and	statistical	analysis	
	
*	Unless	otherwise	specified,	data	was	analyzed	by	Dora	Clara	Tărlungeanu.	
		
Statistical	 values	 including	 the	 exact	 n,	 statistical	 significance,	 definition	 of	 center,	 and	
dispersion	and	precision	measures	are	reported	in	the	Figure	Legends.	Student’s	t-test	was	
mostly	used	and	one-way	ANOVA	was	used	where	appropriate	(i.e.,	multiple	comparisons).	
Data	are	 shown	as	means	 ±	SEM	and	were	 judged	 to	be	 statistically	 significant	when	p	<	
0.05.	 In	 each	 graph	 circles/dots	 represent	 individual	 values.	 All	 data	 sets	 were	 analyzed	
using	Shapiro–Wilk	test	for	normality.	
	
Amino	acid	data		
Amino	acid	levels	were	normalized	on	the	initial	protein	concentration	and	are	displayed	as	
fold	 change	 (log2	 transformed)	 to	 levels	 in	 controls.	 Data	 analysis	was	 done	 in	GraphPad	
Prism	 7	 and	 student’s	 t-test	 was	 used	 to	 test	 for	 significance.	Mouse	 plasma	 amino	 acid	
values	reported	in	Table	S1	represent	mean	±	SEM	obtained	from	n=4	mice	per	genotype.	
Brain	amino	acid	values	represent	mean	±	SEM	obtained	from	4	to	8	mice	per	genotype	per	
time	point	from	at	least	2	independent	experiments.	
	
RNA-sequencing	
Demultiplexed	 raw	 reads	 were	 trimmed	 before	 alignment	 as	 suggested	 by	 the	 library	
preparation	 kit,	 i.e.	 the	 first	 9	 bases	 of	 each	 read	were	 removed	using	 the	 FASTX	 toolkit.	
Trimmed	 reads	 were	 aligned	 to	 the	 mouse	 genome	 using	 STAR	 version	 2.5.4	 (genome:	
GrCm38,	 gene	 annotation:	 Gencode	 release	 M8).	 Reads	 that	 didn’t	 align	 uniquely	 were	
discarded.	 Read	 counts	 per	 gene	 were	 also	 calculated	 using	 STAR	 (option	 -quantMode	
GeneCounts).	 Differential	 expression	 analysis	 was	 performed	 in	 R	 3.2.4	 employing	 the	
Bioconductor	package	DESeq2	version	1.10.1	using	an	FDR	threshold	of	0.05,	a	 local	fit	for	
the	 dispersion	 estimation	 and	 default	 parameters	 otherwise.	 Gene	 Ontology	 enrichment	
analysis	was	 done	 using	 the	 Bioconductor	 package	GOstats	 version	 2.36.0	with	 a	 p-value	
cutoff	of	0.001	and	conditional	testing	enabled.	GO	enrichment	results	were	visualized	using	
a	custom	script.	RNA	sequencing	was	performed	employing	n=3	mice	per	genotype.		
	
*RNA-seq	analysis	was	done	by	Christoph	P.	Dotter	–	IST	Austria.	
	
Protein	data		
	
Western	blot		
Western	 blot	 images	 were	 acquired	 by	 Peqlab	 Fusion	 SL	 Advance	 Multi	 Imaging	 system	
(VWR)	 and	 quantified	 using	 ImageJ	 software.	 Protein	 levels	 are	 displayed	 as	 fold	 change.	
Student’s	t-test	was	used	to	test	for	significance	(GraphPad	Prism	7).	Data	represent	mean	±	
SEM	 obtained	 from	 two	 to	 five	mice	 per	 genotype	 typically	 from	 at	 least	 2	 independent	
experiments.	
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Polysome	profiling		
Analysis	 was	 performed	 blinded	 to	 genotype.	 For	 quantitative	 analysis	 of	 individual	
elements	(e.g.	80S	monosomes,	polysomes,	etc)	from	the	polysome	profiles,	all	traces	were	
first	 exported	 to	 Microsoft	 Excel	 and	 adjusted	 as	 necessary	 to	 ensure	 matching	 x/y-axis	
scales.	Traces	were	then	exported	to	Photoshop	CS5.1	and	ImageJ	for	processing,	baseline	
setting,	 cropping	 and	 pixel	 counting.	 The	 pixel	 counts	 were	 used	 for	 determining	
polysome/monosome	 values	 and	 for	 plot	 generation.	 Student’s	 t-test	 was	 used	 for	 the	
statistical	analysis	(GraphPad	Prism	7).	Data	represents	mean	±	SEM	obtained	from	n=9	KO	
and	 10	 WT	 mice	 from	 two	 independent	 experiments.	 All	 data	 sets	 were	 analyzed	 using	
Shapiro–Wilk	test	for	normality.	
	
*Polysome	profiles	were	analyzed	by	Christoph	Janiesch	and	Kent	Duncan	–	ZMN	Hamburg,	
Germany.	
	
Immunohistochemistry		
Fluorescent	signal	was	detected	using	a	LSM	700	 inverted	confocal	microscope	(Zeiss)	and	
images	 were	 processed	 with	 Photoshop	 CS5.1	 (Adobe	 Systems).	 Control	 and	 mutant	
samples	 were	 always	 treated	 equally	 and	 in	 parallel	 (e.g.	 if	 brightness	 or	 contrast	 were	
adjusted	 identical	 changes	 were	 applied	 for	 all	 the	 samples).	 For	 each	 antibody,	
immunostainings	 were	 repeated	 in	 multiple	 animals	 (typically	 3	 per	 genotype)	 obtaining	
comparable	results.	We	counted	all	parvalbumin,	somatostatin	and	calretinin	 interneurons	
as	 well	 as	 VGAT	 and	 NLGN2	 puncta	 intensity	 on	 coronal	 sections	 at	 different	 positions.	
Neurons/puncta	quantified	 in	a	given	animal	were	added	 together.	Means	and	SEM	were	
calculated	 across	 animals,	 and	 student’s	 t-test	was	 done	 across	 animals	 (n=3	 animals	 per	
genotype).			
	
Neuronal	data		
Analysis	 was	 performed	 blinded	 to	 genotype	 using	 pCLAMP	 10.4	 software	 (Axon	
Instruments/Molecular	Devices).	Statistical	analyses	were	performed	using	Origin	Software	
(Origin	 Inc),	 Clampfit	 and	 R.	 All	 data	 sets	 were	 analyzed	 using	 Shapiro–Wilk	 test	 for	
normality.	Data	sets	with	normal	distributions	were	analyzed	for	significance	using	one-way	
ANOVA	measures	with	Bonferroni	post-hoc	test,	using	*P < 0.05,	**P < 0.005.	Data	sets	with	
non-normal	 distributions	 were	 analyzed	 using	 the	 2-tailed	 Mann-Whitney	 U	 test	 using	
*P < 0.05.	 Exact	 P	 values	 are	 presented	 in	 each	 figure.	 Cumulative	 distributions	 were	
analyzed	 using	 the	 Kolmogorov-Smirnov	 test.	 Data	 represent	 means	 ±	 SEM,	
ncells/nanimals/genotype:	 14/7/Tie2Cre;Slc7a5fl/+	 and	 13/5/Tie2Cre;Slc7a5fl/fl	 (mEPSC);	
16/7/Tie2Cre;Slc7a5fl/+	and	18/5/Tie2Cre;Slc7a5fl/fl	(mIPSC).		
	
*Electrophysiologal	data	for	Slc7a5	mouse	line	was	analyzed	by	Elena	Deliu	–	IST	Austria,	for	
Bckdk	mouse	line	was	analyzed	by	Emanuela	Morelli	–	IST	Austria.	
	
Electron	microscopy		
Analysis	 was	 performed	 blinded	 to	 the	 genotype.	 ATLAS	 5	 array	 tomography	 (Zeiss)	 was	
used	for	image	acquisition	and	3D	reconstruction	of	sample	data.	Image	J	software	was	used	
for	 quantification	 of	 the	 symmetric	 synapse	 vesicular	 pool	 and	 measurement	 of	 the	
presynaptic	terminal	area.	All	data	sets	were	analyzed	using	Shapiro–Wilk	test	for	normality	
and	 met	 the	 criteria	 for	 normality.	 GraphPad	 Prism	 7	 was	 used	 for	 statistical	 analysis	
	
	
applying	 student’s	 t-test.	Data	 represent	means	 ±	 SEM;	nsynapses/genotype:	 27/control	 and	
22/mutant.		
	
*Data	analysis	was	done	by	Dora	Clara	Tărlungeanu	in	collaboration	with	Ryuichi	Shigemoto	
–	IST	Austria.	
	
Behavior		
Quantification	of	the	different	behavioral	parameters	was	done	using	the	EthoVison	XT	11.5	
(Noldus)	 and	UltraVox	XT	 software	 (Noldus).	Data	met	 the	 criteria	 for	normal	distribution	
(Shapiro–Wilk	 test),	 thus	 student’s	 t	 test	was	 used	 for	 statistical	 analysis	 for	most	 of	 the	
behavioral	data.	For	the	three	chamber	test	one-way	ANOVA	with	Fisher’s	post-hoc	test	was	
applied	and	for	the	juvenile	social	 interaction	test	one-way	ANOVA	with	Bonferroni's	post-
hoc	 test	 was	 used	 (GraphPad	 Prism	 7).	 Number	 of	 animals	 employed	 for	 each	 test	 is	
reported	 in	 the	 figure	 legend	 describing	 each	 experiments	 and	 range	 from	 n=6	 to	 n=	 13	
animal	per	genotype.	At	least	two	independent	cohorts	were	examined	for	each	test.		
	
Transport	measurement	data	
For	 the	 efflux	 experiments,	 the	 [3H]His	 efflux	 was	 calculated	 by	 subtracting	 radioactivity	
values	at	each	time	point	from	that	present	in	the	proteoliposomes	at	time	zero.	
Uptake	 data	 were	 fitted	 in	 a	 first-order	 rate	 equation	 to	 obtain	 rate	 constants	 and	 in	
Michaelis–Menten	 or	 Linewever-Burk	 equations.	 Efflux	 data	 were	 fitted	 in	 a	 single	
exponential	decay	equation.	The	Grafit	software	(version	5.0.13)	was	used	for	data	fitting.	
To	measure	the	specific	activity	of	SLC7A5	WT	and	mutants,	protein	quantity	was	estimated	
from	 Coomassie	 blue	 stained	 SDS-PAGE	 gels	 by	 using	 the	 Chemidoc	 imaging	 system	
equipped	 with	 Quantity	 One	 software	 (Bio-Rad)	 as	 previously	 described	 (Galluccio	 et	 al.,	
2012).	Data	represent	mean	±	SD	obtained	from	n=	4	to	5	independent	experiments.	
For	 the	 fibroblast	 leucine	 uptake	 assay	 the	 results	 of	 were	 obtained	 from	 at	 least	 3	
independent	 experiments	 (5	 for	 family	 1426	 and	 3	 for	 family	 1465)	 each	 one	 employing	
fibroblasts	from	at	least	1	unaffected	and	1	affected	individual	of	the	same	family.	For	family	
1426,	 given	 the	 very	 invasive	 procedure,	 we	 obtained	 skin	 biopsies	 only	 from	 2	 affected	
(patient	1426-6	and	1426-19)	and	2	unaffected	individuals	(1426-1	and	1426-2).	The	graph	
in	Figure	11E	 represents	 the	average	of	 the	 transport	 values	obtained	 for	either	both	 the	
affected	or	the	unaffected	subjects	in	all	the	performed	experiments.	As	deducible	from	the	
small	error	bar	we	didn’t	notice	strong	variability	among	individuals	of	the	same	family.	
	
*Proteoliposome	 experiments	 data	 was	 analyzed	 by	 Michele	 Galluccio,	 Mariafrancesca	
Scalise	and	Cesare	Indiveri	–	University	of	Calabria,	Italy.		
	
	
Data	and	software	availability		
	
Data	resources		
The	 data	 reported	 here	 is	 deposited	 into	 GEO	 under	 the	 accession	 numbers:	 GSE87808	
(RNA-seq	Slc7a5)	and	GSE39447	(microarrays	Bckdk),	and	into	NCBI	Sequence	Read	Archive:	
SRS351252	(whole	exome	sequencing).			
	
Additional	resources		
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The	URLs	for	data	presented	herein	are	as	follows:	
Online	Mendelian	Inheritance	in	Man	(OMIM):	http://www.omim.org		
SeattleSeq	Annotation:	http://gvs.gs.washington.edu/			
Genome	browser:	http://www.genome.ucsc.edu/		
HPLC	analysis:	http://www.archimedlife.com/de/		
	
	
3.4 Results	
 SLC7A5	mediates	BCAA	flux	at	the	BBB	3.4.1
Earlier	in	vitro	studies	described	the	sodium	independent	LAT1	as	a	large	neutral	amino	acid	
(LNAA)	transporter,	including	the	BCAAs	(Mastroberardino	et	al.,	1998).	The	light	subunit	of	
the	 carrier,	 encoded	by	SLC7A5,	 is	 sufficient	 to	 transport	 LNAAs	 (Napolitano	et	 al.,	 2015).	
The	 contribution	 of	 SLC7A5	 to	 brain	 LNAA/BCAA	 homeostasis	 in	 vivo,	 however,	 remains	
completely	unknown.		
To	understand	the	physiological	 role	of	Slc7a5	 in	vivo,	we	employed	a	conditional	 (floxed)	
Slc7a5	knock	out	mouse	line	(Slc7a5fl)	 (Sinclair	et	al.,	2013).	 In	wild	type	animals,	Slc7a5	 is	
considerably	expressed	in	the	plasma	membrane	of	the	endothelial	cells	of	the	BBB	during	
development	and	in	adulthood	but	it	is	mostly	undetectable	in	other	tissues	(Figure	6A	and	
Figure	S1A-C).	Thus,	we	crossed	the	Slc7a5fl/fl	mouse	with	the	Tie2Cre	mouse	line,	expressing	
the	Cre	recombinase	starting	from	embryonic	day	(E)	11.5	in	the	endothelial	cells	of	blood	
vessels	and	BBB	(Figure	S1D)	(Kisanuki	et	al.,	2001).	As	expected,	endothelial	cells	of	the	BBB	
of	Tie2Cre;Slc7a5fl/fl	mice	show	complete	lack	of	expression	of	Slc7a5	(Figure	6A).		
The	 exchange	 between	 blood	 and	 cerebrospinal	 fluid	 of	 a	 wide	 range	 of	 metabolically	
important	molecules,	including	amino	acids,	is	known	to	be	constrained	already	early	during	
development,	arising	with	 the	BBB	 formation.	However,	 some	studies	 reported	that	many	
amino	acids,	including	the	BCAAs,	are	transported	into	the	developing	brain	at	much	higher	
rate	than	in	adulthood	(Braun,	Cornford,	&	Oldendorf,	1980;	Lefauconnier	&	Trouve,	1983).	
Whether	this	reflects	a	greater	metabolic	demand	of	the	developing	brain	or	the	immaturity	
of	 the	BBB	 is	unknown	 (R.	 E.	Watson,	Desesso,	Hurtt,	&	Cappon,	2006).	Hence,	we	asked	
how	 removal	 of	 Slc7a5	 from	 the	 BBB	 affects	 brain	 amino	 acid	 levels	 at	 different	
developmental	stages.		
We	 found	 that	 E14.5	Tie2Cre;Slc7a5fl/fl	mice	 don’t	 show	major	 changes	 in	 brain	 LNAA	 and	
BCAA	levels	(Figure	6B),	suggesting	either	that	at	E14.5	the	BBB	is	still	immature,	with	amino	
acids	leaking	into	the	brain,	or	that	another	transporter	may	regulate	LNAA	and	BCAA	fluxes	
across	the	BBB	during	early	development.	 In	contrast,	after	birth	and	 in	adult	stages	brain	
BCAA,	 especially	 leucine	 and	 isoleucine,	 levels	 are	 abnormally	 low	 in	 Tie2Cre;Slc7a5fl/fl	
animals	(Figure	6C-D),	indicating	that	Slc7a5	expression	is	essential	to	regulate	BCAA	uptake	
by	 the	 brain.	 Surprisingly,	 the	 brain	 levels	 of	 several	 other	 LNAAs	 (e.g.	 tyrosine	 and	
tryptophan)	 in	 Slc7a5	 mutants	 are	 comparable	 to	 the	 ranges	 observed	 in	 control	
(Tie2Cre;Slc7a5fl/+)	 animals,	 while	 a	 few	 other	 amino	 acids	 (e.g.	 histidine,	 serine	 and	
phenylalanine)	show	an	elevated	level	in	mutants	compared	to	controls.	In	particular,	brain	
histidine	 concentration	 is	 several	 fold	 higher	 in	 the	 Tie2Cre;Slc7a5fl/fl	 mice	 than	 in	 control	
animals	(Figure	6B-D).	This	result	supports	the	idea	that	SLC7A5	works	as	an	antiporter	and	
that	histidine	is	the	main	counter	amino	acid	(Figure	S2)	(Napolitano	et	al.,	2015).			
	
	
	
	
Figure	6.	Slc7a5	mediates	BCAA	flux	at	the	BBB.		
(A)	Representative	images	showing	Slc7a5	(green)	localization	at	the	BBB	in	control	animals	(Slc7a5fl/fl,	left)	and	
its	 complete	 deletion	 in	 endothelial	 cells	 of	 the	 BBB	 in	 Cre	 positive	 mice	 (Tie2Cre;Slc7a5fl/fl,	 right).	
Immunostainings	were	 performed	 in	 cortical	 slices	 at	 embryonic	 day	 14.5	 (E14.5	 top),	 postnatal	 day	 2	 (P2,	
middle)	and	adulthood	(>P40,	bottom).	Nuclei	were	stained	with	DAPI	(blue).	(B-D)	Brain	amino	acid	levels	in	
Tie2Cre;Slc7a5fl/fl	mice	at	E14.5	(B),	P2-14	(C)	and	>P40	(D).	Levels	of	amino	acids	were	normalized	on	protein	
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concentration	 and	 shown	 as	 fold	 change	 (log2	 transformed)	 to	 levels	 in	 age-matched	 controls.	 In	 red	 are	
represented	the	amino	acids	with	a	fold	change	>1.3	and	P	value	<0.05	(n>4	mice/genotype/time	point).		
See	also	Figure	S1,	S2	and	Table	S1.	
	
Thus,	 in	 the	 absence	 of	 Slc7a5	expression	 at	 the	 BBB,	 the	mammalian	 brain	 accumulates	
histidine	while	failing	to	gather	normal	amounts	of	BCAAs.	 Importantly,	neither	the	serum	
amino	 acid	 profile	 nor	 the	 level	 of	 brain	 neurotransmitters	 are	 affected	 in	 the	
Tie2Cre;Slc7a5fl/fl	animals	(Figure	S2C	and	Table	S1).	While	this	last	result	contradicts	previous	
hypotheses	 (del	 Amo,	 Urtti,	 &	 Yliperttula,	 2008),	 it	 is	 in	 agreement	 with	 our	 in	 vitro	
experiments	 showing	 that	 SLC7A5	does	not	 facilitate	 the	movement	of	 neurotransmitters	
(Figure	S2A-B).	
	
 Deletion	of	Slc7a5	 from	the	BBB	activates	 the	AAR	signal	 transduction	3.4.2
pathway	in	the	brain	
In	 vitro,	 SLC7A5	 transports	 not	 only	 the	 BCAAs	 but	 also	 other	 LNAAs,	 including	
phenylalanine,	 tyrosine	and	 tryptophan	 (Napolitano	et	al.,	2015).	However,	brain	 levels	of	
these	amino	acids	were	not	 reduced	 in	Tie2Cre;Slc7a5fl/fl	mice	but	 rather	 slightly	 increased	
(Figure	 6D).	 This	 suggests	 that	 additional	 BBB-located	 transporters	 might	 efficiently	
compensate	 for	Slc7a5	 loss	by	mediating	the	passage	of	several	LNAAs,	but	not	of	BCAAs.	
Indeed,	RNA	sequencing	of	mouse	brain	revealed	a	significant	up-regulation	of	Slc7a1	and	
Slc7a3	genes	(Figure	7A-B)	encoding	for	the	amino	acid	transporters	Cat1	and	Cat3	(Fotiadis,	
Kanai,	&	Palacin,	2013).	This	finding	suggests	that	 in	vivo	Cat1	and	Cat3	may	contribute	to	
preserve	brain	levels	of	LNAAs,	other	than	BCAAs,	in	the	Tie2Cre;Slc7a5fl/fl	mice.		
Furthermore,	 differential	 gene	 expression	 analysis	 revealed	 the	 up-regulation	 of	 genes	
implicated	in	serine	biosynthesis	in	Tie2Cre;Slc7a5fl/fl	mice	(Figure	7B),	explaining	the	modest	
but	significant	increase	in	brain	serine	level	observed	in	the	mutant	animals	(Figure	2D).	An	
increase	 in	 the	 expression	 of	 genes	 encoding	 for	 amino	 acid	 transporters	 and	 serine	
biosynthetic	 enzymes	 has	 been	 previously	 linked	 to	 the	 activation	 of	 the	 AAR,	 a	 process	
implemented	by	individual	cells	to	respond	to	amino	acid	deprivation	(Kilberg,	Shan,	&	Su,	
2009).	 Consistently,	 RNAseq	 analysis	 of	 Tie2Cre;Slc7a5fl/fl	 mouse	 brain,	 revealed	 the	 up-
regulation	of	a	number	of	other	amino	acid-related	genes	(e.g.	aminoacyl-tRNA	synthetases)	
(Figure	7A-B).	Among	 them	we	noticed	a	 significant	up-regulation	of	mRNAs	encoding	 for	
the	amino	acid	responsive	transcription	factors	Atf4	and	Atf5	and	the	eukaryotic	 initiation	
factor	4E	binding	protein	4ebp1	(Figure	7A),	all	part	of	the	AAR	pathway.	Atf4	and	Atf5	have	
been	implicated	in	the	regulation	of	the	central	nervous	system	development	and	function.	
Specifically,	Atf4	modulates	 synaptic	 plasticity	 and	 long-term	memory	 formation	 (Chen	 et	
al.,	2003),	while	Atf5	has	been	implicated	in	cell	growth	and	development,	especially	in	the	
nervous	system	(Angelastro	et	al.,	2003).	Aberrant	expression	of	Atf4	and/or	Atf5	has	been	
implicated	 in	 cognitive	 dysfunctions	 and	 neuropsychiatric	 abnormalities,	 including	 altered	
emotional	behavior	(Green	et	al.,	2008)	and	behavioral	inflexibility	(Trinh	et	al.,	2012).	
Importantly,	 our	 gene	 expression	 analysis	 didn’t	 reveal	 any	 abnormality	 ascribable	 to	
increased	histidine	levels,	suggesting	that,	despite	histidine	being	the	most	affected	amino	
acid	 by	 Slc7a5	 deletion,	 changes	 in	 its	 level	 do	 not	 lead	 to	 severe	 molecular	 defects.	
Similarly,	we	didn’t	detect	changes	attributable	to	alterations	of	other	amino	acids	such	as	
phenylalanine.		
	
	
	
	
Figure	7.	Activation	of	the	amino	acid	response	pathway	in	the	brain	of	Slc7a5	mutant	mice.		
(A)	 RNA	 sequencing	 of	 adult	 brain	 in	 Tie2Cre;Slc7a5fl/+	 and	 Tie2Cre;Slc7a5fl/fl	 mice	 revealed	 131	 differentially	
expressed	genes	(FDR-adjusted	P-value	≤	0.05).	The	heat	map	displays	log	transformed	count	data	normalized	
to	 library	 size.	 Genes	 expressed	 at	 lower	 levels	 in	 Tie2Cre;Slc7a5fl/fl	 (40	 genes)	 are	 displayed	 at	 the	 top	 and	
genes	 up-regulated	 in	 Tie2Cre;Slc7a5fl/fl	 (91	 genes)	 are	 shown	 at	 the	 bottom.	 Zoomed	 rows	 on	 the	 right	
emphasize	 differentially	 expressed	 genes	 associated	 with	 amino	 acid	 import	 (GO:0089718),	 tRNA	
aminoacylation	(GO:0006418)	and	amino	acid	response,	respectively	(n=3	mice/genotype).	
(B)	 Results	 of	 GO	 Enrichment	 analysis	 on	 the	 set	 of	 131	 differentially	 expressed	 genes.	 Terms	 are	 sorted	
according	to	P-value	with	the	most	significantly	enriched	terms	at	the	top:	GO	terms	for	molecular	functions	
(GO:MF,	 left,	blue);	GO	terms	for	biological	processes	(GO:BP,	right,	green).	The	 length	of	each	bar	 indicates	
the	P-value	while	the	width	indicates	the	amount	of	genes	in	the	set	associated	with	the	term.	RNA-seq	was	
done	at	Vienna	Biocenter,	RNA-seq	analysis	was	done	by	Christoph	Dotter	–IST	Austria.	
(C)	Western	blot	analysis	from	cortical	lysates	of	Tie2Cre;Slc7a5fl/+	(control)	and	Tie2Cre;Slc7a5fl/fl	mice,	indicating	
that	mutants	exhibit	increased	phospho-eIF2α	and	total	4EBP1	protein	levels	but	normal	levels	of	total	eIF2α,	
phospho-4EBP1,	 phospho-S6K,	 S6K,	 phospho-eIF4E	 and	 eIF4E.	 Tubulin	 was	 used	 as	 internal	 control.	
Representative	blots	(left)	and	fold	change	ratio	(right);	*P<0.05	(means	±	SEM;	n≥4	mice/genotype).		
(D)	 Polysome	 profile	 from	 cortical	 lysates	 of	 control	 and	 Tie2Cre;Slc7a5fl/fl	mice.	 Typical	 tracings	 indicating	
positions	 of	 40S,	 60S	 and	 80S	 ribosome	 peaks	 and	 polysome	 (P)/monosome	 (M)	 ratio	 quantifications;	
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***P<0.001	(right	inset:	means	±	SEM;	n=10	control	and	n=9	mutant	mice).	Polysome	profile	analysis	was	done	
by	Christoph	Janiesch	and	Kent	Duncan	–	ZMN	Hamburg,	Germany.		
	
 Altered	mRNA	translation	in	Slc7a5	mutant	mice	3.4.3
Amino	 acid	 deprivation	 and	 activated	 AAR	 signaling	 pathway	 are	 associated	 with	
suppression	 of	 protein	 synthesis	 via	 phosphorylation	 of	 the	 translation	 initiation	 factor	
eIF2α.	 In	 the	 past	 few	 years	 several	 genes	 regulating	 mRNA	 translation	 have	 been	
implicated	 in	cognitive	deficits	 (Costa-Mattioli	et	al.,	2005;	Gkogkas	et	al.,	2013;	Santini	et	
al.,	2013).	We	therefore	examined	the	effect	of	Slc7a5	knock	out	at	the	BBB	on	translation	
and	associated	pathways	in	the	brain.	
To	assess	the	impact	of	leucine	and	isoleucine	deficiency	on	mRNA	translation	in	the	brain	
of	 Tie2Cre;Slc7a5fl/fl	 mice,	 we	 first	 performed	 western	 blot	 analysis	 of	 neocortical	 lysates	
obtained	from	wild-type	and	mutant	animals.	Specifically,	we	evaluated	the	expression	and	
activity	status	of	a	number	of	proteins	involved	in	the	regulation	of	protein	synthesis	(Figure	
7C).	 We	 observed	 a	 significant	 increase	 in	 the	 total	 levels	 of	 4EBP1	 protein	 (Figure	 7C),	
consistent	with	 increased	4EBP1	mRNA	levels	seen	in	our	RNAseq	data	(Figure	7A),	and	of	
phosphorylated	 eukaryotic	 initiation	 factor	 2	 alpha	 (eIF2α)	 (Figure	 7C),	 indicating	 that	
removal	of	Slc7a5	from	the	BBB	and	the	consequent	decrease	in	brain	BCAA	concentration	
may	lead	to	the	suppression	of	cap-dependent	translation	initiation.	In	contrast,	in	none	of	
our	experiments	did	we	detect	abnormal	activation	of	the	mammalian	target	of	rapamacyin	
(mTOR)	pathway	(Figure	7C),	whose	activity	was	shown	to	be	regulated	by	leucine	levels	in	
vitro	(Wolfson	et	al.,	2016).	This	may	suggest	that	in	vivo,	under	chronic	leucine	deficiency,	
the	mTOR	complex	is	alternatively	regulated.	
To	 test	whether	 abnormal	 regulation	of	 4EBP1	 and	eIF2α	 	in	mice	 lacking	Slc7a5	 leads	 to	
changes	in	translation	efficiency	in	the	brain,	we	performed	polysome	profiling	of	wild	type	
and	 Tie2Cre;Slc7a5fl/fl	 cortices.	 Importantly,	 in	 Tie2Cre;Slc7a5fl/fl	 mouse	 cortical	 lysates	 we	
observed	 a	 significant	 shift	 of	 ribosomes	 from	 actively	 translating	 polysomes	 toward	 the	
monosomal	 fraction	 (Figure	 7D),	 the	 hallmark	 of	 decreased	 translation	 initiation.	 We	
conclude	 that	 BCAA	 shortage	 and	 associated	 effects	 of	 4EBP1	 levels	 and	 increased	 eIF2α	
phosphorylation	elicit	deficient	translation	initiation	in	the	brain.		
	
 Slc7a5	 conditional	 knock	 out	 animals	 show	 motor	 delay	 and	 autism-3.4.4
related	phenotypes	
Behavioral	 impairments	 resulting	 from	 abnormal	 regulation	 of	 cap-dependent	 translation	
have	 been	 previously	 described	 (Banko	 &	 Klann,	 2008;	 Santini	 et	 al.,	 2013;	 Trinh	 et	 al.,	
2012).	Thus,	we	tested	Tie2Cre;Slc7a5fl/fl	mice	for	global	behavioral	changes.	Tie2Cre;Slc7a5fl/fl	
mice	are	born	at	Mendelian	 ratio	and	appear	normal	 in	 size	but	display	 kyphosis	 (44%	of	
mutant	mice)	and	hind	limb	clasping	(89%	of	mutant	mice).	In	an	open	field	Tie2Cre;Slc7a5fl/fl	
mice	show	reduced	explorative	behavior	and	lower	velocity	(Figure	8A).	Rearing,	a	form	of	
vertical	 exploration,	 was	 significantly	 reduced	 in	 the	 Tie2Cre;Slc7a5fl/fl	 mice	 (Figure	 8B).	
Nonetheless,	 Slc7a5	mutant	mice	 and	wild	 type	 littermates	 have	 similar	 habituation	 time	
course	(Figure	S3A),	suggesting	that	the	diminished	activity	results	from	locomotion	defects	
rather	than	a	faster	habituation	to	the	field.	Therefore	we	tested	the	Tie2Cre;Slc7a5fl/fl	mice	
for	 fine	 motor	 coordination	 and	 locomotion	 problems.	 Indeed,	 Tie2Cre;Slc7a5fl/fl	 animals	
	
	
presented	significant	difficulties	in	the	walking	beam	test	(Figure	8C)	and	gait	abnormalities	
(Figure	8D-E).		
Since	 in	our	previous	work	we	 implicated	BCAA	deficiency	 in	ASD	 (Novarino	et	 al.,	
2012a),	we	tested	Tie2Cre;Slc7a5fl/fl	for	autism-like	phenotypes.	Tie2Cre;Slc7a5fl/fl	do	not	show	
excessive	 grooming	 or	 perseverative	 behaviors	 (Figure	 S3B),	 activities	 which	 can	 be,	
however,	severely	complicated	by	the	presence	of	motor	deficits	 in	the	mutants.	Thus,	we	
tested	Tie2Cre;Slc7a5fl/fl	mice	for	social	interaction	abnormalities.	We	first	employed	a	three-
chamber	social	arena	to	probe	the	mutant	animals	for	self-initiated	interactions	with	a	wild-
type	 unfamiliar	mouse.	 This	 analysis	 revealed	 that	while	wild-type	mice	 have	more	 close	
interactions	with	 an	 unfamiliar	mouse	 than	 an	 object,	 the	Tie2Cre;Slc7a5fl/fl	mice	 show	 no	
preference	between	these	two	(Figure	8F).	We	then	tested	juvenile	animals	for	social	play	
and	 found	 that	Tie2Cre;Slc7a5fl/fl	mice	 tend	 to	 stay	 farther	apart	 from	 their	 cage-mate	and	
display	 a	 decreased	 number	 of	 nose-to-nose	 contacts	 (Figure	 8G).	 Finally,	 we	 measured	
isolation-induced	ultrasonic	vocalizations	(USV)	emitted	by	mouse	pups	separated	from	the	
mother.	 Tie2Cre;Slc7a5fl/fl	 pups	 display	 increased	 number	 of	 USV	 starting	 from	 P8	 when	
compared	with	their	wild-type	littermates	(Figure	8H),	a	behavior	observed	in	other	autism	
models	(Gkogkas	et	al.,	2013).	 Interestingly,	 the	excessive	number	of	USVs	emitted	by	the	
mutant	pups	may	be	due	to	an	increased	repetition	of	a	specific	repertoire	of	vocalization	
patterns	(Romano,	Michetti,	Caruso,	Laviola,	&	Scattoni,	2013).		
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Figure	8.	Neurobehavioral	abnormalities	in	the	Tie2Cre;Slc7a5fl/fl	mice.		
(A-D)	 Decreased	 exploratory	 behavior	 and	 locomotion	 abnormalities	 in	 the	 Tie2Cre;Slc7a5fl/fl	 mice.	 (A)	 Open	
field	 test.	 Representative	 trajectories	 (left)	 and	 quantification	 of	 the	 total	 distance	moved	 (middle)	 and	 the	
velocity	 (right)	 indicating	 that	Tie2Cre;Slc7a5fl/fl	mice	 are	outperformed	by	 controls;	 **P<0.01	 (means	±	 SEM;	
n=10	 mice/genotype).	 (B)	 Comparison	 of	 the	 number	 of	 rearings	 pointing	 out	 deficiencies	 in	 the	 mutants;	
**P<0.01	(means	±	SEM;	n=10	mice/genotype)	(C)	Walking	beam	performance	on	training	days	(Day	1,	Day	2)	
and	on	 the	 three	 trials	of	 the	 test	day	 (Day	3),	 showing	elevated	 latency	 to	 cross	 the	beam	 in	 the	mutants;	
*P<0.05,	 **P<0.01	 (means	 ±	 SEM;	 n=7	 mice/genotype).	 (D)	 Representative	 images	 of	 control	 (left)	 and	
Tie2Cre;Slc7a5fl/fl	 strides	 (right)	 in	 the	 gait	 test.	 Forepaw	 (red)	 and	 hindpaw	 (blue).	 (E)	 Altered	 gait	 of	 the	
	
	
Tie2Cre;Slc7a5fl/fl	 mice	 is	 evidenced	 by	 inter-genotype	 comparison	 of	 stride,	 sway	 and	 stance	 length	
quantifications;	*P<0.05,	**P<0.01,	***P<0.001	(means	±	SEM;	n=7	mice/genotype).			
(F)	Three	chamber	social	 interaction	test	(left)	and	quantifications	(right)	of	the	number	of	contacts	with	the	
caged	mouse	 (M)	 or	with	 the	 caged	 object	 (O)	 revealing	 abnormal	 social	 interaction	 pattern	 in	 the	mutant	
mice	 (mutants	 show	 no	 preference	 for	 the	 M	 over	 the	 O,	 as	 opposed	 to	 controls);	 **P<0.01,	 N.S.	 not	
significant	(means	±	SEM;	n=12	mice/genotype).		
(G)	Juvenile	Tie2Cre;Slc7a5fl/fl	mice	display	fewer	reciprocal	social	interactions.	Slc7a5	mutant	mice	tend	to	stay	
farther	apart	from	their	cage	mate	(heat-map	and	bottom	left	graph)	and	exhibit	fewer	nose-to-nose	contacts	
(bottom	right	graph).	WT=	Slc7a5fl/+;	KO=	Tie2Cre;Slc7a5fl/fl.	*P<0.05	(means	±	SEM;	n=8	mice/genotype).		
(H)	Isolation	induced	USV	at	various	postnatal	days	show	that	Tie2Cre;Slc7a5fl/fl	mice	emit	an	increased	number	
of	calls	starting	at	P8.	*P<0.05	(means	±	SEM;	n=10	mice/genotype).		
See	also	Figure	S3.	
	
 Inhibitory	activity	defects	in	Tie2Cre;Slc7a5fl/fl	mice	3.4.5
Social	 interaction	 abnormalities	 have	 been	 suggested	 to	 arise	 from	 cortical	
excitation/inhibition	 imbalance	(Yizhar	et	al.,	2011),	a	correlation	also	observed	 in	animals	
with	 abnormal	 regulation	 of	 translation	 (Gkogkas	 et	 al.,	 2013;	 Santini	 et	 al.,	 2013).	 We	
evaluated	synaptic	function	in	21	days	old	Tie2Cre;Slc7a5fl/fl	mice	using	whole-cell	recordings	
of	 pyramidal	 neurons	 in	 layer	 2/3	 of	 the	 somatosensory	 cortex.	 Examination	 of	 synaptic	
transmission	revealed	a	slight	increase	in	the	amplitude	of	miniature	excitatory	postsynaptic	
currents	(mEPSCs)	and	a	marked	reduction	in	the	frequency	of	miniature	inhibitory	synaptic	
currents	(mIPSCs)	(Figure	9A-B),	indicating	a	significant	excitation/inhibition	imbalance.		
To	determine	whether	the	synaptic	alterations	in	Tie2Cre;Slc7a5fl/fl	mice	are	selective	to	the	
somatosensory	cortex,	we	performed	the	same	experiment	in	other	brain	regions.	Given	the	
locomotion	abnormalities	observed	 in	Tie2Cre;Slc7a5fl/fl	mice,	we	 tested	 inputs	 received	by	
the	 Purkinje	 cells.	 Similarly	 to	 the	 neocortex,	 Tie2Cre;Slc7a5fl/fl	 mouse	 cerebellar	 Purkinje	
cells	display	a	significant	reduction	in	mIPSC	frequency	(Figure	S3C-D).	
Changes	 in	mIPSC	 frequency	are	generally	due	 to	differences	 in	 the	number	of	 functional	
synaptic	sites	and/or	in	the	presynaptic	release	probability	at	existing	sites	(changes	in	the	
GABA	 vesicular	 pool	 or	 vesicular	 turnover	 rate).	 Therefore,	 we	 examined	 overall	 brain	
morphology	 (Figure	 S4A),	 cortical	 layering	 (Figure	 S4B)	 and	 inhibitory	 neuron	 distribution	
(Figure	S4C)	and	found	that	for	these	parameters	somatosensory	cortices	of	mutant	animals	
were	 undistinguishable	 from	 the	 control.	 We	 further	 looked	 for	 differences	 in	 pre-	 and	
postsynaptic	markers	of	inhibitory	synapses.	Importantly,	we	observed	that	the	intensity	of	
the	 vesicular	 GABA	 transporter	 (VGAT)	 staining,	 a	 marker	 for	 GABAergic	 presynaptic	
terminals,	was	lower	in	the	somatosensory	cortices	of	Tie2Cre;Slc7a5fl/fl	mice	(Figure	9C	and	
Figure	 S4D).	 However,	 the	 GABAergic	 postsynaptic	 marker	 neuroligin	 2	 (Varoqueaux,	
Jamain,	 &	 Brose,	 2004)	 appeared	 qualitatively	 and	 quantitatively	 similar	 in	 the	
somatosensory	 cortex	 of	 the	 mutant	 and	 control	 mice	 (Figure	 9D	 and	 Figure	 S4E).	 The	
marked	reduction	of	VGAT	and	normal	neuroligin	2	protein	 levels	 in	Tie2Cre;Slc7a5fl/fl	mice	
were	also	confirmed	by	western	blot	analysis	of	 cortical	 lysates	 (Figure	9E).	To	determine	
whether	the	reduction	in	VGAT	staining	intensity	was	due	to	a	specific	lessening	of	VGAT	or	
a	 decline	 in	 the	 number	 of	 VGAT-containing	 vesicles	 we	 analyzed	 inhibitory	 synapses	 by	
electron	 microscopy.	 In	 agreement	 with	 the	 electrophysiology	 results,	 we	 detected	 a	
significant	reduction	of	vesicle	number	in	symmetric	synapses	in	the	somatosensory	cortices	
of	Tie2Cre;Slc7a5fl/fl	mice	compared	with	control	animals	(Figure	9F).	
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Figure	9.	Excitation/inhibition	imbalance	in	Tie2Cre;Slc7a5fl/fl	somatosensory	cortex.	
(A-B)	 Left:	 Representative	 mEPSC	 (A)	 and	 mIPSC	 (B)	 recordings	 from	 Tie2Cre;Slc7a5fl/+	 and	 Tie2Cre;Slc7a5fl/fl	
somatosensory	cortex	(SCX)	layers	2-3	pyramidal	neurons;	Right:	Cumulative	probability	distributions	of	peak	
amplitudes	and	inter-event	intervals	of	mEPSC	(A)	and	mIPSC	(B)	in	the	two	genotypes.	Insets:	quantifications	
of	 mean	 amplitudes	 and	 mean	 frequencies	 of	 the	 corresponding	 currents,	 with	 significant	 differences	 in	
mutants	 versus	 controls.	 D=0.093,	 P<10-11	 (mEPSC	 amplitudes)	 and	 D=0.099,	 P<10-15	 (mIPSC	 interevent	
intervals);	 (means	 ±	 SEM,	 ncells/nanimals/genotype:	 14/7/Tie2
Cre;Slc7a5fl/+	 and	 13/5/Tie2Cre;Slc7a5fl/fl	 (mEPSC);	
16/7/Tie2Cre;Slc7a5fl/+	and	18/5/Tie2Cre;Slc7a5fl/fl	(mIPSC).	Electrophysiological	experiments	were	done	by	Elena	
Deliu	–	IST	Austria.	
(C)	 Representative	 confocal	 images	 of	 VGAT-positive	 synaptic	 puncta	 (green)	 in	 control	 (left)	 and	
Tie2Cre;Slc7a5fl/fl	 (right)	 cortical	 sections	 displaying	 decreased	 staining	 intensity	 in	 the	 mutants.	 Nuclei	 were	
stained	with	DAPI	(blue).		
	
	
(D)	 Confocal	 imaging	 of	 cortical	 sections	 labeled	 for	 Neuroligin	 2	 (NLGN2,	 red)	 of	 control	 (left)	 and	
Tie2Cre;Slc7a5fl/fl	 (right)	 animals	 revealing	 no	 difference	 between	 genotypes.	 Nuclei	 were	 stained	 with	 DAPI	
(blue).	Scale	bar	as	in	(C).	
(E)	Western	 blot	 analysis	 from	 cortical	 lysates	 indicating	 decreased	 VGAT	 (top)	 and	 similar	 NLGN2	 protein	
levels	(middle)	in	Tie2Cre;Slc7a5fl/fl	mice	compared	with	controls.	GAPDH	(bottom)	was	used	as	internal	control.		
(F)	Electron	microscopy	imaging	of	the	SCX	layers	2-3	showing	that	Tie2Cre;Slc7a5fl/fl	mice	have	a	decreased	area	
of	 GABAergic	 boutons	 and	 decreased	 density	 of	 vesicles	 per	 bouton.	 Typical	 micrograph	 images	 (left),	
summary	 graphs	 of	 presynaptic	 area	 (middle)	 and	 vesicle	 density	 (right);	 ***P<0.001	 (means	 ±	 SEM;	
nsynapses/genotype:	27/control	and	22/mutant).	Electron	microscopy	experiments	were	done	together	with	the	
EM	facility	and	Ryuichi	Shigemoto	-	IST	Austria.	
See	also	Figure	S4	and	S5.	
	
 Tie2Cre;Slc7a5fl/fl	mutant	mice	resemble	Bckdk	knock	out	animals	3.4.6
The	reduction	in	brain	BCAA	levels	observed	in	Tie2Cre;Slc7a5fl/fl	adult	mice	is	comparable	to	
what	we	measured	 in	Bckdk-/-	 animals	 (Novarino	et	 al.,	 2012a).	Bckdk-/-	mice,	 in	 addition,	
display	 reduced	serum	BCAA	 levels	and	a	marked	 increase	 in	brain	 levels	of	 several	other	
LNAAs	 (Novarino	 et	 al.,	 2012a)	 but	 normal	 neurotransmitter	 concentrations	 (Figure	 S5G).	
Thus,	it	remained	unclear	whether	neurological	abnormalities	in	BCKDK	mutant	patients	and	
mice	 are	 due	 to	 alterations	 in	 serum	 or	 brain	 BCAA.	 Alternatively,	 the	 pathological	
conditions	observed	in	patients	carrying	mutations	in	BCKDK	could	be	due	to	increased	brain	
LNAA	levels.		
We	 compared	Bckdk-/-	 and	Tie2Cre;Slc7a5fl/fl	mouse	 lines	 and	 observed	 a	 great	 phenotypic	
overlap.	 Similarly	 to	 Tie2Cre;Slc7a5fl/fl	 mice,	 Bckdk	 mutants	 show	 motor	 coordination	
abnormalities,	 autism-related	 behaviors,	 decreased	 mIPSC	 frequency	 (Figure	 S5A-F)	 and	
activation	 of	 the	 AAR	 pathway	 (Novarino	 et	 al.,	 2012a,	 2012b)	 implying	 that	Bckdk-/-	 and	
Tie2Cre;Slc7a5fl/fl	mice	share	pathophysiological	mechanisms.		
	
 SLC7A5	mutations	in	patients	with	ASD	and	motor	delay	3.4.7
Given	the	essential	role	of	SLC7A5	in	regulating	brain	BCAA	homeostasis	and	the	phenotypic	
overlap	 between	Bckdk	 and	 Slc7a5	mutant	mice,	we	 reasoned	 that	mutations	 in	 SLC7A5,	
could	 lead	 to	ASD	and	motor	 abnormalities	 in	humans.	 Thus,	we	 collaboratively	 screened	
whole	 exome	 sequencing	 (WES)	 data	 from	 more	 than	 2000	 families	 with	 documented	
parental	 consanguinity,	 presenting	 with	 children	 with	 various	 neurological	 diseases.	 We	
identified	 two	 independent	 families	with	multiple	 children	 affected	 by	ASD,	microcephaly	
and	motor	problems	all	harboring	homozygous	missense	mutations	in	the	gene	SLC7A5.		
Family	1426	is	a	consanguineous	family	with	two	branches	and	5	affected	individuals	(Figure	
10A-C).	WES	analysis	of	patients	1426-5	and	1426-19	(Figure	10A)	identified	a	unique	shared	
homozygous	missense	variant	in	the	SLC7A5	gene	(Table	S2).	The	homozygous	mutation	falls	
in	a	linkage	pick	with	LOD	score	>4	(Figure	S6A)	and	segregates	with	the	disorder	in	the	rest	
of	 the	 family	 (confirmed	 by	 Sanger	 sequencing).	 The	 A246V	 mutation	 changes	 a	 highly	
conserved	alanine	situated	in	a	stretch	of	preserved	amino	acids	predicted	to	be	important	
for	 amino	 acid	 transport	 (Figure	 10A-B).	 In	 an	 additional	 cohort	 of	 1000	
neurodevelopmental	disorder	patients	analyzed	by	WES	we	identified	Family	1465	including	
two	 patients	 with	 identical	 ASD,	 microcephaly	 and	 motor	 delay	 (Figure	 10A-C)	 sharing	 a	
predicted	deleterious	homozygous	mutation	(Figure	S6B)	in	SLC7A5	leading	to	the	change	of	
the	 conserved	 proline	 in	 position	 375	 to	 a	 leucine	 (P375L)	 (Figure	 10A).	 Both	 genetic	
variants	 were	 not	 present	 in	 more	 than	 200	 ethnically-matched,	 healthy	 control	
47	
	
chromosomes,	 nor	 in	 our	 data	 set	 of	 over	 2000	 chromosomes	 or	 in	 publicly	 available	
databases	(Table	S2).		
	
	
Figure	10.	Mutations	in	the	human	SLC7A5	lead	to	ASD	and	motor	deficits.	
(A)	 SLC7A5	 mutations	 identified	 in	 families	 1426	 and	 1465	 in	 individuals	 with	 ASD,	 motor	 deficits	 and	
microcephaly.	Pedigrees	1426	and	1465	display	first-cousin	consanguinity,	five	and	two	affected	patients	(solid	
symbols)	respectively	and	unaffected	members	(open	symbols)	
(B)	MRI	from	one	patient	for	each	family	showing	microcephaly	and	thin	corpus	callosum	but	normal	axial	T1	
sequence	of	the	brain.	Control	child	brain	MRIs	were	obtained	from	unrelated	individuals.			
(C)	 Clinical	 presentation	 of	 patients	 from	 family	 1426	 and	 1465.	 HC,	 head	 circumference;	 SD,	 standard	
deviation;	GTC,	generalized	tonic	clonic;	N/A	not	available;	CC,	corpus	callosum.	
Patient	 recruitment	was	done	by	Majdi	Kara,	Fatma	Mujgan	Sonmez,	Kaya	Bilguvar,	Anide	 Johansen,	Seham	
Esharif,	Tawfeg	Ben-Omran,	Meral	Topcu,	Murat	Gunel	and	Joseph	Gleeson.	WES	analysis	was	done	by	Ahmet	
Okay	Caglayan	and	Gaia	Novarino.	
See	also	Table	S2.	
	
	
	
 Functional	assessment	of	SLC7A5	A246V	and	P375L	mutations	3.4.8
We	mapped	the	two	genetic	variants	onto	a	homology	model	of	SLC7A5	(Geier	et	al.,	2013).	
A246	is	located	in	transmembrane	helix	6	in	close	proximity	to	the	extracellular	side	and	to	
the	channel	(Figure	11B).	Mutation	of	this	residue	to	the	larger	valine	is	therefore	likely	to	
impact	 the	 transporter's	 structure	 by	 disrupting	 helix–helix	 packing	 and	 ligand	 transport.	
P375	is	located	in	transmembrane	helix	9	in	close	proximity	to	the	cytoplasmic	side	(Figure	
11B).	 Proline	 often	 plays	 a	 key	 role	 in	 introducing	 kinks	 in	 helices	 and	 allowing	
conformational	changes	 important	for	transporter	 function.	Thus,	mutation	of	this	residue	
to	leucine	is	likely	to	disrupt	the	flexibility	required	for	transport	by	SLC7A5.	
To	 validate	 the	 functional	 impact	 of	 the	 A246V	 and	 P375L	 substitution	 we	 performed	
transport	 assays.	 Therefore,	 the	 recombinant	 A246V	 and	 P375L	 mutant	 proteins	 were	
successfully	 expressed	 (Figure	 S7A),	 reconstituted	 in	 proteoliposomes	 (Figure	 11C-D)	 and	
tested	with	a	series	of	transport	assays	(Napolitano	et	al.,	2015).	
From	 transport	 time	 course	 analysis	 it	 was	 evident	 that	 the	mutant	 A246V	 was	 virtually	
inactive	 (Figure	 11C).	 As	 predicted	 by	 the	 homology	 model	 (Figure	 11B)	 the	 functional	
defect	may	be	ascribed	to	a	higher	steric	hindrance	of	the	valine	side	chain	with	respect	to	
that	 of	 alanine.	 To	 verify	 this	 hypothesis	 and	 that	 the	 functional	 change	 was	 specifically	
ascribed	to	the	pathological	variant	we	analyzed	an	artificial	mutant,	A246G,	(Figure	S7A)	in	
which	 the	 246	 side	 chain	 had	 been	 abolished.	 In	 contrast	 to	 the	 patient-specific	 A246V	
mutation,	the	A246G	variant	didn’t	show	any	transport	defect	(Figure	11C	and	Figure	S7B).	
To	 exclude	 that	 the	 loss	 of	 activity	 observed	 in	 the	 A246V	 mutant	 could	 be	 due	 to	
reconstitution	 failing,	 we	 assessed	 the	 efficiency	 of	 protein	 reconstitution.	 We	 found	 no	
differences	in	the	reconstitution	of	the	A246V	mutant	compared	to	the	WT	protein	(Figure	
S7A).	Taken	together,	all	the	data	confirmed	that	the	substitution	of	A246V	was	functionally	
disruptive.	
In	 contrast,	 the	P375L	mutant	 showed	no	significant	variations	 in	 time	dependent	activity	
and	 external	 Km	with	 respect	 to	WT	 (Figure	 S7C-D).	Owing	 to	 the	 location	 of	 P375	 in	 an	
intracellular	moiety	of	the	protein	(Figure	11B),	we	determined	also	the	internal	Km	for	this	
mutant	(about	25	mM;	27	±	9.9)	(Figure	S7E).	 Interestingly,	the	Km	value	was	roughly	five	
times	 that	 of	 the	 WT	 (about	 5	 mM;	 5.2	 ±	 2.3),	 suggesting	 that	 some	 variations	 in	 the	
substrate	binding/translocation	pathway	may	occur	upon	mutation.	We	further	performed	
efflux	experiments	for	evaluating	possible	differences	in	the	antiport	reaction	catalyzed	by	
SLC7A5.	The	measurements	were	performed	using	intraliposomal	histidine	concentration	(2	
mM),	to	create	conditions	similar	to	the	intracellular	environment.	Surprisingly,	the	mutant	
P375L	was	mostly	 uncoupled.	 Indeed,	while	WT	 showed	 a	 very	 slow	 efflux	 in	 absence	 of	
external	 substrate,	 according	 to	 its	 antiport	 mode,	 the	 mutant	 unidirectional	 efflux	 was	
much	 faster	with	 a	 nearly	 complete	 proteoliposome	 emptying	 (Figure	 11D).	 The	 anomaly	
observed	in	the	P375L	mutant	indicates	that,	in	vivo,	loss	of	intracellular	SLC7A5	substrate(s)	
impairs	the	driving	force	for	taking	up	SLC7A5	substrates.	
To	further	validate	the	functional	impact	of	SLC7A5	mutation	in	the	patient-specific	genetic	
background,	we	obtained	human	dermal	fibroblasts	from	two	affected	and	a	few	unaffected	
members	of	Family	1426	and	Family	1465	and	performed	[3H]-leucine	uptake	assay	(Sinclair	
et	al.,	2013).	SLC7A5	transcript	is	expressed	in	human	dermal	fibroblasts	and	its	level	is	not	
affected	by	 the	missense	mutations	 (Figure	S7F).	Cells	 carrying	 the	homozygous	A246V	or	
P375L	variant,	however,	show	a	significant	reduction	in	[3H]-leucine	uptake	when	compared	
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with	control	cells	(Figure	11E).	Thus,	the	substitution	of	the	SLC7A5	alanine	246	into	a	valine,	
or	of	the	proline	375	into	a	leucine,	is	sufficient	to	significantly	reduce	the	SLC7A5-mediated	
BCAA	uptake.	
	
	
Figure	11.	A246V	and	P375L	mutations	compromise	SLC7A5	function.	
(A)	Conservation	of	the	SLC7A5	A246	and	P375	in	several	species.		
(B)	 Side,	 top	 and	 bottom	 views	 of	 the	 predicted	 structure	 of	 SLC7A5	 in	 complex	 with	 tryptophan	 showing	
SLC7A5	 backbone	 atoms	 (gray	 ribbon),	 atoms	 of	 the	 residues	 constituting	 the	 missense	 mutations	 (yellow	
spheres)	 and	 the	 ligand	 tryptophan	 (green	 sticks);	 oxygen	 atoms	 (red)	 and	 nitrogen	 atoms	 (blue).	 In	 silico	
analysis	done	by	Avner	Schlessinger.		
(C)	 SLC7A5	 wild-type,	 A246V	 and	 A246G	 mutants	 over-expressed	 and	 purified	 by	 fast	 protein	 liquid	
chromatography	 were	 reconstituted	 in	 proteoliposomes.	 Transport	 is	 followed	 as	 uptake	 (red	 arrow)	 of	
external	[3H]His	in	exchange	with	internal	His.	Transport	was	started	by	adding	external	5	µM	[3H]His	at	time	
	
	
zero	 to	 proteoliposomes	 containing	 10	 mM	 His	 reconstituted	 with	 SLC7A5-WT	 (○),	 SLC7A5-A246V	 ( )	 or	
SLC7A5-A246G	(●)	and	stopped	at	the	indicated	times	(means	±	SD;	n=5	experiments).		
(D)	Time	dependence	of	[3H]His	efflux	from	proteoliposomes	reconstituted	with	SLC7A5-WT	or	SLC7A5-P375L	
was	measured.	Proteoliposomes	 reconstituted	with	SLC7A5-WT	 (○,	●)	or	SLC7A5-P375L	 ( , ),	 containing	2	
mM	His	were	radioactivity-preloaded.	Efflux	was	measured	in	absence	(○, ;	uniport)	or	presence	of	external	1	
mM	 His	 (●, ;	 antiport).	 Percentage	 of	 His	 efflux	 was	 calculated	 with	 respect	 to	 time	 0	 (means	 ±	 SD;	 n=4	
experiments).	 Proteoliposome	 experiments	 were	 done	 by	 Michele	 Galluccio,	 Mariafrancesca	 Scalise	 and	
Cesare	Indiveri	–	University	of	Calabria,	Italy.		
(E)	Radio-labeled	leucine	([3H]Leu)	transport	analysis	in	human	fibroblasts	from	affected	(A)	and	unaffected	(U)	
members	of	families	1426	and	1465	illustrating	a	significant	reduction	in	leucine	uptake	by	the	cells	of	affected	
patients.	Specificity	of	leucine	uptake	was	assessed	by	competition	with	10	mM	cold	leucine	(Leu)	or	10	mM	2	
BCH;	 ***P<0.001	 (means	 ±	 SEM;	N≥3	 experiments	 performed	 with	 fibroblasts	 from	 two	 patients	 and	 one	
healthy	control/family).	
See	also	Figure	S7.	
	
 BCAA	 intracerebroventricular	 injections	 rescue	 neurological	3.4.9
abnormalities	in	adult	Slc7a5	mutant	mice		
The	 identification	 of	 ASD	 patients	 carrying	 mutations	 in	 the	 SLC7A5	 gene	 prompted	 the	
question	whether	this	condition	is	potentially	treatable.	Therefore,	we	injected	leucine	and	
isoleucine	 stereotaxically	 into	 the	brain	of	 adult	Tie2Cre;Slc7a5fl/fl	mice	 for	3	weeks	 (Figure	
12A).	 Injected	mice	were	 then	 tested	 for	 some	of	 the	behavioral	phenotypes	described	 in	
Figure	3	and	brain	amino	acid	levels.	Notably,	after	3	weeks	of	i.c.v.	leucine	and	isoleucine	
delivery	 (Figure	 12A)	 their	 brain	 level	 was	 normalized	 (Figure	 12B	 and	 Table	 S3)	 and	 the	
mutant	 mice	 showed	 a	 significant	 improvement	 in	 neurobehavioral	 abnormalities.	
Specifically,	we	observed	a	decreased	number	of	Tie2Cre;Slc7a5fl/fl	mice	showing	the	clasping	
(50%	of	injected	vs	89%	of	non	injected	mutant	mice)	and	the	kyphosis	phenotype	(25%	of	
injected	vs	44%	of	non	 injected	mutant	mice).	Most	 importantly,	we	could	not	detect	any	
difference	 between	 treated	 Tie2Cre;Slc7a5fl/fl	 and	 wild	 type	 mice	 in	 the	 open	 field	 test	
neither	in	velocity	and	distance	moved	nor	in	the	number	of	rearings	(Figure	12C).	The	gait	
of	 the	 injected	Tie2Cre;Slc7a5fl/fl	mice	was	 improved	with	 a	 complete	 normalization	 of	 the	
sway	 length	 (Figure	 12D).	 Importantly,	 wild	 type	 animals	 injected	 with	 the	
leucine/isoleucine	 mixture	 were	 indistinguishable	 from	 the	 non-injected	 animals	 of	 the	
corresponding	 genotype	 (Figure	 12C-D),	 indicating	 that	 leucine	 and	 isoleucine	 specifically	
improve	behavior	of	Slc7a5	mutants.	Worth	mentioning	 is	 the	 fact	 that	 the	 rescue	of	 the	
social	and	vocalization	abnormalities	could	not	be	tested	given	technical	issues	presented	by	
the	presence	of	the	implanted	pump	and	the	size	of	the	animals	(see	methods).	
Although	further	tests	are	required	to	determine	the	extent	and	efficacy	of	the	treatment,	
our	data	suggest	that	certain	neurobehavioral	abnormalities	observed	in	Slc7a5	mutants	can	
be	rescued	by	i.c.v.	administration	of	leucine	and	isoleucine	in	adulthood.	Even	if	we	cannot	
entirely	disregard	a	role	of	 the	 increased	 level	of	other	amino	acids,	 these	results	support	
the	idea	that	the	reduction	in	brain	leucine	and	isoleucine	levels	is	the	determinant	factor	in	
the	 appearance	 of	 the	 neurological	 phenotypes	 observed	 in	 humans	 and	 mice	 lacking	
SLC7A5	expression.	
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Figure	12.	Normalization	of	Tie2Cre;Slc7a5fl/fl	mouse	behavior	after	leucine	and	isoleucine	i.c.v.	administration.	
(A)	Timeline	of	treatment	and	HPLC	and	behavioral	tests.		
(B)	Brain	levels	of	leucine	(left)	and	isoleucine	(right)	in	age-matched	animals	receiving	(+)	or	not	receiving	(-)	
the	 i.c.v.	 treatment.	 Amino	 acid	 levels	 were	 normalized	 to	 protein	 concentration	 and	 to	 wild-type	 levels.	
**P<0.01,	***P<0.001	(means	±	SEM;	n=8	mice/genotype).		
(C)	Quantification	of	 the	 total	 distance	moved	 (left),	 velocity	 (middle)	 and	number	of	 rearings	 (right)	 in	 the	
open	 field	 revealing	 similar	 behavior	 in	 treated	 (+)	 Tie2Cre;Slc7a5fl/fl	 mice	 and	 non-treated	 (-)	 or	 treated	 (+)	
controls	 (Tie2Cre;Slc7a5fl/+)	 but	 significant	 differences	 with	 non-treated	 (-)	 Tie2Cre;Slc7a5fl/fl	 mice;	 *P<0.05,	
**P<0.01	(means	±	SEM;	n=10	(-)	control,	n=4	(+)	control,	n=11	(-)	mutant	and	n=8	(+)	mutant).		
(D)	Similar	sway	length	in	treated	(+)	mutant	mice	and	non-treated	(-)	or	treated	(+)	control	(Tie2Cre;Slc7a5fl/+)	
animals	but	significant	difference	with	non-treated	(-)	Tie2Cre;Slc7a5fl/fl	mice;	**P<0.01	(means	±	SEM;	n=10	(-)	
control,	n=4	(+)	control,	n=11	(-)	mutant	and	n=8	(+)	mutant).		
See	also	Table	S3.		
	
	
	
 Conditional	 deletion	 of	 Slc7a5	 in	 the	 neuroprogenitor	 cells	 leads	 to	3.4.10
microcephaly		
The	 patients	 identified	with	 homozygous	 SLC7A5	 missense	mutations	 presented	 not	 only	
with	ASD	and	motor	abnormalities	but	also	with	microcephaly	 (see	Figure	10B).	However,	
the	 Tie2Cre;Slc7a5fl/fl	mouse	 model	 employed	 here	 did	 not	 recapitulate	 the	 microcephalic	
phenotype	 described	 in	 patients.	 Intrigued	 by	 this	 observation	we	wanted	 to	 understand	
whether	this	could	be	due	to	a	human	vs.	mouse	species	difference	or	due	to	the	expression	
of	Slc7a5	in	other	tissues	than	the	endothelial	cells	of	the	BBB.	We	have	shown	already	that	
at	E14.5	Tie2Cre;Slc7a5fl/fl	mice	don’t	show	major	changes	 in	brain	LNAAs	and	BCAAs	 levels	
(Figure	6B),	suggesting	that	at	E14.5	the	BBB	might	be	immature,	with	amino	acids	leaking	
promiscuously	 into	 the	 brain.	 Thus,	 specific	 brain	 cell	 types	 developing	 at	 this	 time	 point	
receive	all	 the	amino	acids	necessary	 for	growth	and	proliferation.	These	amino	acids	are	
employed	either	directly	as	building	blocks	 for	protein	 synthesis	or	as	 signaling	molecules	
for	 important	pathways	 involved	 in	cell	proliferation	 like	mTOR	(See	chapter	1).	Given	our	
observations	and	making	use	of	the	Cre	lines	we	had	available	at	our	institute,	we	addressed	
the	 role	 of	 Slc7a5	 in	 brain	 development	 by	 conditionally	 deleting	 it	 in	 neural	 progenitors	
using	 the	 Slc7a5	 floxed	 mice	 and	 the	 well	 described	 Nestin-Cre	 mice	 (Dubois,	 Hofmann,	
Kaloulis,	 Bishop,	 &	 Trumpp,	 2006).	 By	 day	 E14.5/E15	 full	 recombination	 occurred	 in	 all	
progenitor	cell	types	present	in	the	neuroectoderm,	the	developing	mesonephros	and	in	the	
somites	 (Dubois	 et	 al.,	 2006).	 The	 NestinCre;Slc7a5fl/fl	 knockout	 mice	 were	 born	 at	 the	
expected	Mendelian	ratio	and	their	body	weight	was	decreased	compared	to	the	controls	
(Figure	 13A,B)	 -	 we	 used	 Slc7a5fl/fl	 or	 Slc7a5fl/+	 as	 controls.	 Furthermore,	 the	
NestinCre;Slc7a5fl/fl	mice	had	a	decreased	milk	 content	 in	 their	 stomachs,	were	weak	 (data	
not	 shown)	 and	 died	 within	 one	 or	 two	 days	 from	 birth.	 The	 NestinCre;Slc7a5fl/fl	 brains	
appeared	 smaller	 (Figure	 13C)	 and	 their	 weight	 was	 significantly	 decreased	 compared	 to	
controls	 (Figure	 13D)	 with	 a	 decreased	 brain	 to	 body	 size	 ratio	 observable	 at	 E19.5/P0	
(Figure	13E),	suggesting	developmental	defects.	The	difference	in	brain	size	could	be	either	
due	to	a	decrease	in	cell	number	or	cell	size	or	to	an	increase	in	cell	death.	To	investigate	
the	cause	of	the	observed	microcephaly	we	analyzed	the	gross	morphology	of	the	knockout	
brains	at	P0,	by	means	of	Nissl	staining,	and	found	a	decrease	in	cortical	thickness	compared	
to	 control	 animals	 (Figure	 13F).	 Preliminary	 immunolabelings	 of	 the	 projection	 neurons	
sitting	 in	 lower	 layers	 (Ctip2+)	 or	 upper	 layers	 (Cux1+)	 suggested	 a	 slight	 but	 significant	
reduction	 in	 the	 density	 of	 the	 upper	 layer	 Cux1+	 neurons	 in	 P0	 mice,	 as	 compared	 to	
controls	 (Figure	 13G).	 To	 exclude	 a	 possible	 effect	 of	 the	 Nestin-Cre	 line	 itself	 on	 the	
observed	 reduction	 in	 upper	 layer	 neurons,	 which	 develop	 around	 E14.5	 the	 same	 time	
when	 the	 Nestin-Cre	 line	 is	 fully	 active,	 we	 also	 compared	 the	 cortical	 layers	 of	
NestinCre;Slc7a5+/+	mice	 to	 control	 animals	 and	 observed	 no	 significant	 differences	 (Figure	
13G).	Since	a	decrease	in	cell	proliferation	can	be	attributable	to	defects	in	mTOR	signaling,	
we	performed	western	blot	analysis	on	whole	brain	lysates	at	different	developmental	time	
points	 and	 identified	 a	 significant	 increase	 in	 the	 levels	 of	 4EBP1	 protein	 in	 the	 brains	 of	
NestinCre;Slc7a5fl/fl	mice	at	P0	(Figure	13H)	supporting	thus	the	idea	that	increased	blockade	
of	 protein	 elongation	 affects	 overall	 protein	 synthesis	 and	 leads	 to	 a	 defective	 cell	
proliferation.	 However,	 given	 that	 the	 Nestin-Cre	mediated	 recombination	 occurs	 also	 in	
several	other	tissues	(Dubois	et	al.,	2006)	it	is	important	to	bear	in	mind	the	risk	of	potential	
complex	phenotypes	due	to	multi-organ	defects.	Further	experiments	will	be	performed	to	
elucidate	 the	 exact	 cause	 of	 the	 microcephaly,	 like	 neurogenesis	 control	 (BrdU	 &	 Ki67	
labeling);	 cell	 death	 quantification	 or	 the	 implications	 of	 peripheral	 organs	 on	 the	
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microcephaly	 onset	 due	 to	 the	 recombination	pattern	of	 the	Nestin-cre	 line.	 So	 far	 these	
preliminary	data	indicate	that	the	microcephaly	of	NestinCre;Slc7a5fl/fl	mice	at	P0	is	the	result	
of	a	decrease	in	cortical	cell	numbers.		
	
	
	
	
	
Figure	13.	Slc7a5	deletion	from	neural	progenitor	cells	leads	to	microcephaly.	
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(A).	Body	size	of	control	Slc7a5fl/fl	animals	(left)	and	mutant	NestinCre;Slc7a5fl/fl	(right)	animals	at	P0.	Scale	bar	=	
5	mm.		
(B).	Body	weight	of	mutant	NestinCre;Slc7a5fl/fl	animals	 (right,	 red	bar)	 is	 significantly	decreased	compared	to	
control	animals	(left,	grey	bar)	at	P0.	***P	<0.001	(means	±	SEM;	n=14	animals/genotype).	
(C).	Brain	size	of	control	Slc7a5fl/fl	animals	(left)	and	mutant	NestinCre;Slc7a5fl/fl	(right)	animals	at	P0.	Scale	bar	=	
5	mm.	
(D).	Brain	weight	of	mutant	NestinCre;Slc7a5fl/fl	animals	 (right,	red	bar)	 is	significantly	decreased	compared	to	
control	animals	(left,	grey	bar)	at	P0.	***P	<0.001	(means	±	SEM;	n=14	animals/genotype).	
(E).	 Decreased	 brain/body	 ratio	 in	 mutant	 NestinCre;Slc7a5fl/fl	 animals	 (right,	 red	 bar)	 compared	 to	 control	
animals	(left,	grey	bar)	at	P0.	**P	<0.01	(means	±	SEM;	n=14	animals/genotype).	
(F).	 Nissl	 staining	 of	 control	 Slc7a5fl/fl	 animals	 (upper	 panel)	 and	 mutant	 NestinCre;Slc7a5fl/fl	 (middle	 panel)	
animals	at	P0.	Decreased	cortical	thickness	in	mutants	(lower	panel,	right)	compared	to	controls	(lower	panel,	
left).	Scale	bar	=	500	um.	
(G).	 Immunolabeling	of	upper	cortical	 layer	neurons	(Cux1+,	green)	and	 lower	cortical	 layer	neurons	(Ctip2+,	
red)	at	P0.	Decreased	cell	number	and	staining	intensity	in	mutant	NestinCre;Slc7a5fl/fl	animals	(middle	column)	
compared	to	controls	(left	column)	or	to	NestinCre;Slc7a5+/+	animals	carrying	only	the	Nestin-	Cre	recombinase	
(right	column).	Cux1+	cell	numbers	(lower	left	graph)	are	decreased	in	mutant	NestinCre;Slc7a5fl/fl	animals	(red	
bar)	compared	to	controls	 (grey	bar)	or	to	NestinCre;Slc7a5+/+	animals	 (white	bar).	Ctip2+	cell	numbers	 (lower	
right	graph)	are	similar	 in	all	 three	genotypes.	*P<0.05;	n.s.	=	not	significant	 (means	±	SEM;	n=5	animals	 for	
control	and	mutants,	n=2	for	NestinCre;Slc7a5+/+).	Scale	bar	=	100um.	
(H).	Western	blot	analysis	from	whole	brain	lysates	of	control	Slc7a5fl/fl	and	NestinCre;Slc7a5fl/fl	mice,	indicating	
that	 mutants	 exhibit	 increased	 total	 4EBP1	 and	 phospho-4EBP1	 protein	 levels	 at	 P0.	 Gapdh	 was	 used	 as	
internal	 control.	 Representative	 blots	 (left)	 and	 quantification	 (right);	 **P<0.01	 (means	 ±	 SEM;	 n=6	
animals/genotype).	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
3.5 Discussion		
Although	 SLC7A5	has	 been	described	 as	 a	 BBB	 amino	 acid	 transporter,	 studies	 accurately	
verifying	 its	expression	or	examining	 its	 function	at	 the	BBB	are	completely	missing	 in	 the	
literature.	 Moreover,	 transport	 studies	 were	 performed	 using	 only	 in	 vitro	 systems	 thus	
lacking	 the	 expression	 of	 other	 carriers	 with	 possibly	 overlapping	 substrates	 and	 its	
physiological	importance	remained	almost	completely	undetermined.		
Our	 study	 shows	 that	 SLC7A5	 loss	 of	 function	 leads	 to	 ASD	 and	 motor	 dysfunctions	 in	
humans	and	mice.	This	fits	with	our	previous	work	in	which	we	have	shown	that	mutations	
implicated	in	abnormal	BCAA	catabolism	lead	to	ASD	and	fine	motor	coordination	problems	
(Novarino	et	al.,	2012a).	Along	the	same	line,	an	increase	in	the	brain	levels	of	these	same	
amino	 acids	 leads	 to	 the	 maple	 syrup	 urine	 disorder,	 characterized	 by	 cognitive	
dysfunctions,	 seizures	 and	 hypotonia	 (Menkes,	 Hurst,	 &	 Craig,	 1954;	 Snyderman,	 Norton,	
Roitman,	&	Holt,	 1964;	 Zinnanti	 et	 al.,	 2009).	 Although	we	 acknowledge	 that	 ASD	due	 to	
SLC7A5	mutations	may	be	an	extremely	rare	condition,	the	present	study	indicates	that	fine-
tuning	 of	 brain	 BCAA	 and	 LNAA	 concentrations	 is	 key	 for	 normal	 brain	 function	 and	 that	
mutations	affecting	genes	contributing	to	BCAA	homeostasis	and	the	downstream	signaling	
cascade	may	underlie	a	larger	subgroup	of	ASD.	In	addition,	this	work	has	several	important	
pathophysiological	implications.	
We	show	that	Slc7a5	expression	at	the	BBB	is	particularly	 important	to	set	a	correct	brain	
BCAA	 concentration.	 In	 fact,	 a	 lack	 of	 Slc7a5	 expression	 at	 the	 BBB	 leads	 to	 a	 significant	
reduction	 in	 brain	 BCAA	 levels,	 particularly	 leucine	 and	 isoleucine.	 Surprisingly,	we	 didn’t	
detect	 significant	 reductions	 in	 the	 brain	 levels	 of	 the	 other	 LNAAs,	which	 in	 the	mutant	
mice	 are	 rather	 slightly	 increased,	 indicating	 that	 additional	 carriers	 are	 involved	 in	 their	
transport.	Among	the	most	altered	amino	acids,	beside	leucine	and	isoleucine,	we	detected	
histidine,	 suggesting	 that	 this	 amino	 acid	 may	 have	 a	 special	 role	 in	 the	 function	 of	 the	
transporter.	Noteworthy,	the	normal	brain	histamine	levels	(Figure	S2C)	as	well	as	the	RNA-
seq	 data	 obtained	 from	mutant	mice	 exclude	 an	 alteration	 of	 histaminergic	 transmission.	
Moreover,	 abnormally	 high	 serum	 and	 cerebrospinal	 fluid	 histidine	 levels	 have	 been	
reported	 in	 healthy	 individuals	 implying	 that	 increased	 histidine	 concentration	 is	 non-
pathological	(Lam,	Cleary,	Wraith,	&	Walter,	1996).		
Furthermore,	we	show	that	deletion	of	Slc7a5	from	the	BBB	leads	to	activation	of	the	AAR	
pathway	 and	 reduced	 cap-dependent	 translation.	 How	 exactly	 abnormal	 regulation	 of	
translation	leads	to	the	observed	phenotypes	in	SLC7A5	mutant	humans	and	mice	remains	
to	be	investigated.	However,	we	observed	that	inhibitory	neurons	may	be	more	sensitive	to	
altered	amino	acid	levels	as	Atf5,	a	key	molecule	in	the	AAR	pathway,	has	been	reported	to	
be	preferentially	expressed	in	GABA-synthetizing	neurons	(Zeisel	et	al.,	2015).	Accordingly,	
we	 found	 that	 deletion	 of	 Slc7a5	 from	 the	 BBB	 is	 sufficient	 to	 reduce	 cortical	 inhibitory	
activity,	 resulting	 in	 cortical	 excitation/inhibition	 imbalance	 and	 probably	 causing	 the	
observed	neurological	complications.	In	addition,	we	also	found	that	the	deletion	of	Slc7a5	
from	the	neural	progenitor	cells	(i.e.	NestinCre;Slc7a5fl/fl	line)	recapitulates	the	microcephaly	
observed	 in	 patients	 carrying	 SLC7A5	 missense	 mutations.	 Based	 on	 our	 preliminary	
findings,	the	microcephaly	is	the	result	of	a	decrease	in	cortical	upper	layer	cell	numbers	but	
the	exact	mechanism	of	onset	requires	further	investigation.		
Notably,	 besides	 representing	 a	 new	 subgroup	 of	 ASD,	 BCAA-related	 ASD	 may	 also	
represent	 a	 group	 of	 treatable	 conditions.	 Indeed,	 BCAA	 dietary	 administration	 in	BCKDK	
null	 mice	 and	 humans	 (Novarino	 et	 al.,	 2012a)	 as	 well	 as	 leucine	 and	 isoleucine	 i.c.v.	
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injection	 in	 adult	 Tie2Cre;Slc7a5fl/fl	 mice	 lead	 to	 a	 significant	 improvement	 of	 the	
neurobehavioral	abnormalities.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
4 Chapter	4	-	Conclusions	and	future	directions	
	
Science	 is	 always	 in	 a	 constant	 evolution,	 and	 research	 into	 complex	 disorders	 such	 as	
autism	makes	no	exception.	Many	advances	have	been	made	not	only	 in	the	technologies	
being	used,	but	also	in	the	way	autism	is	defined.	The	transition	from	autism	to	ASD	brought	
along	 not	 only	 a	widening	 in	 the	 phenotypes	 that	 characterize	 this	 disorder	 but	 also	 the	
recognition	 of	 a	 complex	 gene-environment	 susceptibility	 landscape.	 Unequivocally,	 the	
recent	 progress	 in	 genomic	 technologies	 has	 revolutionized	 our	 knowledge	 about	 the	
genetics	of	ASD	and	NDDs	in	general.	Furthermore,	the	increasing	numbers	of	international,	
large	study	cohorts	that	combine	ASD	patients	data	and	scientific	knowledge	from	research	
groups	 all	 over	 the	 world	 have	 led	 to	 a	 series	 of	 reproducible	 scientific	 findings.	 Taken	
together	all	these	efforts	help	understand	the	susceptibility	landscape	and	set	the	stage	for	
preventive	and	personalized	therapeutic	research.		
ASD	may	be	viewed	as	one	of	the	more	complex	of	the	complex	diseases.	Starting	with	the	
complex	phenotypic	spectrum,	which	includes	known	genetic	disorders	(i.e.	FXS,	RS),	to	the	
male	bias	observed	within	numerous	cases,	to	the	abundant	genetic	findings,	and	finally	to	
the	 increased	 potential	 for	 gene-gene	 interactions,	 gene-environment	 interactions,	 and	
epigenetic	effects	there	are	ample	proofs	for	complexity.		
To	 tackle	 these	 complexities,	 the	aim	set	 forth	 in	 this	 study	was	 to	navigate	 from	autistic	
phenotype	 to	 genetic	 disentangling	 of	 risk	 factors,	 from	 risk	 gene	 to	 animal	 models	 and	
eventually	 to	 preclinical	 evidence	 for	 a	 potential	 personalized	 therapy	 approach.	 We	
initialized	 this	 study	 by	 pondering	 on	 the	 role	 of	 the	 BCAAs	 in	 brain	 function	 and	
development	 based	 on	 the	 results	 obtained	 in	 a	 previous	 publication	 where	 patients	
presenting	with	ASD,	 ID	and	epilepsy	were	 carriers	of	homozygous	mutations	 in	 the	gene	
BCKDK	-	 involved	in	BCAA	metabolism	–	and	displayed	abnormally	low	levels	of	serum	and	
brain	 BCAAs.	Given	 that	 BCAAs	 appeared	 to	 be	 essential	 for	 the	 brain,	 factors	 facilitating	
their	 uptake	 would	 have	 also	 been	 critical	 for	 the	 proper	 function	 of	 the	 CNS.	 Thus,	 we	
showed	 that	 the	 solute	 carrier	 transporter	 7a5	 (Slc7a5),	 a	 large	 amino	 acid	 transporter	
located	mainly	at	the	BBB,	has	an	essential	role	in	maintaining	normal	levels	of	brain	BCAAs.	
Furthermore,	 we	 continued	 the	 quest	 of	 understanding	 the	 role	 of	 this	 transporter	 and	
identified	 several	 patients	 with	 ASD,	 microcephaly	 and	 motor	 delay	 carrying	 deleterious	
homozygous	mutations	in	the	SLC7A5.	In	mice,	deletion	of	Slc7a5	from	the	endothelial	cells	
of	 the	BBB	 led	 to	decreased	 levels	of	brain	BCAAs,	altered	cap-dependent	 translation	and	
severe	 neurological	 phenotype.	 However,	 BCAA	 i.c.v.	 administration	 ameliorated	 certain	
abnormal	behaviors	in	the	adult	mutant	mice.		
Disrupted	protein	translation	has	been	described	in	multiple	models	of	syndromic	ASD	(See	
Chapter	 1)	 and	 the	 connection	 between	 uncontrolled	 translation	 and	 ASD	 has	 become	
strong	 enough	 to	 initiate	 a	 series	 of	 studies	 using	 pharmacological	 inhibitors	 for	multiple	
forms	of	ASD	(See	2.5).	In	our	findings,	due	to	a	BCAA	deficiency	further	downstream	amino	
acid	starvation	cascades	become	active	leading	to	a	stall	 in	protein	production	opposed	to	
the	 uncontrolled	 over-translation	 of	 proteins	 seen	 in	 other	 ASD	models	where	 the	mTOR	
pathway	 is	 affected.	 Thus,	 even	 if	 by	 different	 means,	 the	 numerous	 disruptions	 are	
inhibiting	normal	cellular	responses	that	guard	the	integrity	of	protein	translation	pointing	
out	that	too	much	or	too	little	synthesis	leads	in	the	end	to	similar	phenotypes.		
Worth	reiterating,	in	light	of	the	pathophysiological	hypothesis	underlying	ASD	(See	1.7.1),	is	
the	fact	that	the	deletion	of	Slc7a5	from	the	BBB	was	sufficient	to	reduce	cortical	inhibitory	
activity,	 altering	 the	 excitation/inhibition	 balance	 and	 probably	 causing	 the	 neurological	
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phenotype.	 Similarly,	 most	 of	 the	 functionally	 characterized	 ASD-mutations	 lead	 to	 an	
imbalance	 in	 the	 excitation/inhibition	 ratio	 (See	 1.7.1).	 Thus,	 drugs	 acting	 on	 GABA	
transmission	are	considered	an	opportunity	for	the	treatment	of	ASD	and	epilepsy	(Braat	&	
Kooy,	 2015).	 It	 is	 therefore	 tempting	 to	 reason	 that	 identifying	 the	 rules	by	which	 simple	
molecules	 such	 as	 the	 BCAAs	may	 regulate	 GABAergic	 transmission	might	 have	 a	 crucial	
impact	on	the	development	of	novel	individualized	therapeutic	strategies	for	ASD.	
In	conclusion,	the	results	provided	in	this	work	-	even	though	in	their	infancy	-	represent	a	
good	foundation	for	further	studies	investigating	how	amino	acids	contribute	to	normal	and	
diseased	brain	states.		
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6 Appendix	1.	Supplemental	figures	and	tables		
	
	
	
Figure	S	1.	Slc7a5	and	Tie2Cre	expression	at	the	BBB,	Related	to	Figure	6		
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(A)	Representative	images	of	cortical	slices	stained	with	Slc7a5	(left)	and	the	endothelial	cell	marker	MECA	32	
(middle)	 antibodies.	 The	 merged	 image	 (right)	 displays	 the	 co-localization	 of	 the	 two	 markers	 in	 control	
animals.		
(B)	Human	mRNA	expression	profile	in	different	tissues	(top)	reveals	almost	exclusive	expression	of	SLC7A5	in	
the	cortex.	Sampled	tissues	are:	cortex,	kidney,	skeletal	muscle,	lung,	spleen,	testis,	liver.	GAPDH	(bottom)	was	
used	as	internal	control.		
(C)	Representative	Slc7a5	(green)	immunostained	mouse	tissue	slices	from	control	Slc7a5fl/fl	(top)	and	mutant	
Tie2CreSlc7a5fl/fl	 (bottom)	animals.	Tissues	were	sampled	from	adult	 (>P40)	mice	and	they	 include:	 liver	(left),	
lung	(middle)	and	kidney	(right).	Nuclei	were	stained	with	DAPI	(blue).		
(D)	Tie2-driven	Cre	recombinase	expression	in	the	BBB	was	verified	by	crossing	Tie2Cre	mice	with	the	reporter	
line	Gt26Sor.	Gt26Sor	mice	express	 cell-membrane	 localized	 red	 fluorescencent	protein	 (RFP)	 in	widespread	
cells	and	tissues	prior	to	Cre	recombinase	exposure	and	cell	membrane-localized	green	fluorescencent	protein	
(GFP)	in	Cre	recombinase	expressing	cells.	Note	GFP	staining	in	the	endothelial	cells	of	the	BBB	(right).	Images	
were	obtained	from	the	cerebral	cortex	of	2	days	old	(P2)	mice.	 Immunohistochemical	staining	was	done	by	
Mike	Liu.		
	
	
	
	
	
Figure	S	2.	Slc7a5	does	not	transport	neurotransmitters,	Related	to	Figure	6	
		
(A-B)	 Left:	 Schematic	of	 the	 in	vitro	 transport	assay	 -	 transport	 followed	as	uptake	 (A)	of	external	 [3H]His	 in	
exchange	to	internal	substrate	(S)	or	as	efflux	(B)	of	internal	[3H]His	in	exchange	with	external	substrate	(S)	in	
proteoliposomes	 with	 reconstituted	 SLC7A5	 protein.	 Right:	 SLC7A5-mediated	 His	 uptake	 (A)	 and	 efflux	 (B)	
analysis	indicates	the	inability	of	SLC7A5	to	transport	the	tested	neurotransmitters.	Transport	was	started	by	
adding	 5	 µM	 [3H]His	 at	 time	 0	 to	 proteoliposomes	 containing	 10	mM	 His,	 or	 the	 tested	 neurotransmitter,	
reconstituted	with	human	SLC7A5	and	stopped	at	the	indicated	times.	Percentage	of	His	efflux	(B,	%	Residual	
activity)	was	calculated	with	 respect	 to	 time	0	 for	each	experimental	condition.	His-histidine;	L-DOPA,	L-3,4-
dihydroxyphenylalanine;	Ach-acethylcholine.	
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(C)	Normal	brain	neurotransmitter	levels	in	brain	lysates	of	Tie2Cre;Slc7a5fl/fl	(red	bars)	mice.	Neurotransmitter	
levels	were	quantified	by	HPLC	and	normalized	on	protein	concentration	and	on	control	(Tie2Cre;Slc7a5fl/+,	grey	
bars)	littermate	levels	(means	±	SD;	n=4	mice	per	genotype).	
Proteoliposome	study	was	done	by	Michele	Galluccio,	Mariafrancesca	Scalise	and	Cesare	Indiveri	–	University	
of	Calabria.	
	
	
	
Figure	S	3.	Behavioral	and	electrophysiological	alterations	in	Tie2Cre;Slc7a5fl/fl	mice,	Related	to	Figure	8	and	9		
(A)	 Tie2Cre;Slc7a5fl/fl	 (red)	 and	 Tie2Cre;Slc7a5fl/+	 (grey)	 show	 similar	 habituation	 kinetics	 in	 the	 open	 field.	
Distance	 moved	 in	 the	 open	 field	 was	 analyzed	 in	 5-minute	 bins	 over	 the	 course	 of	 20	 minutes.	
Tie2Cre;Slc7a5fl/fl	 mice	 moved	 less	 at	 all	 given	 points	 *P<0.05,	 **P<0.01	 (means	 ±	 SEM;	 n=10	 mice	 per	
genotype).	
	
	
(B)	Marble	burying	test	shows	no	significant	difference	between	the	number	of	marbles	buried	by	the	control	
Tie2Cre;Slc7a5fl/+	and	the	mutant	Tie2Cre;Slc7a5fl/fl;	N.S.,	not	significant	(means	±	SEM;	n=10	mice	per	genotype;	
circles	represent	individual	values).		
(C-D)	Left:	Representative	mEPSC	(B)	and	mIPSC	(C)	recordings	from	Tie2Cre;Slc7a5fl/+	(grey)	and	Tie2Cre;Slc7a5fl/fl	
(red)	 cerebellar	 Purkinje	 cells.	 Right:	 Cumulative	probability	 distributions	of	 peak	 amplitudes	 and	 interevent	
intervals	 of	mEPSC	 (B)	 and	mIPSC	 (C)	 in	 the	 two	 genotypes.	 Insets:	 quantifications	of	mean	amplitudes	 and	
mean	frequencies	of	the	corresponding	currents,	along	with	absolute	P	values.	Significant	reduction	in	mIPSC	
mean	 frequency	 in	 mutants	 versus	 controls	 is	 indicated.	 Result	 confirmed	 by	 cumulative	 probability	
distribution	 analysis,	 Kolmogorov-Smirnov	 test:	 D=0.109;	 *P<0.05	 (means	 ±	 SEM;	 ncells/nanimals/genotype:	
7/3/Tie2Cre;Slc7a5fl/+	 and	 6/3/Tie2Cre;Slc7a5fl/fl;	 circles	 indicate	 individual	 values).	 mEPSCs	 and	 mIPSCs	 were	
recorded	from	the	same	cell.	Elctrophysiological	experiment	was	done	by	Elena	Deliu	–	IST	Austria.		
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Figure	S	4.	Absence	of	gross	alterations	in	brain	architecture	of	Tie2Cre;Slc7a5fl/fl	mice,	Related	to	Figure	9.	
(A)	 Nissl	 staining	 of	 sagittal	 sections	 of	 adult	 mouse	 brain	 indicating	 no	 differences	 in	 gross	 morphology	
between	the	control	Tie2Cre;Slc7a5fl/+	and	mutant	Tie2Cre;Slc7a5fl/fl	mice.	Scale	bar	=	1	mm.	
(B)	 Immunostaining	of	Cux1	(green,	upper	 layer	neurons)	and	Ctip2	 (red,	 lower	 layer	neurons)	shows	similar	
cortical	layer	distribution	in	the	two	genotypes.	Scale	bar	=	100	um.	
(C)	Representative	 images	 (left)	 and	quantifications	 (right)	 indicating	 similar	numbers	of	parvalbumin-	 (top),	
somatostatin-	(middle)	and	calretinin-	(bottom)	positive	interneurons	in	the	cortices	of	wild-type	and	mutant	
mice;	 N.	 S.,	 not	 significant	 (means	 ±	 SEM;	 n=3	mice	 per	 genotype;	 filled	 circles	 indicate	 individual	 values).	
Nuclei	were	stained	with	DAPI	(blue).	Scale	bar	=	200	um.	
(D)	 Fluorescence	 intensity	 quantification	 of	 VGAT	 puncta	 in	 control	 Tie2Cre;Slc7a5fl/+	 compared	 to	 mutant	
Tie2Cre;Slc7a5fl/fl	mice;	**P<0.01	(means	±	SEM;	n=3	mice	per	genotype).		
(E)	 Fluorescence	 intensity	 quantification	 of	 NLGN2	 puncta	 displaying	 no	 difference	 between	 control	
Tie2Cre;Slc7a5fl/+	and	mutant	Tie2Cre;Slc7a5fl/fl	mice;	N.S.,	not	significant	(means	±	SEM;	n=3	mice	per	genotype).		
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Figure	S	5.	Phenotypic	characterization	of	Bckdk-/-	animals,	Related	to	Figure	9.	
(A)	Representative	open	field	trajectories	(left)	and	quantification	of	the	total	distance	moved	(middle)	and	the	
velocity	during	exploration	(right);	**P<0.01	(means	±	SEM;	n=25	mice	per	genotype;	circles	indicate	individual	
values).		
	
	
(B)	 Comparison	 of	 the	 number	 of	 rearings	 (anxiogenic	 forms	 of	 vertical	 exploration)	 of	 the	 two	 genotypes	
during	the	open	field	test,	pointing	out	deficiencies	in	the	mutants;	***P<0.001	(means	±	SEM;	n=18	mice	per	
genotype;	circles	indicate	individual	values).		
(C)	Performance	on	the	walking	beam	throughout	 the	training	days	 (Day1,	Day2)	and	the	three	trials	on	the	
test	day	(Day3),	showing	elevated	latency	to	cross	the	beam	in	the	mutants;	*P<0.05	(means	±	SEM;	n=23	mice	
per	genotype).		
(D)	Stride	length	quantifications	in	the	gait	test	reveal	locomotor	deficiencies	in	Bckdk-/-	mice;	*P<0.05	(means	
±	SEM;	n=20	mice	per	genotype;	circles	indicate	individual	values).			
(E)	Bar	graph	quantifications	of	the	number	of	contacts	with	the	caged	mouse	(M)	or	with	the	caged	object	(O)	
in	 the	 three-chamber	 sociability	 test,	 revealing	 abnormal	 social	 interaction	 pattern	 in	 the	 mutant	 mice	
(mutants	 show	 no	 preference	 for	 the	M	 over	 O,	 as	 opposed	 to	 controls);	 ***P<0.001,	 N.S.,	 not	 significant	
(means	±	SEM;	n=16	mice	per	genotype;	circles	indicate	individual	values).	
(F)	Left:	Representative	mEPSC	(top)	and	mIPSC	(bottom)	recordings	from	control	Bckdk+/+	(black)	and	Bckdk-/-	
(red)	somatosensory	cortex	 layers	2-3	pyramidal	neurons;	Right:	Cumulative	probability	distributions	of	peak	
amplitudes	 and	 interevent	 intervals	 of	 mEPSC	 (top)	 and	 mIPSC	 (bottom)	 in	 the	 two	 genotypes.	 Insets:	
quantifications	 of	 mean	 amplitudes	 and	 mean	 frequencies	 of	 the	 corresponding	 currents.	 The	 significant	
reduction	in	mIPSC	mean	frequency	detected	in	the	mutants	versus	controls	is	indicated	as	absolute	P	value:	
*P<0.05	(means	±	SEM;	n>3	animals/genotype;	number	of	recorded	cells	is	noted	on	each	column).	
(G)	 Normal	 brain	 neurotransmitter	 levels	 in	 brain	 lysates	 of	 Bckdk-/-	 mice.	 Neurotransmitter	 levels	 were	
quantified	by	HPLC	and	normalized	on	protein	concentration	and	on	control	littermate	(Bckdk+/+)	 levels;	N.S.,	
not	significant	(means	±	SEM;	n=4	mice	per	genotype).	
Bckdk-/-	experiments	were	done	by	Emanuela	Morelli.		
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Figure	S	6.	Genotyping	information	of	Family	1426	and	1465,	Related	to	Figure	10.	
(A)	Homozygosity	map	for	Family	1426.	Blocks	of	homozygosity	are	depicted	as	peaks.	The	red	arrow	indicates	
the	interval	that	includes	SLC7A5.		
(B)	 Sequence	 chromatograms	 of	 all	members	 of	 Family	 1465	 including	 the	 affected	 siblings	 and	 the	 carrier	
parents.	
WES	was	done	by	Ahmet	Okay	Caglayan	and	Gaia	Novarino.	
	
	
	
	
	
Figure	S	7.	Characterization	of	SLC7A5-A246V,	-A246G	and	SLC7A5-P375L	mutants,	Related	to	Figure	11.	
(A)	Western	blot	analysis	of	the	indicated	SLC7A5	mutants	in	comparison	with	the	WT	protein	reconstituted	in	
proteoliposomes	(top	and	middle	panels).	To	evaluate	the	efficiency	of	reconstituted	SLC7A5,	proteoliposomes	
reconstituted	 with	 WT	 or	 SLC7A5	 A246V	 were	 separated	 from	 liposomes	 (not	 containing	 reconstituted	
protein)	 by	 ultracentrifugation;	 blots	 of	 reconstituted	 proteins	 (proteoliposome)	 and	of	 the	 purified	 protein	
before	reconstitution	(purified)	are	included	in	the	bottom	panel.		
(B)	 SLC7A5-WT	 and	 SLC7A5-A246G-mediated	 transport	 rate	 (upon	 reconstitution	 in	 proteoliposomes)	 is	
dependent	on	external	His	concentration	showing	similar	patterns	for	the	two	proteins.	[3H]-His	was	added	at	
the	indicated	concentration	to	proteoliposomes	containing	10	mM	His,	and	transport	stopped	after	10	min	(i.e.	
within	 the	 initial	 linear	 range	 of	 the	 time	 course).	 Data	 were	 fitted	 according	 to	 Lineweaver–Burk	 plot	 as	
reciprocal	transport	rate	vs	reciprocal	His	concentration	(means	±	SD;	n=3	independent	experiments).	
(C)	 Time-course	 of	 the	 transport	 mediated	 by	 SLC7A5-WT	 and	 P375L	 reconstituted	 in	 proteoliposomes,	
showing	 that	 the	P375L	mutant	protein	 is	 functional.	 Transport	was	 started	by	adding	5	µM	 [3H]His	at	 time	
zero	to	proteoliposomes	containing	10	mM	His	reconstituted	with	WT-	or	P375L-	SLC7A5	and	stopped	at	the	
indicated	times	as	described	in	the	Experimental	Procedure	(means	±	SD;	n=5	independent	experiments).	
(D)	 Rate	 of	 SLC7A5-mediated	 transport	 dependent	 on	 external	 His	 concentration.	 Transport	 rate	 was	
measured	 adding	 [3H]His	 at	 the	 indicated	 concentration	 to	 proteoliposomes	 containing	 10	 mM	 His	
reconstituted	with	WT-	or	P375L-SLC7A5	protein.	Transport	was	 stopped	after	10	min,	 i.e.,	within	 the	 initial	
linear	 range	of	 the	 time	 course.	Data	were	 fitted	according	 to	 Lineweaver–Burk	plot	 as	 reciprocal	 transport	
rate	vs	reciprocal	His	concentration.	(Means	±	SD;	n=3	independent	experiments).	
(E)	Rate	of	SLC7A5-mediated	transport	dependent	on	internal	His	concentration.	Transport	rate	was	measured	
adding	50	µM	[3H]His	to	proteoliposomes,	containing	the	indicated	His	concentrations,	reconstituted	with	WT-	
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or	P375L-	SLC7A5	protein.	Transport	was	stopped	after	10	min,	i.e.,	within	the	initial	linear	range	of	the	time	
course.	Data	were	fitted	according	to	Lineweaver-Burk	(or	Michaelis-Menten)	plot	as	reciprocal	transport	rate	
vs	reciprocal	His	concentration.	(Means	±	SD;	n=3	independent	experiments).	
(F)	Representative	immunoblot	showing	SLC7A5	transcript	expression	in	human	dermal	fibroblasts;	expression	
level	is	not	affected	by	the	A246V	missense	mutation	(n=3	independent	experiments).	
Proteoliposome	study	was	done	by	Michele	Galluccio,	Mariafrancesca	Scalise	and	Cesare	Indiveri	–	University	
of	Calabria,	Italy.	
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